Information on EC 1.4.3.4 - monoamine oxidase

Please wait a moment until all data is loaded. This message will disappear when all data is loaded.
Specify your search results
Mark a special word or phrase in this record:
Select one or more organisms in this record:
Show additional data
Do not include text mining results
Include (text mining) results (more...)
Include results (AMENDA + additional results, but less precise; more...)


The expected taxonomic range for this enzyme is: Eukaryota

EC NUMBER
COMMENTARY
1.4.3.4
-
RECOMMENDED NAME
GeneOntology No.
monoamine oxidase
REACTION
REACTION DIAGRAM
COMMENTARY
ORGANISM
UNIPROT ACCESSION NO.
LITERATURE
RCH2NHR' + H2O + O2 = RCHO + R'NH2 + H2O2
show the reaction diagram
mechanism of monoamine oxidase A and B
-
RCH2NHR' + H2O + O2 = RCHO + R'NH2 + H2O2
show the reaction diagram
ping-pong kinetic mechanism
-
RCH2NHR' + H2O + O2 = RCHO + R'NH2 + H2O2
show the reaction diagram
ping-pong kinetic mechanism
-
RCH2NHR' + H2O + O2 = RCHO + R'NH2 + H2O2
show the reaction diagram
mechanism; mechanism of monoamine oxidase A
-
RCH2NHR' + H2O + O2 = RCHO + R'NH2 + H2O2
show the reaction diagram
mechanism
-
RCH2NHR' + H2O + O2 = RCHO + R'NH2 + H2O2
show the reaction diagram
catalysis occur via proton abstraction mechanisms
P21397
RCH2NHR' + H2O + O2 = RCHO + R'NH2 + H2O2
show the reaction diagram
catalysis occur via proton abstraction mechanisms
P21396
RCH2NHR' + H2O + O2 = RCHO + R'NH2 + H2O2
show the reaction diagram
reaction mechanism of C-H bond cleavage, MAO B shows H tunneling to contribute in the H transfer step, overview
-
RCH2NHR' + H2O + O2 = RCHO + R'NH2 + H2O2
show the reaction diagram
reaction mechanism of C-H bond cleavage, overview. MAO oxidation of benzylamines and phenethylamines exhibit large deuterium kinetic isotope effects showing, in most instances, that C-H bond cleavage is rate limiting in catalysis
-
RCH2NHR' + H2O + O2 = RCHO + R'NH2 + H2O2
show the reaction diagram
reaction mechanism of C-H bond cleavage, overview
-
RCH2NHR' + H2O + O2 = RCHO + R'NH2 + H2O2
show the reaction diagram
-
-
-
-
REACTION TYPE
ORGANISM
UNIPROT ACCESSION NO.
COMMENTARY
LITERATURE
Deamination
-
-
-
-
oxidation
-
-
-
-
redox reaction
-
-
-
-
reduction
-
-
-
-
PATHWAY
KEGG Link
MetaCyc Link
Arginine and proline metabolism
-
aromatic biogenic amine degradation (bacteria)
-
Biosynthesis of secondary metabolites
-
dopamine degradation
-
Drug metabolism - cytochrome P450
-
Glycine, serine and threonine metabolism
-
Histidine metabolism
-
Isoquinoline alkaloid biosynthesis
-
melatonin degradation II
-
Metabolic pathways
-
noradrenaline and adrenaline degradation
-
phenylalanine degradation IV (mammalian, via side chain)
-
Phenylalanine metabolism
-
putrescine degradation III
-
salidroside biosynthesis
-
serotonin degradation
-
tryptophan degradation VI (via tryptamine)
-
tryptophan degradation X (mammalian, via tryptamine)
-
Tryptophan metabolism
-
Tyrosine metabolism
-
SYSTEMATIC NAME
IUBMB Comments
amine:oxygen oxidoreductase (deaminating)
A mitochondrial outer-membrane flavoprotein (FAD) that catalyses the oxidative deamination of neurotransmitters and biogenic amines [3]. Acts on primary amines, and also on some secondary and tertiary amines. It differs from EC 1.4.3.21, primary-amine oxidase as it can oxidize secondary and tertiary amines but not methylamine. This enzyme is inhibited by acetylenic compounds such as chlorgyline, 1-deprenyl and pargyline but, unlike EC 1.4.3.21 and EC 1.4.3.22 (diamine oxidase), it is not inhibited by semicarbazide.
SYNONYMS
ORGANISM
UNIPROT ACCESSION NO.
COMMENTARY
LITERATURE
adrenaline oxidase
-
-
-
-
amine-oxygen oxidoreductase
-
-
epinephrine oxidase
-
-
-
-
MAO
-
-
-
-
MAO
Coregonus lavaretus ludoga
-
-
MAO
Q6NSN2
-
MAO
Danio rerio Turku
-
-
-
MAO
P27338
-
MAO A
-
-
MAO A
P21398
-
MAO A
-
-
MAO A
Q64133
-
MAO A
-
isoform
MAO B
-
-
MAO B
P56560
-
MAO B
-
isoform
MAO B
-
-
MAO B
Q8BW75
-
MAO B
-
-
MAO type B
P27338
-
MAO-A
Q64133
-
MAO-A
P21397
-
MAO-A
-
-
MAO-A
-
-
MAO-A
-
isoform
MAO-A
P21397
-
MAO-A
P21936
-
MAO-A
Q6Q2J0
-
MAO-B
-
-
MAO-B
-
-
MAO-B
-
-
MAO-B
-
isoform
MAO-B
P21396
-
MAO-B
Q5UL99
-
MAO-B
Rattus norvegicus Wistar
P19643
-
-
MAO-N
P46882
-
MAOA
-
-
MAOA
Rattus norvegicus MAO-A
-
-
-
MAOB
P21397
-
MAOB
P19643
-
monoamine oxidase
-
-
-
-
monoamine oxidase
-
-
monoamine oxidase
P21397, P27338
-
monoamine oxidase
-
-
monoamine oxidase
Q64133
-
monoamine oxidase
-
-
monoamine oxidase A
-
-
monoamine oxidase A
P21398
-
monoamine oxidase A
-
-
monoamine oxidase A
-
-
monoamine oxidase A
-
-
monoamine oxidase A
-
-
monoamine oxidase A
Q64133
-
monoamine oxidase A
-
-
monoamine oxidase A
P21397
-
monoamine oxidase A
-
-
monoamine oxidase A
-
-
monoamine oxidase A
-
isoform
monoamine oxidase B
-
-
monoamine oxidase B
P56560
-
monoamine oxidase B
-
-
monoamine oxidase B
-
-
monoamine oxidase B
-
-
monoamine oxidase B
P21397
-
monoamine oxidase B
-
-
monoamine oxidase B
-
-
monoamine oxidase B
Q8BW75
-
monoamine oxidase B
-
-
monoamine oxidase B
-
-
monoamine oxidase B
-
-
monoamine oxidase B
-
-
monoamine oxidase B
-
-
monoamine oxidase B
-
-
monoamine oxidase B
-
isoform
monoamine oxidase B
P21396
-
monoamine oxidase type B
P27338
-
monoamine oxidase-A
-
-
monoamine oxidase-A
P21397
-
monoamine oxidase-A
-
-
monoamine oxidase-A
P21396
-
monoamine oxidase-B
-
-
monoamine oxidase-B
P27338
-
monoamine oxidase-B
-
-
monoamine oxidaseA
P21397
-
monoamine oxidases A
-
-
monoamine oxidases B
-
-
monoamine-oxidase-A
P21397
-
monoamine:O2 oxidoreductase (deaminating)
-
-
-
-
monoamine:O2 oxidoreductase, deaminating
-
-
monoamine:O2-oxidoreductase deaminating
Coregonus lavaretus ludoga
-
-
semicarbazide-sensitive amine oxidase
-
-
serotonin deaminase
-
-
-
-
tyraminase
-
-
-
-
tyramine oxidase
-
-
-
-
zMAO
-
-
monoaminoxidase B
P27338
-
additional information
-
isoforms differ in inhibitor sensitivity
additional information
-
isoforms differ in inhibitor sensitivity; MAO-A and MAO-B are 2 different isoenzymic forms which differ in substrate specificity, distribution among tissues and their structures
additional information
-
MAO is a novel type of disulfide oxidoreductase
additional information
-
the N-terminal region of the two isoenzymes is not involved in the different specificity of the two isoenzymes for substrates and inhibitors
additional information
-
isoforms differ in inhibitor sensitivity; MAO-A and MAO-B are 2 different isoenzymic forms which differ in substrate specificity, distribution among tissues and their structures
additional information
-
MAO-A and MAO-B are 2 different isoenzymic forms which differ in substrate specificity, distribution among tissues and their structures
additional information
-
isoforms differ in inhibitor sensitivity; MAO-A and MAO-B are 2 different isoenzymic forms which differ in substrate specificity, distribution among tissues and their structures
CAS REGISTRY NUMBER
COMMENTARY
9001-66-5
-
ORGANISM
COMMENTARY
LITERATURE
SEQUENCE CODE
SEQUENCE DB
SOURCE
two amine oxidases isolated: the first one corresponds to the copper-dependent enzyme, the second one is an evolutionary prototype form of MAO-A and B
-
-
Manually annotated by BRENDA team
cultivar Miechikara
-
-
Manually annotated by BRENDA team
MAO A and MAO B are encoded by separate genes
-
-
Manually annotated by BRENDA team
Coregonus lavaretus ludoga
-
-
-
Manually annotated by BRENDA team
of Turku strain
-
-
Manually annotated by BRENDA team
Danio rerio Turku
of Turku strain
-
-
Manually annotated by BRENDA team
white leghorn
-
-
Manually annotated by BRENDA team
expressed in Pichia pastoris strain KM71
SwissProt
Manually annotated by BRENDA team
expressed in Saccharomyces cerevisiae
SwissProt
Manually annotated by BRENDA team
isozyme MAO A
-
-
Manually annotated by BRENDA team
isozyme MAO-B
-
-
Manually annotated by BRENDA team
Korean individuals
-
-
Manually annotated by BRENDA team
male children
-
-
Manually annotated by BRENDA team
MAO-A and MAO-B are encoded by separate genes
-
-
Manually annotated by BRENDA team
MAO-B; isozyme MAO B
SwissProt
Manually annotated by BRENDA team
MAOA
SwissProt
Manually annotated by BRENDA team
MAOB
SwissProt
Manually annotated by BRENDA team
recombinant
SwissProt
Manually annotated by BRENDA team
recombinant
SwissProt
Manually annotated by BRENDA team
transgenic C57Bl6 mice inducibly expressing human MAO-B selectively within astrocytes
SwissProt
Manually annotated by BRENDA team
European lamprey
-
-
Manually annotated by BRENDA team
female scrapie-infected hamsters
-
-
Manually annotated by BRENDA team
MAO A and MAO B are encoded by separate genes
-
-
Manually annotated by BRENDA team
Tg8 is a transgenic mouse strain lacking a functional MAO A gene
SwissProt
Manually annotated by BRENDA team
wild-type FVB/N and Tg-CYP2D6 mice
-
-
Manually annotated by BRENDA team
American mink, several isozymes
-
-
Manually annotated by BRENDA team
baboon
-
-
Manually annotated by BRENDA team
; nine-week-old male Wistar rats
SwissProt
Manually annotated by BRENDA team
expressed in Pichia pastoris strain KM71
SwissProt
Manually annotated by BRENDA team
male Sprague-Dawley
SwissProt
Manually annotated by BRENDA team
male Wistar rats
SwissProt
Manually annotated by BRENDA team
MAO A and MAO B are encoded by separate genes
-
-
Manually annotated by BRENDA team
MAO-A; male albino rats, isozyme MAO-A
SwissProt
Manually annotated by BRENDA team
MAO-B; male albino rats, isozyme MAO-B
SwissProt
Manually annotated by BRENDA team
pregnant Sprague-Dawley
-
-
Manually annotated by BRENDA team
Sprague Dawley
SwissProt
Manually annotated by BRENDA team
Wistar
SwissProt
Manually annotated by BRENDA team
Wistar rats, several isozymes
-
-
Manually annotated by BRENDA team
Rattus norvegicus MAO-A
MAO-A
-
-
Manually annotated by BRENDA team
Rattus norvegicus Wistar
Wistar
SwissProt
Manually annotated by BRENDA team
-
SwissProt
Manually annotated by BRENDA team
GENERAL INFORMATION
ORGANISM
UNIPROT ACCESSION NO.
COMMENTARY
LITERATURE
malfunction
-
abnormal MAO A activity is implicated in several neuropsychiatric disorders, such as depression, autism, and attention deficit hyperactivity disorder, which show sexual dimorphism
malfunction
-
polymorphisms in the gene encoding MAOA are implicated in autism spectrum disorder,overview
malfunction
-
the first step of the bioactivation of the Parkinsonian-inducing pro-neurotoxin 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine, MPTP, is catalyzed by MAO-B, resulting in the ultimate product, 1-methyl-4-phenylpyridinium, a mitochondrial toxin that causes selective degeneration of nigrostriatal dopaminergic neurons in humans and experimental animals
malfunction
-
individual polymorphisms of the promoter of MAO-A gene might partly explain the increased vulnerability of maltreated male children for externalizing behaviour, overview
physiological function
-
MAO-Bis implicated in the pathology of neurodegenerative diseases
physiological function
-
MAO A catalyzes the oxidative deamination of monoamine neurotransmitters, such as serotonin, and plays a critically important role in brain development and functions
physiological function
-
MAO-A eliminates the drug 5-MeO-DMT through oxidative deamination. MAO-A-mediated deamination is the major metabolic pathway for 5-MeO-DMT
physiological function
-
MAO-A eliminates the drug 5-MeO-DMT through oxidative deamination
physiological function
-
MAO A and MAO B play roles in the oxidative catabolism of important amine neurotransmitters including serotonin, dopamine, and epinephrine. Inhibition of MAO B results in a protective effect from this cell-destructive bio-activation. MAO A functions specifically in the oxidative metabolism of serotonin although it also oxidizes dopamine effectively
physiological function
-
MAO-A and MAO-B play roles in the oxidative catabolism of important amine neurotransmitters including serotonin, dopamine, and epinephrine. Inhibition of MAO-B results in a protective effect from this cell-destructive bio-activation. MAO-A functions specifically in the oxidative metabolism of serotonin although it also oxidizes dopamine effectively
physiological function
-
MAO A and MAO B play roles in the oxidative catabolism of important amine neurotransmitters including serotonin, dopamine, and epinephrine. Inhibition of MAO B results in a protective effect from this cell-destructive bio-activation. MAO A functions specifically in the oxidative metabolism of serotonin although it also oxidizes dopamine effectively
physiological function
-
MAO maintains physiological level of mediators in the presynaptic nerve terminal. The biological role of MAO is associated with the regulation of the level of mediators in nerve structures and, therefore, with different functions of the nervous system
physiological function
-
the enzyme is important in the regulation of serotonin and dopamine levels
metabolism
-
monoamine oxidase are key role enzymes in the catabolism of amines like dopamine, norepinephrine, epinephrine, serotonin, and 2-phenylethylamine
additional information
-
zMAO exhibits no immuno-chemical cross-reactivity with polyclonal anti-sera raised against human MAO-A
SUBSTRATE
PRODUCT                      
REACTION DIAGRAM
ORGANISM
UNIPROT ACCESSION NO.
COMMENTARY
(Substrate)
LITERATURE
(Substrate)
COMMENTARY
(Product)
LITERATURE
(Product)
Reversibility
r=reversible
ir=irreversible
?=not specified
(1R,6S)-3-methyl-6-phenyl-3-aza-bicyclo[4.1.0]heptane + H2O + O2
?
show the reaction diagram
-
MAO-B catalyzed ring alpha-carbon oxidation of 3-methyl-6-phenyl-3-aza-bicyclo[4.1.0]heptane is enantioselective with an almost 5fold preference for the (1R,6S) enantiomer based on Vmax/Km values
-
-
?
(1S,6R)-3-methyl-6-phenyl-3-azabicyclo[4.1.0]heptane + H2O + O2
?
show the reaction diagram
-
MAO-B catalyzed ring alpha-carbon oxidation of 3-methyl-6-phenyl-3-aza-bicyclo[4.1.0]heptane is enantioselective with an almost 5fold preference for the (1R,6S) enantiomer based on Vmax/Km values
-
-
?
1,4-dibenzyl-1-cyclopropyl-1,2,3,6-tetrahydropyridine
?
show the reaction diagram
-
-
-
-
?
1-(4-bromophenyl)methanamine + H2O + O2
4-bromobenzaldehyde + NH3 + H2O2
show the reaction diagram
-
-
-
-
?
1-(4-bromophenyl)methanamine + H2O + O2
4-bromobenzaldehyde + NH3 + H2O2
show the reaction diagram
-
-
-
-
?
1-(4-chlorophenyl)methanamine + H2O + O2
4-chlorobenzaldehyde + NH3 + H2O2
show the reaction diagram
-
-
-
-
?
1-(4-chlorophenyl)methanamine + H2O + O2
4-chlorobenzaldehyde + NH3 + H2O2
show the reaction diagram
-
-
-
-
?
1-(4-fluorophenyl)methanamine + H2O + O2
4-fluorobenzaldehyde + NH3 + H2O2
show the reaction diagram
-
-
-
-
?
1-(4-fluorophenyl)methanamine + H2O + O2
4-fluorobenzaldehyde + NH3 + H2O2
show the reaction diagram
-
-
-
-
?
1-(4-methoxyphenyl)methanamine + H2O + O2
4-methoxybenzaldehyde + NH3 + H2O2
show the reaction diagram
-
-
-
-
?
1-(4-methoxyphenyl)methanamine + H2O + O2
4-methoxybenzaldehyde + NH3 + H2O2
show the reaction diagram
-
-
-
-
?
1-(4-methylphenyl)methanamine + H2O + O2
4-methylbenzaldehyde + NH3 + H2O2
show the reaction diagram
-
-
-
-
?
1-(4-methylphenyl)methanamine + H2O + O2
4-methylbenzaldehyde + NH3 + H2O2
show the reaction diagram
-
-
-
-
?
1-methyl-3-(4-chlorophenyl)-3-pyrroline + H2O + O2
?
show the reaction diagram
-
-
-
-
?
1-methyl-3-phenyl-3-pyrroline + H2O + O2
1-methyl-3-phenylpyrrole + NH3 + H2O2
show the reaction diagram
-
oxidation is a 2-electron process. Rapid clearance of 1-methyl-3-phenylpyrrole from the brain may contribute to their lack of neurotoxicity
-
-
?
1-methyl-4-(1-methylpyrrol-2-yl)-1,2,3,6-tetrahydropyridine + H2O + O2
?
show the reaction diagram
-
-
-
-
?
1-methyl-4-(1-methylpyrrol-2-yl)-1,2,3,6-tetrahydropyridine + H2O + O2
?
show the reaction diagram
-
i.e. MMTP
-
-
?
1-methyl-4-(1-methylpyrrol-2-yl)-1,2,3,6-tetrahydropyridine + H2O + O2
?
show the reaction diagram
-
i.e. MMTP, is oxidized to the corresponding dihydropyridinium metabolite, MMDP+
-
-
?
1-methyl-4-(1-methylpyrrol-2-yl)1,2,3,6-tetrahydropyridine + H2O + O2
?
show the reaction diagram
-
-
-
-
?
1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine + H2O + O2
?
show the reaction diagram
-
-
-
-
?
1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine + H2O + O2
?
show the reaction diagram
-
-
-
-
?
1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine + H2O + O2
?
show the reaction diagram
-
-
-
-
?
1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine + H2O + O2
?
show the reaction diagram
-
-
-
-
?
1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine + H2O + O2
?
show the reaction diagram
-
1-methyl-4-phenylpyridinium is the ultimate product
-
-
?
1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine + H2O + O2
1-methyl-4-phenyl-2,3-dihydropyridinium + NH3 + H2O2
show the reaction diagram
-
-
-
-
?
1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine + H2O + O2
1-methyl-4-phenylpyridinium + NH3 + H2O2
show the reaction diagram
-
the parkinsonian inducing agent 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine is oxidized to 1-methyl-4-phenylpyridinium MPP+, a 4-electron oxidation product and a potent mitochondrial toxin
-
-
?
1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine + H2O + O2
1-methyl-4-phenyl-2,3-dihydropyridinium + 1-methyl-4-phenylpyridinium
show the reaction diagram
-
activation of the neurotoxin to neurotoxic pyridinium cations
-
-
?
1-methyl-4-phenyl-1,2,5,6-tetrahydropyridine + H2O + O2
?
show the reaction diagram
Q6NSN2
-
-
-
?
1-methylhistamine + H2O + O2
?
show the reaction diagram
P19643, P21396
reaction with MAO-A at 1 mM substrate, no activity at 0.1 mM substrate
-
-
?
1-methylhistamine + H2O + O2
1-methyl-1H-imidazol-4-ylacetaldehyde + NH3 + H2O2
show the reaction diagram
P19643, P21396
reaction with MAO-B at 1 mM substrate, no activity at 0.1 mM substrate
-
-
?
1-methylhistamine + O2 + H2O
1-methyl-1H-imidazol-4-ylacetaldehyde + NH3 + H2O2
show the reaction diagram
P19643, P21396
-
-
-
?
1-[4-(trifluoromethyl)phenyl]methanamine + H2O + O2
4-(trifluoromethyl)benzaldehyde + NH3 + H2O2
show the reaction diagram
-
-
-
-
?
1-[4-(trifluoromethyl)phenyl]methanamine + H2O + O2
4-(trifluoromethyl)benzaldehyde + NH3 + H2O2
show the reaction diagram
-
-
-
-
?
1-[4-(trifluoromethyl)phenyl]methanamine + H2O + O2
4-(trifluoromethyl)benzaldehyde + NH3 + H2O2
show the reaction diagram
-
-
-
-
?
2 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine + 2 H2O + 3 O2
1-methyl-4-phenyl-2,3-dihydropyridinium + 1-methyl-4-phenylpyridinium + 4 H2O2
show the reaction diagram
-
activation of the neurotoxin to neurotoxic pyridinium cations. MPTP easily crosses the blood-brain barrier and is preferentially metabolized by MAO-B present in glial cells to 1-methyl-4-phenyl-2,3-dihydropyridinium. This enzymatic metabolite is subsequently oxidized to 1-methyl-4-phenylpyridinium, which is selectively uptaken by dopaminergic cells, producing inhibition of complex I of mitochondria, energy depletion, oxidative stress and cell death
1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine is metabolically oxidized by alpha-carbon oxidation by MAO enzymes to give 1-methyl-4-phenyl-2,3-dihydropyridinium and hydrogen peroxide, which, in a further step, is readily oxidized to 1-methyl-4-phenylpyridinium, that is a directly-acting neurotoxic substance
-
?
2-phenylethylamine + H2O + O2
2-phenylethanal + NH3 + H2O2
show the reaction diagram
-
-
-
-
?
2-phenylethylamine + H2O + O2
2-phenylethanal + NH3 + H2O2
show the reaction diagram
-
-
-
?
2-phenylethylamine + H2O + O2
2-phenylethanal + NH3 + H2O2
show the reaction diagram
-
-
-
?
2-phenylethylamine + H2O + O2
2-phenylethanal + NH3 + H2O2
show the reaction diagram
-
-
-
?
2-phenylethylamine + H2O + O2
2-phenylethanal + NH3 + H2O2
show the reaction diagram
-
-
-
?
2-phenylethylamine + H2O + O2
2-phenylethanal + NH3 + H2O2
show the reaction diagram
-
-
-
?
2-phenylethylamine + H2O + O2
2-phenylethanal + NH3 + H2O2
show the reaction diagram
-
-
-
?
2-phenylethylamine + H2O + O2
2-phenylethanal + NH3 + H2O2
show the reaction diagram
-
-
-
?
2-phenylethylamine + H2O + O2
2-phenylethanal + NH3 + H2O2
show the reaction diagram
-
-
-
-
?
2-phenylethylamine + H2O + O2
2-phenylethanal + NH3 + H2O2
show the reaction diagram
-
-
-
-
-
2-phenylethylamine + H2O + O2
2-phenylethanal + NH3 + H2O2
show the reaction diagram
-
-
-
?
2-phenylethylamine + H2O + O2
2-phenylethanal + NH3 + H2O2
show the reaction diagram
-
-
-
?
2-phenylethylamine + H2O + O2
2-phenylethanal + NH3 + H2O2
show the reaction diagram
-
-
-
?
2-phenylethylamine + H2O + O2
2-phenylethanal + NH3 + H2O2
show the reaction diagram
-
-
-
?
2-phenylethylamine + H2O + O2
2-phenylethanal + NH3 + H2O2
show the reaction diagram
-
-
-
-
?
2-phenylethylamine + H2O + O2
2-phenylethanal + NH3 + H2O2
show the reaction diagram
-
-
-
?
2-phenylethylamine + H2O + O2
2-phenylethanal + NH3 + H2O2
show the reaction diagram
-
-
-
-
?
2-phenylethylamine + H2O + O2
2-phenylethanal + NH3 + H2O2
show the reaction diagram
P21397
-
-
?
2-phenylethylamine + H2O + O2
2-phenylethanal + NH3 + H2O2
show the reaction diagram
-
-
-
-
-
2-phenylethylamine + H2O + O2
2-phenylethanal + NH3 + H2O2
show the reaction diagram
-
-
-
-
?
2-phenylethylamine + H2O + O2
2-phenylethanal + NH3 + H2O2
show the reaction diagram
-
-
-
-
?
2-phenylethylamine + H2O + O2
2-phenylethanal + NH3 + H2O2
show the reaction diagram
-
-
-
-
?
2-phenylethylamine + H2O + O2
2-phenylethanal + NH3 + H2O2
show the reaction diagram
Coregonus lavaretus ludoga
-
-
-
-
?
2-phenylethylamine + H2O + O2
2-phenylethanal + NH3 + H2O2
show the reaction diagram
-
MAO-B selective substrate
-
?
2-phenylethylamine + H2O + O2
2-phenylethanal + NH3 + H2O2
show the reaction diagram
-
MAO-B selective substrate
-
?
2-phenylethylamine + H2O + O2
2-phenylethanal + NH3 + H2O2
show the reaction diagram
-
MAO-B selective substrate
-
-
?
2-phenylethylamine + H2O + O2
2-phenylethanal + NH3 + H2O2
show the reaction diagram
-
MAO-B selective substrate
-
?
2-phenylethylamine + H2O + O2
2-phenylethanal + NH3 + H2O2
show the reaction diagram
P19643, P21396
reaction with MAO-A
-
-
?
2-phenylethylamine + H2O + O2
2-phenylethanal + NH3 + H2O2
show the reaction diagram
P19643, P21396
reaction with MAO-B
-
-
?
2-phenylethylamine + H2O + O2
2-phenylethanal + NH3 + H2O2
show the reaction diagram
-
proposed pathways for amine oxidation: the amine substrate may bind to oxidised enzyme (E/FADox), leading to the release of product imine via a binary (1) or ternary (2) pathway. The relative contributions of these pathways cannot be determined directly by steady-state approaches. In following pathway 1, the unoccupied reduced enzyme (E/FADred) is generated, to which substrate may also bind. Reoxidation of the E/FADred–S species (pathway 3) bypasses direct regeneration of E/FADox, with the consequence that imine released subsequent to this step, whether through the binary or ternary pathways leading from E/FADred–imine, is a product of substrate binding to a second enzyme species
-
-
?
2-phenylethylamine + H2O + O2
2-phenylethanal + NH3 + H2O2
show the reaction diagram
-
9% activity compared to n-propylamine
-
-
?
2-phenylethylamine + H2O + O2
2-phenylethanal + NH3 + H2O2
show the reaction diagram
Rattus norvegicus MAO-A
-
-
-
?
2-phenylethylamine + H2O + O2
?
show the reaction diagram
-
-
-
-
?
2-phenylethylamine + H2O + O2
phenylpyruvate + NH3 + H2O2
show the reaction diagram
-
-
-
-
?
2-phenylethylamine + H2O + O2
2-phenylacetaldehyde + NH3 + H2O2
show the reaction diagram
-
the enzyme shows high substrate specificity for phenethylamine (100% activity)
-
-
?
3-methyl-6-phenyl-3-aza-bicyclo[4.1.0]heptane + H2O + O2
?
show the reaction diagram
-
MAO-B selective substrate, no activity with MAO-A
-
-
?
3-phenyl-3-pyrroline + H2O + O2
4-phenyl-2H-pyrrole + ?
show the reaction diagram
P56560
-
4-phenyl-2H-pyrrole rapidly tautomerizes to 5-phenyl-2H-pyrrole
-
?
3-phenylethylamine + H2O + O2
?
show the reaction diagram
-
-
-
-
?
3-phenylpropylamine + H2O + O2
3-phenylpropanal + NH3 + H2O2
show the reaction diagram
-
-
-
?
3-pyrroline + 2,4,5-trihydroxyphenylalanine quinone + H2O + O2
? + H2O2 + NH3
show the reaction diagram
P56560
3-pyrrolines are mechanism-based inactivators of the quinone-dependent amine oxidases but only substrates of the flavin-dependent amine oxidases
-
-
?
4-aminomethylpyridine dihydrochloride + H2O + O2
?
show the reaction diagram
-
3% substrate activity of 1 mM 4-aminomethylpyridine dihydrochloride as percentage of the activity of the best substrate (serotonin, 1 mM) for various amine oxidases, 4% substrate activity of 1 mM 4-aminomethylpyridine dihydrochloride as percentage of the activity of the best substrate (1 mM) for various amine oxidases
-
-
?
4-carboxybenzylamine + H2O + O2
?
show the reaction diagram
-
-
-
-
?
4-dimethylaminophenethylamine + H2O + O2
?
show the reaction diagram
-
substrate of MAO-B
-
-
?
4-dimethylaminophenylethylamine + H2O + O2
?
show the reaction diagram
-
substrate of MAO-B
-
-
?
4-phenylbutylamine + H2O + O2
4-phenylbutanal + NH3 + H2O2
show the reaction diagram
-
proposed pathways for amine oxidation: the amine substrate may bind to oxidised enzyme (E/FADox), leading to the release of product imine via a binary (1) or ternary (2) pathway. The relative contributions of these pathways cannot be determined directly by steady-state approaches. In following pathway 1, the unoccupied reduced enzyme (E/FADred) is generated, to which substrate may also bind. Reoxidation of the E/FADred–S species (pathway 3) bypasses direct regeneration of E/FADox, with the consequence that imine released subsequent to this step, whether through the binary or ternary pathways leading from E/FADred–imine, is a product of substrate binding to a second enzyme species
-
-
?
4-phenylbutylamine + H2O + O2
?
show the reaction diagram
-
-
-
-
?
4-tryptamine + H2O + O2
?
show the reaction diagram
-
-
-
-
?
4-tyramine + H2O + O2
4-hydroxyphenylacetaldehyde + NH3 + H2O2
show the reaction diagram
-
-
-
-
?
4-tyramine + H2O + O2
4-hydroxyphenylacetaldehyde + NH3 + H2O2
show the reaction diagram
-
in vivo activity, overview
-
-
?
4-tyramine + H2O + O2
4-hydroxyphenylacetaldehyde + NH3 + H2O2
show the reaction diagram
-
substrate for both hMAO-A and hMAO-B
-
-
?
4-tyramine + H2O + O2
?
show the reaction diagram
-
-
-
-
?
4-tyramine + H2O + O2
?
show the reaction diagram
-
substrate for both hMAO-A and hMAO-B
-
-
?
5-hydroxytryptamine + H2O + O2
?
show the reaction diagram
-
-
-
-
?
5-hydroxytryptamine + H2O + O2
(5-hydroxy-1H-indol-3-yl)acetaldehyde + NH3 + H2O2
show the reaction diagram
-
-
-
-
?
5-methoxy-N,N-dimethyltryptamine + H2O O2
?
show the reaction diagram
-
i.e. 5-MeO-DMT, a psychoactive indolealkylamine drug found in a variety of plant preparations, e.g. Virola snuffs and Ayahuasca, and venom of psychoactive toads, e.g. Colorado River Bufo alvarius. 5-MeO-DMT is known as a nonselective 5-HT receptor agonist. MAO-A eliminates the drug 5-MeO-DMT through oxidative deamination
-
-
?
5-methoxy-N,N-dimethyltryptamine + H2O O2
?
show the reaction diagram
-
i.e. 5-MeO-DMT, a psychoactive indolealkylamine drug found in a variety of plant preparations, e.g. Virola snuffs and Ayahuasca, and venom of psychoactive toads, e.g. Colorado River Bufo alvarius
-
-
?
benzylamine + H2O + O2
benzaldehyde + NH3 + H2O2
show the reaction diagram
-
-
-
-
-
benzylamine + H2O + O2
benzaldehyde + NH3 + H2O2
show the reaction diagram
-
-
-
?
benzylamine + H2O + O2
benzaldehyde + NH3 + H2O2
show the reaction diagram
-
-
-
?
benzylamine + H2O + O2
benzaldehyde + NH3 + H2O2
show the reaction diagram
-
-
-
?
benzylamine + H2O + O2
benzaldehyde + NH3 + H2O2
show the reaction diagram
-
-
-
?
benzylamine + H2O + O2
benzaldehyde + NH3 + H2O2
show the reaction diagram
-
-
-
?
benzylamine + H2O + O2
benzaldehyde + NH3 + H2O2
show the reaction diagram
-
-
-
-
?
benzylamine + H2O + O2
benzaldehyde + NH3 + H2O2
show the reaction diagram
-
-
-
?
benzylamine + H2O + O2
benzaldehyde + NH3 + H2O2
show the reaction diagram
-
-
-
?
benzylamine + H2O + O2
benzaldehyde + NH3 + H2O2
show the reaction diagram
-
-
-
?
benzylamine + H2O + O2
benzaldehyde + NH3 + H2O2
show the reaction diagram
-
-
-
?
benzylamine + H2O + O2
benzaldehyde + NH3 + H2O2
show the reaction diagram
-
-
-
-
?
benzylamine + H2O + O2
benzaldehyde + NH3 + H2O2
show the reaction diagram
-
-
-
?
benzylamine + H2O + O2
benzaldehyde + NH3 + H2O2
show the reaction diagram
-
-
-
?
benzylamine + H2O + O2
benzaldehyde + NH3 + H2O2
show the reaction diagram
-
-
-
?
benzylamine + H2O + O2
benzaldehyde + NH3 + H2O2
show the reaction diagram
-
-
-
?
benzylamine + H2O + O2
benzaldehyde + NH3 + H2O2
show the reaction diagram
-
-
-
-
-
benzylamine + H2O + O2
benzaldehyde + NH3 + H2O2
show the reaction diagram
-
-
-
?
benzylamine + H2O + O2
benzaldehyde + NH3 + H2O2
show the reaction diagram
-
-
-
?
benzylamine + H2O + O2
benzaldehyde + NH3 + H2O2
show the reaction diagram
-
-
-
-
?
benzylamine + H2O + O2
benzaldehyde + NH3 + H2O2
show the reaction diagram
-
-
-
?
benzylamine + H2O + O2
benzaldehyde + NH3 + H2O2
show the reaction diagram
-
-
-
?
benzylamine + H2O + O2
benzaldehyde + NH3 + H2O2
show the reaction diagram
-
-
-
-
?
benzylamine + H2O + O2
benzaldehyde + NH3 + H2O2
show the reaction diagram
-
-
-
-
?
benzylamine + H2O + O2
benzaldehyde + NH3 + H2O2
show the reaction diagram
-
-
-
-
?
benzylamine + H2O + O2
benzaldehyde + NH3 + H2O2
show the reaction diagram
-
-
-
-
?
benzylamine + H2O + O2
benzaldehyde + NH3 + H2O2
show the reaction diagram
-
-
-
-
?
benzylamine + H2O + O2
benzaldehyde + NH3 + H2O2
show the reaction diagram
P21397
-
-
-
?
benzylamine + H2O + O2
benzaldehyde + NH3 + H2O2
show the reaction diagram
P27338
-
-
-
?
benzylamine + H2O + O2
benzaldehyde + NH3 + H2O2
show the reaction diagram
P21396
-
-
-
?
benzylamine + H2O + O2
benzaldehyde + NH3 + H2O2
show the reaction diagram
-
-
-
-
?
benzylamine + H2O + O2
benzaldehyde + NH3 + H2O2
show the reaction diagram
-
-
-
-
?
benzylamine + H2O + O2
benzaldehyde + NH3 + H2O2
show the reaction diagram
-
-
-
-
?
benzylamine + H2O + O2
benzaldehyde + NH3 + H2O2
show the reaction diagram
-
-
-
-
?
benzylamine + H2O + O2
benzaldehyde + NH3 + H2O2
show the reaction diagram
-
-
-
-
?
benzylamine + H2O + O2
benzaldehyde + NH3 + H2O2
show the reaction diagram
-
-
-
-
?
benzylamine + H2O + O2
benzaldehyde + NH3 + H2O2
show the reaction diagram
Coregonus lavaretus ludoga
-
-
-
-
?
benzylamine + H2O + O2
benzaldehyde + NH3 + H2O2
show the reaction diagram
-
MAO-B selective substrate
-
-
benzylamine + H2O + O2
benzaldehyde + NH3 + H2O2
show the reaction diagram
-
MAO-B selective substrate
-
?
benzylamine + H2O + O2
benzaldehyde + NH3 + H2O2
show the reaction diagram
-
analogs
-
?
benzylamine + H2O + O2
benzaldehyde + NH3 + H2O2
show the reaction diagram
-
MAO-A
-
-
?
benzylamine + H2O + O2
benzaldehyde + NH3 + H2O2
show the reaction diagram
-
MAO-A
-
-
?
benzylamine + H2O + O2
benzaldehyde + NH3 + H2O2
show the reaction diagram
-
monoamine oxidase B
-
-
?
benzylamine + H2O + O2
benzaldehyde + NH3 + H2O2
show the reaction diagram
-
monoamine oxidase B
-
-
?
benzylamine + H2O + O2
benzaldehyde + NH3 + H2O2
show the reaction diagram
P19643
monoamine oxidase B
-
-
?
benzylamine + H2O + O2
benzaldehyde + NH3 + H2O2
show the reaction diagram
Q8BW75
monoamine oxidase B
-
-
?
benzylamine + H2O + O2
benzaldehyde + NH3 + H2O2
show the reaction diagram
-
monoamine oxidase B
-
-
?
benzylamine + H2O + O2
benzaldehyde + NH3 + H2O2
show the reaction diagram
P19643, P21396
reaction with MAO-A
-
-
?
benzylamine + H2O + O2
benzaldehyde + NH3 + H2O2
show the reaction diagram
P19643, P21396
reaction with MAO-B
-
-
?
benzylamine + H2O + O2
benzaldehyde + NH3 + H2O2
show the reaction diagram
-
insights into the interactions that take place on activation of the amine substrate by the aromatic cage residues in MAO-B Tyr398 and Try435
-
-
?
benzylamine + H2O + O2
benzaldehyde + NH3 + H2O2
show the reaction diagram
-
proposed pathways for amine oxidation: the amine substrate may bind to oxidised enzyme (E/FADox), leading to the release of product imine via a binary (1) or ternary (2) pathway. The relative contributions of these pathways cannot be determined directly by steady-state approaches. In following pathway 1, the unoccupied reduced enzyme (E/FADred) is generated, to which substrate may also bind. Reoxidation of the E/FADred–S species (pathway 3) bypasses direct regeneration of E/FADox, with the consequence that imine released subsequent to this step, whether through the binary or ternary pathways leading from E/FADred–imine, is a product of substrate binding to a second enzyme species
-
-
?
benzylamine + H2O + O2
benzaldehyde + NH3 + H2O2
show the reaction diagram
-
11% activity compared to tyramine
-
-
?
benzylamine + H2O + O2
benzaldehyde + NH3 + H2O2
show the reaction diagram
-
32% activity compared to tyramine
-
-
?
benzylamine + H2O + O2
benzaldehyde + NH3 + H2O2
show the reaction diagram
-
60% activity compared to 2-phenylethylamine
-
-
?
benzylamine + H2O + O2
benzaldehyde + NH3 + H2O2
show the reaction diagram
-
74% activity compared to n-propylamine
-
-
?
benzylamine + H2O + O2
benzylaldehyde + NH3 + H2O2
show the reaction diagram
-
-
-
-
?
benzylamine + H2O + O2
benzylaldehyde + NH3 + H2O2
show the reaction diagram
-
-
-
-
?
benzylamine + O2 + H2O
benzaldehyde + NH3 + H2O2
show the reaction diagram
P19643, P21396
-
-
-
?
beta-phenylethylamine + H2O + O2
beta-phenylethanal + NH3 + H2O2
show the reaction diagram
-
-
-
-
?
beta-phenylethylamine + H2O + O2
2-phenylethanal + NH3 + H2O2
show the reaction diagram
-
-
-
-
?
beta-phenylethylamine + O2 + H2O
beta-phenylethanal + NH3 + H2O2
show the reaction diagram
P19643, P21396
-
-
-
?
dopamine + H2O + O2
(3,4-dihydroxyphenyl)acetaldehyde + NH3 + H2O2
show the reaction diagram
-
-
-
-
?
dopamine + H2O + O2
(3,4-dihydroxyphenyl)acetaldehyde + NH3 + H2O2
show the reaction diagram
-
-
-
?
dopamine + H2O + O2
(3,4-dihydroxyphenyl)acetaldehyde + NH3 + H2O2
show the reaction diagram
-
-
-
?
dopamine + H2O + O2
(3,4-dihydroxyphenyl)acetaldehyde + NH3 + H2O2
show the reaction diagram
-
-
-
?
dopamine + H2O + O2
(3,4-dihydroxyphenyl)acetaldehyde + NH3 + H2O2
show the reaction diagram
-
-
-
?
dopamine + H2O + O2
(3,4-dihydroxyphenyl)acetaldehyde + NH3 + H2O2
show the reaction diagram
-
-
-
?
dopamine + H2O + O2
(3,4-dihydroxyphenyl)acetaldehyde + NH3 + H2O2
show the reaction diagram
-
-
-
?
dopamine + H2O + O2
(3,4-dihydroxyphenyl)acetaldehyde + NH3 + H2O2
show the reaction diagram
-
-
-
-
?
dopamine + H2O + O2
(3,4-dihydroxyphenyl)acetaldehyde + NH3 + H2O2
show the reaction diagram
P21397
-
-
?
dopamine + H2O + O2
(3,4-dihydroxyphenyl)acetaldehyde + NH3 + H2O2
show the reaction diagram
-
-
-
-
?
dopamine + H2O + O2
(3,4-dihydroxyphenyl)acetaldehyde + NH3 + H2O2
show the reaction diagram
Q6NSN2
-
-
-
?
dopamine + H2O + O2
(3,4-dihydroxyphenyl)acetaldehyde + NH3 + H2O2
show the reaction diagram
-
nonselective substrate
-
-
-
dopamine + H2O + O2
?
show the reaction diagram
-
-
-
-
?
epinephrine + H2O + O2
?
show the reaction diagram
-
-
-
-
?
ethanolamine + H2O + O2
glycolaldehyde + NH3 + H2O2
show the reaction diagram
-
50% activity compared to n-propylamine
-
-
?
ethylamine + H2O + O2
ethanal + NH3 + H2O2
show the reaction diagram
-
-
-
?
ethylamine + H2O + O2
ethanal + NH3 + H2O2
show the reaction diagram
-
84% activity compared to n-propylamine
-
-
?
hexylamine + H2O + O2
hexanal + NH3 + H2O2
show the reaction diagram
-
7% activity compared to n-propylamine
-
-
?
histamine + H2O + O2
1H-imidazol-4-ylacetaldehyde + NH3 + H2O2
show the reaction diagram
-
-
-
-
?
histamine + H2O + O2
1H-imidazol-4-ylacetaldehyde + NH3 + H2O2
show the reaction diagram
Coregonus lavaretus ludoga
-
-
-
-
?
histamine + H2O + O2
1H-imidazol-4-ylacetaldehyde + NH3 + H2O2
show the reaction diagram
P19643, P21396
reaction with MAO-B at 1 mM substrate, no activity at 0.1 mM substrate
-
-
?
histamine + H2O + O2
?
show the reaction diagram
-
-
-
-
?
histamine + H2O + O2
?
show the reaction diagram
P19643, P21396
reaction with MAO-A at 1 mM substrate, no activity at 0.1 mM substrate
-
-
?
histamine + O2 + H2O
1H-imidazol-4-ylacetaldehyde + NH3 + H2O2
show the reaction diagram
P19643, P21396
-
-
-
?
kynuramine + H2O + O2
3-(2-aminophenyl)-3-oxopropanal + NH3 + H2O2
show the reaction diagram
-
-
-
?
kynuramine + H2O + O2
3-(2-aminophenyl)-3-oxopropanal + NH3 + H2O2
show the reaction diagram
-
-
-
?
kynuramine + H2O + O2
3-(2-aminophenyl)-3-oxopropanal + NH3 + H2O2
show the reaction diagram
-
-
-
?
kynuramine + H2O + O2
3-(2-aminophenyl)-3-oxopropanal + NH3 + H2O2
show the reaction diagram
-
-
-
?
kynuramine + H2O + O2
3-(2-aminophenyl)-3-oxopropanal + NH3 + H2O2
show the reaction diagram
-
-
-
-
?
kynuramine + H2O + O2
3-(2-aminophenyl)-3-oxopropanal + NH3 + H2O2
show the reaction diagram
-
-
-
-
?
kynuramine + H2O + O2
3-(2-aminophenyl)-3-oxopropanal + NH3 + H2O2
show the reaction diagram
-
-
-
?
kynuramine + H2O + O2
3-(2-aminophenyl)-3-oxopropanal + NH3 + H2O2
show the reaction diagram
-
-
-
?
kynuramine + H2O + O2
3-(2-aminophenyl)-3-oxopropanal + NH3 + H2O2
show the reaction diagram
-
-
-
?
kynuramine + H2O + O2
3-(2-aminophenyl)-3-oxopropanal + NH3 + H2O2
show the reaction diagram
-
-
-
-
?
kynuramine + H2O + O2
3-(2-aminophenyl)-3-oxopropanal + NH3 + H2O2
show the reaction diagram
P21397
-
-
-
?
kynuramine + H2O + O2
3-(2-aminophenyl)-3-oxopropanal + NH3 + H2O2
show the reaction diagram
-
-
-
-
?
kynuramine + H2O + O2
3-(2-aminophenyl)-3-oxopropanal + NH3 + H2O2
show the reaction diagram
P21397
-
-
-
?
kynuramine + H2O + O2
3-(2-aminophenyl)-3-oxopropanal + NH3 + H2O2
show the reaction diagram
-
-
-
-
?
kynuramine + H2O + O2
3-(2-aminophenyl)-3-oxopropanal + NH3 + H2O2
show the reaction diagram
P21396
-
-
-
?
kynuramine + H2O + O2
3-(2-aminophenyl)-3-oxopropanal + NH3 + H2O2
show the reaction diagram
P19643, P21396
-
-
-
?
kynuramine + H2O + O2
3-(2-aminophenyl)-3-oxopropanal + NH3 + H2O2
show the reaction diagram
-
-
-
-
?
kynuramine + H2O + O2
3-(2-aminophenyl)-3-oxopropanal + NH3 + H2O2
show the reaction diagram
-
-
-
-
?
kynuramine + H2O + O2
3-(2-aminophenyl)-3-oxopropanal + NH3 + H2O2
show the reaction diagram
P21398
-
-
-
?
kynuramine + H2O + O2
3-(2-aminophenyl)-3-oxopropanal + NH3 + H2O2
show the reaction diagram
-
-
-
-
?
kynuramine + H2O + O2
3-(2-aminophenyl)-3-oxopropanal + NH3 + H2O2
show the reaction diagram
-
nonselective substrate
-
-
-
kynuramine + H2O + O2
3-(2-aminophenyl)-3-oxopropanal + NH3 + H2O2
show the reaction diagram
-
MAO-A
-
-
?
kynuramine + H2O + O2
3-(2-aminophenyl)-3-oxopropanal + NH3 + H2O2
show the reaction diagram
-
MAO-A
-
-
?
kynuramine + H2O + O2
3-(2-aminophenyl)-3-oxopropanal + NH3 + H2O2
show the reaction diagram
-
MAO-A, MAO-B
-
-
?
kynuramine + H2O + O2
3-(2-aminophenyl)-3-oxopropanal + NH3 + H2O2
show the reaction diagram
-
monoamine oxidase A
-
-
?
kynuramine + H2O + O2
?
show the reaction diagram
-
-
-
-
?
kynuramine + H2O + O2
?
show the reaction diagram
-
-
-
-
?
kynuramine + H2O + O2
4-hydroxyquinoline + NH3 + H2O2
show the reaction diagram
-
-
-
-
?
kynuramine + H2O + O2
4-hydroxyquinoline + NH3 + H2O2
show the reaction diagram
-
-
-
-
?
kynuramine + H2O + O2
4-hydroxyquinoline + NH3 + H2O2
show the reaction diagram
-
-
-
-
?
methoxytryptamine + H2O + O2
?
show the reaction diagram
-
-
-
-
?
methoxytryptamine + H2O + O2
?
show the reaction diagram
-
-
-
-
-
n-butylamine + H2O + O2
butyraldehyde + NH3 + H2O2
show the reaction diagram
-
98% activity compared to n-propylamine
-
-
?
N-methylhistamine + H2O + O2
1H-imidazol-4-ylacetaldehyde + methylamine + H2O2
show the reaction diagram
-
-
-
-
?
N-methylhistamine + H2O + O2
1H-imidazol-4-ylacetaldehyde + methylamine + H2O2
show the reaction diagram
-
-
-
-
?
n-pentylamine + H2O + O2
pentaldehyde + NH3 + H2O2
show the reaction diagram
-
56% activity compared to n-propylamine
-
-
?
n-propylamine + H2O + O2
propionaldehyde + NH3 + H2O2
show the reaction diagram
-
100% activity
-
-
?
noradrenaline + H2O + O2
?
show the reaction diagram
-
-
-
-
?
noradrenaline + H2O + O2
?
show the reaction diagram
-
-
-
-
?
norepinephrine + H2O + O2
?
show the reaction diagram
-
-
-
-
?
p-nitrobenzylamine + H2O + O2
4-nitrobenzaldehyde + NH3 + H2O2
show the reaction diagram
-
poor substrate for wild-type enzyme and mutant enzymes Y435H and Y435F
-
-
?
p-nitrobenzylamine + H2O + O2
4-nitrobenzaldehyde + NH3 + H2O2
show the reaction diagram
-
insights into the interactions that take place on activation of the amine substrate by the aromatic cage residues in MAO-B Tyr398 and Try435
-
-
?
p-nitrophenylethylamine + H2O + O2
4-nitrophenylacetaldehyde + NH3 + H2O2
show the reaction diagram
-
good substrate for wild-type and mutant enzymes Y435H, Y435F, Y435L and Y435W
-
-
?
p-trifluoromethyl-benzylamine + H2O + O2
4-trifluoromethylbenzaldehyde + NH3 + H2O2
show the reaction diagram
-
-
-
-
?
p-tyramine + H2O + O2
(4-hydroxyphenyl)acetaldehyde + NH3 + H2O2
show the reaction diagram
-
-
-
-
?
p-tyramine + H2O + O2
(4-hydroxyphenyl)acetaldehyde + NH3 + H2O2
show the reaction diagram
-
MAO-B
-
-
?
p-tyramine + H2O + O2
4-hydroxyphenylethanal + NH3 + H2O2
show the reaction diagram
-
monoamine oxidase A, monoamine oxidase B
-
-
?
phenylbutylamine + H2O + O2
2-phenylbutanal + NH3 + H2O2 + NH3 + H2O2
show the reaction diagram
-
-
-
-
?
phenylethylamine + H2O + O2
2-phenylethanal + NH3 + H2O2
show the reaction diagram
-
-
-
-
?
phenylethylamine + H2O + O2
2-phenylethanal + NH3 + H2O2
show the reaction diagram
-
-
-
-
?
phenylethylamine + H2O + O2
2-phenylethanal + NH3 + H2O2
show the reaction diagram
-
-
-
-
?
phenylethylamine + H2O + O2
2-phenylethanal + NH3 + H2O2
show the reaction diagram
P21397
-
-
-
?
phenylethylamine + H2O + O2
2-phenylethanal + NH3 + H2O2
show the reaction diagram
P21396
-
-
-
?
phenylethylamine + H2O + O2
2-phenylethanal + NH3 + H2O2
show the reaction diagram
-
-
-
-
?
phenylethylamine + H2O + O2
2-phenylethanal + NH3 + H2O2
show the reaction diagram
Q6NSN2
-
-
-
?
phenylethylamine + H2O + O2
2-phenylethanal + NH3 + H2O2
show the reaction diagram
-
MAO-A
-
-
?
phenylethylamine + H2O + O2
2-phenylethanal + NH3 + H2O2
show the reaction diagram
-
MAO-A
-
-
?
phenylethylamine + H2O + O2
phenylethanal + NH3 + H2O2
show the reaction diagram
-
-
-
-
?
phenylethylamine + H2O + O2
2-phenylethanal + NH3 + H2O2 + NH3 + H2O2
show the reaction diagram
-
-
-
-
?
pyrrolidine + 2,4,5-trihydroxyphenylalanine quinone + H2O + O2
? + H2O2 + NH3
show the reaction diagram
P56560
-
-
-
?
RCH2NH2 + H2O + O2
RCHO + NH3 + H2O2
show the reaction diagram
P21397
-
-
-
?
RCH2NH2 + H2O + O2
RCHO + NH3 + H2O2
show the reaction diagram
-
-
-
-
?
RCH2NH2 + H2O + O2
RCHO + NH3 + H2O2
show the reaction diagram
-
-
-
-
?
RCH2NH2 + H2O + O2
RCHO + NH3 + H2O2
show the reaction diagram
-
-
-
-
?
RCH2NH2 + H2O + O2
RCHO + NH3 + H2O2
show the reaction diagram
-
-
-
-
?
RCH2NH2 + H2O + O2
RCHO + NH3 + H2O2
show the reaction diagram
-
specificity
-
-
?
RCH2NH2 + H2O + O2
RCHO + NH3 + H2O2
show the reaction diagram
-
specificity
-
?
RCH2NH2 + H2O + O2
RCHO + NH3 + H2O2
show the reaction diagram
-
specificity
-
?
RCH2NH2 + H2O + O2
RCHO + NH3 + H2O2
show the reaction diagram
-
no activity with spermidine
-
-
RCH2NH2 + H2O + O2
RCHO + NH3 + H2O2
show the reaction diagram
-
no activity with spermidine
-
-
?
RCH2NH2 + H2O + O2
RCHO + NH3 + H2O2
show the reaction diagram
-
no activity with histamine
-
-
RCH2NH2 + H2O + O2
RCHO + NH3 + H2O2
show the reaction diagram
-
no activity with histamine
-
-
?
RCH2NH2 + H2O + O2
RCHO + NH3 + H2O2
show the reaction diagram
-
no activity with histamine
-
?
RCH2NH2 + H2O + O2
RCHO + NH3 + H2O2
show the reaction diagram
-
no activity with histamine
-
-
?
RCH2NH2 + H2O + O2
RCHO + NH3 + H2O2
show the reaction diagram
-
no activity with spermine
-
-
?
RCH2NH2 + H2O + O2
RCHO + NH3 + H2O2
show the reaction diagram
-
phenylethylhydrazine
-
-
r
RCH2NH2 + H2O + O2
RCHO + NH3 + H2O2
show the reaction diagram
-
phenylethylhydrazine
-
-
?
RCH2NH2 + H2O + O2
RCHO + NH3 + H2O2
show the reaction diagram
-
phenylethylhydrazine
-
r
RCH2NH2 + H2O + O2
RCHO + NH3 + H2O2
show the reaction diagram
-
norepinephrine
-
-
?
RCH2NH2 + H2O + O2
RCHO + NH3 + H2O2
show the reaction diagram
-
norepinephrine, no activity with octopamine
-
-
?
RCH2NH2 + H2O + O2
RCHO + NH3 + H2O2
show the reaction diagram
-
benzylhydrazine
-
?
RCH2NH2 + H2O + O2
RCHO + NH3 + H2O2
show the reaction diagram
-
oxidizes primary, secondary and tertiary amines
-
?
RCH2NH2 + H2O + O2
RCHO + NH3 + H2O2
show the reaction diagram
-
5-hydroxytryptamine, MAO-A selective substrate
-
-
?
RCH2NH2 + H2O + O2
RCHO + NH3 + H2O2
show the reaction diagram
-
5-hydroxytryptamine, MAO-A selective substrate
-
-
?
RCH2NH2 + H2O + O2
RCHO + NH3 + H2O2
show the reaction diagram
-
5-hydroxytryptamine, MAO-A selective substrate
-
?
RCH2NH2 + H2O + O2
RCHO + NH3 + H2O2
show the reaction diagram
-
5-hydroxytryptamine, MAO-A selective substrate
-
-
?
RCH2NH2 + H2O + O2
RCHO + NH3 + H2O2
show the reaction diagram
-
4-hydroxy-3-methoxy-2-phenylethylamine, nonselective substrate, 4-methoxy-2-phenylethylamine, 5-methoxytryptamine
-
-
?
RCH2NH2 + H2O + O2
RCHO + NH3 + H2O2
show the reaction diagram
-
octopamine
-
-
?
RCH2NH2 + H2O + O2
RCHO + NH3 + H2O2
show the reaction diagram
-
isoamylamine
-
-
?
RCH2NH2 + H2O + O2
RCHO + NH3 + H2O2
show the reaction diagram
-
n-butylamine
-
-
?
RCH2NH2 + H2O + O2
RCHO + NH3 + H2O2
show the reaction diagram
-
3-hydroxytyramine
-
-
?
RCH2NH2 + H2O + O2
RCHO + NH3 + H2O2
show the reaction diagram
-
o-, m-, p-chlorobenzylamine, alpha-methylbenzylamine
-
-
?
RCH2NH2 + H2O + O2
RCHO + NH3 + H2O2
show the reaction diagram
-
alpha-methylbenzylamine
-
?
RCH2NH2 + H2O + O2
RCHO + NH3 + H2O2
show the reaction diagram
-
amylamine
-
-
RCH2NH2 + H2O + O2
RCHO + NH3 + H2O2
show the reaction diagram
-
amylamine
-
-
?
RCH2NH2 + H2O + O2
RCHO + NH3 + H2O2
show the reaction diagram
-
responsible for the catabolism of various biogenic amine neurotransmitters as well as for the metabolism of certain exogenous amines
-
?
RCH2NH2 + H2O + O2
RCHO + NH3 + H2O2
show the reaction diagram
-
responsible for the catabolism of various biogenic amine neurotransmitters as well as for the metabolism of certain exogenous amines
-
-
-
RCH2NH2 + H2O + O2
RCHO + NH3 + H2O2
show the reaction diagram
-
responsible for the catabolism of various biogenic amine neurotransmitters as well as for the metabolism of certain exogenous amines
-
-
?
RCH2NH2 + H2O + O2
RCHO + NH3 + H2O2
show the reaction diagram
-
important functions in the metabolism of biogenic amines in the central nervous system and peripheral tissues
-
?
RCH2NH2 + H2O + O2
RCHO + NH3 + H2O2
show the reaction diagram
-
important functions in the metabolism of biogenic amines in the central nervous system and peripheral tissues
-
-
?
RCH2NH2 + H2O + O2
RCHO + NH3 + H2O2
show the reaction diagram
-
important functions in the metabolism of biogenic amines in the central nervous system and peripheral tissues
-
?
RCH2NH2 + H2O + O2
RCHO + NH3 + H2O2
show the reaction diagram
Rattus norvegicus MAO-A
-
-
-
-
?
serotonin + H2O + O2
(5-hydroxy-1H-indol-3-yl)acetaldehyde + NH3 + H2O2
show the reaction diagram
-
-
-
-
?
serotonin + H2O + O2
(5-hydroxy-1H-indol-3-yl)acetaldehyde + NH3 + H2O2
show the reaction diagram
-
-
-
-
-
serotonin + H2O + O2
(5-hydroxy-1H-indol-3-yl)acetaldehyde + NH3 + H2O2
show the reaction diagram
-
-
-
?
serotonin + H2O + O2
(5-hydroxy-1H-indol-3-yl)acetaldehyde + NH3 + H2O2
show the reaction diagram
-
-
-
?
serotonin + H2O + O2
(5-hydroxy-1H-indol-3-yl)acetaldehyde + NH3 + H2O2
show the reaction diagram
-
-
-
?
serotonin + H2O + O2
(5-hydroxy-1H-indol-3-yl)acetaldehyde + NH3 + H2O2
show the reaction diagram
-
-
-
?
serotonin + H2O + O2
(5-hydroxy-1H-indol-3-yl)acetaldehyde + NH3 + H2O2
show the reaction diagram
-
-
-
?
serotonin + H2O + O2
(5-hydroxy-1H-indol-3-yl)acetaldehyde + NH3 + H2O2
show the reaction diagram
-
-
-
-
?
serotonin + H2O + O2
(5-hydroxy-1H-indol-3-yl)acetaldehyde + NH3 + H2O2
show the reaction diagram
-
-
-
?
serotonin + H2O + O2
(5-hydroxy-1H-indol-3-yl)acetaldehyde + NH3 + H2O2
show the reaction diagram
-
-
-
?
serotonin + H2O + O2
(5-hydroxy-1H-indol-3-yl)acetaldehyde + NH3 + H2O2
show the reaction diagram
-
-
-
-
?
serotonin + H2O + O2
(5-hydroxy-1H-indol-3-yl)acetaldehyde + NH3 + H2O2
show the reaction diagram
-
-
-
?
serotonin + H2O + O2
(5-hydroxy-1H-indol-3-yl)acetaldehyde + NH3 + H2O2
show the reaction diagram
-
-
-
-
?
serotonin + H2O + O2
(5-hydroxy-1H-indol-3-yl)acetaldehyde + NH3 + H2O2
show the reaction diagram
-
-
-
-
?
serotonin + H2O + O2
(5-hydroxy-1H-indol-3-yl)acetaldehyde + NH3 + H2O2
show the reaction diagram
-
-
-
-
?
serotonin + H2O + O2
(5-hydroxy-1H-indol-3-yl)acetaldehyde + NH3 + H2O2
show the reaction diagram
-
-
-
-
?
serotonin + H2O + O2
(5-hydroxy-1H-indol-3-yl)acetaldehyde + NH3 + H2O2
show the reaction diagram
P21397
-
-
-
?
serotonin + H2O + O2
(5-hydroxy-1H-indol-3-yl)acetaldehyde + NH3 + H2O2
show the reaction diagram
-
-
-
-
?
serotonin + H2O + O2
(5-hydroxy-1H-indol-3-yl)acetaldehyde + NH3 + H2O2
show the reaction diagram
P21397
-
-
-
?
serotonin + H2O + O2
(5-hydroxy-1H-indol-3-yl)acetaldehyde + NH3 + H2O2
show the reaction diagram
-
-
-
-
?
serotonin + H2O + O2
(5-hydroxy-1H-indol-3-yl)acetaldehyde + NH3 + H2O2
show the reaction diagram
-
-
-
-
?
serotonin + H2O + O2
(5-hydroxy-1H-indol-3-yl)acetaldehyde + NH3 + H2O2
show the reaction diagram
P21396
-
-
-
?
serotonin + H2O + O2
(5-hydroxy-1H-indol-3-yl)acetaldehyde + NH3 + H2O2
show the reaction diagram
-
-
-
-
?
serotonin + H2O + O2
(5-hydroxy-1H-indol-3-yl)acetaldehyde + NH3 + H2O2
show the reaction diagram
Q6NSN2
-
-
-
?
serotonin + H2O + O2
(5-hydroxy-1H-indol-3-yl)acetaldehyde + NH3 + H2O2
show the reaction diagram
-
-
-
-
?
serotonin + H2O + O2
(5-hydroxy-1H-indol-3-yl)acetaldehyde + NH3 + H2O2
show the reaction diagram
-
-
-
-
?
serotonin + H2O + O2
(5-hydroxy-1H-indol-3-yl)acetaldehyde + NH3 + H2O2
show the reaction diagram
-
-
-
-
?
serotonin + H2O + O2
(5-hydroxy-1H-indol-3-yl)acetaldehyde + NH3 + H2O2
show the reaction diagram
Coregonus lavaretus ludoga
-
-
-
-
?
serotonin + H2O + O2
(5-hydroxy-1H-indol-3-yl)acetaldehyde + NH3 + H2O2
show the reaction diagram
-
MAO-A
-
-
?
serotonin + H2O + O2
(5-hydroxy-1H-indol-3-yl)acetaldehyde + NH3 + H2O2
show the reaction diagram
-
MAO-A
-
-
?
serotonin + H2O + O2
(5-hydroxy-1H-indol-3-yl)acetaldehyde + NH3 + H2O2
show the reaction diagram
-
MAO-A
-
-
?
serotonin + H2O + O2
(5-hydroxy-1H-indol-3-yl)acetaldehyde + NH3 + H2O2
show the reaction diagram
-
monoamine oxidase A
-
-
?
serotonin + H2O + O2
(5-hydroxy-1H-indol-3-yl)acetaldehyde + NH3 + H2O2
show the reaction diagram
P19643, P21396
reaction with MAO-A
-
-
?
serotonin + H2O + O2
(5-hydroxy-1H-indol-3-yl)acetaldehyde + NH3 + H2O2
show the reaction diagram
-
MAO A catalyzes the oxidative deamination of monoamine neurotransmitters, such as serotonin. MAO A is a putative target gene directly regulated by a transcription factor encoded by the sex-determining region Y, SRY, gene located on the Y chromosome, via the functional SRY-binding site in the MAO A core promoter
-
-
?
serotonin + H2O + O2
(5-hydroxy-1H-indol-3-yl)acetaldehyde + NH3 + H2O2
show the reaction diagram
-
substrate of MAO-A
-
-
?
serotonin + H2O + O2
(5-hydroxy-1H-indol-3-yl)acetaldehyde + NH3 + H2O2
show the reaction diagram
-
substrate of MAO-A
-
-
?
serotonin + H2O + O2
(5-hydroxy-1H-indol-3-yl)acetaldehyde + NH3 + H2O2
show the reaction diagram
-
27% activity compared to tyramine
-
-
?
serotonin + H2O + O2
(5-hydroxy-1H-indol-3-yl)acetaldehyde + NH3 + H2O2
show the reaction diagram
-
85% activity compared to tyramine
-
-
?
serotonin + H2O + O2
(5-hydroxy-1H-indol-3-yl)acetaldehyde + NH3 + H2O2
show the reaction diagram
Danio rerio Turku
-
MAO-A
-
-
?
serotonin + H2O + O2
(5-hydroxy-1H-indol-3-yl)acetaldehyde + NH3 + H2O
show the reaction diagram
-
-
-
-
?
serotonin + O2 + H2O
(5-hydroxy-1H-indol-3-yl)acetaldehyde + NH3 + H2O2
show the reaction diagram
P19643, P21396
5-hydroxytryptamine, MAO-A
-
-
?
tryptamine + H2O + O2
1H-indol-3-yl-acetaldehyde + NH3 + H2O2
show the reaction diagram
-
-
-
?
tryptamine + H2O + O2
1H-indol-3-yl-acetaldehyde + NH3 + H2O2
show the reaction diagram
-
-
-
?
tryptamine + H2O + O2
1H-indol-3-yl-acetaldehyde + NH3 + H2O2
show the reaction diagram
-
-
-
?
tryptamine + H2O + O2
1H-indol-3-yl-acetaldehyde + NH3 + H2O2
show the reaction diagram
-
-
-
?
tryptamine + H2O + O2
1-H-indol-3-yl-acetaldehyde + NH3 + H2O2
show the reaction diagram
-
-
-
-
-
tryptamine + H2O + O2
1-H-indol-3-yl-acetaldehyde + NH3 + H2O2
show the reaction diagram
-
-
-
-
?
tryptamine + H2O + O2
1-H-indol-3-yl-acetaldehyde + NH3 + H2O2
show the reaction diagram
-
-
-
-
?
tryptamine + H2O + O2
1-H-indol-3-yl-acetaldehyde + NH3 + H2O2
show the reaction diagram
Coregonus lavaretus ludoga
-
-
-
-
?
tryptamine + H2O + O2
1-H-indol-3-yl-acetaldehyde + NH3 + H2O2
show the reaction diagram
-
73% activity compared to tyramine
-
-
?
tryptamine + H2O + O2
1-H-indol-3-yl-acetaldehyde + NH3 + H2O2
show the reaction diagram
-
80% activity compared to tyramine
-
-
?
tryptamine + H2O + O2
?
show the reaction diagram
-
-
-
-
?
tryptamine + H2O + O2
(1H-indol-3-yl)acetaldehyde + NH3 + H2O2
show the reaction diagram
-
-
-
-
?
tyramine + H2O + O2
4-hydroxyphenylethanal + NH3 + H2O2
show the reaction diagram
-
-
-
-
?
tyramine + H2O + O2
4-hydroxyphenylethanal + NH3 + H2O2
show the reaction diagram
-
-
-
-
?
tyramine + H2O + O2
(4-hydroxyphenyl)acetaldehyde + NH3 + H2O2
show the reaction diagram
-
-
-
?
tyramine + H2O + O2
(4-hydroxyphenyl)acetaldehyde + NH3 + H2O2
show the reaction diagram
-
-
-
?
tyramine + H2O + O2
(4-hydroxyphenyl)acetaldehyde + NH3 + H2O2
show the reaction diagram
-
-
-
?
tyramine + H2O + O2
(4-hydroxyphenyl)acetaldehyde + NH3 + H2O2
show the reaction diagram
-
-
-
?
tyramine + H2O + O2
(4-hydroxyphenyl)acetaldehyde + NH3 + H2O2
show the reaction diagram
-
-
-
?
tyramine + H2O + O2
(4-hydroxyphenyl)acetaldehyde + NH3 + H2O2
show the reaction diagram
-
-
-
?
tyramine + H2O + O2
(4-hydroxyphenyl)acetaldehyde + NH3 + H2O2
show the reaction diagram
-
-
-
?
tyramine + H2O + O2
(4-hydroxyphenyl)acetaldehyde + NH3 + H2O2
show the reaction diagram
-
-
-
?
tyramine + H2O + O2
(4-hydroxyphenyl)acetaldehyde + NH3 + H2O2
show the reaction diagram
-
-
-
?
tyramine + H2O + O2
(4-hydroxyphenyl)acetaldehyde + NH3 + H2O2
show the reaction diagram
-
-
-
?
tyramine + H2O + O2
(4-hydroxyphenyl)acetaldehyde + NH3 + H2O2
show the reaction diagram
-
-
-
-
?
tyramine + H2O + O2
(4-hydroxyphenyl)acetaldehyde + NH3 + H2O2
show the reaction diagram
-
-
-
?
tyramine + H2O + O2
(4-hydroxyphenyl)acetaldehyde + NH3 + H2O2
show the reaction diagram
-
-
-
?
tyramine + H2O + O2
(4-hydroxyphenyl)acetaldehyde + NH3 + H2O2
show the reaction diagram
-
-
-
-
?
tyramine + H2O + O2
(4-hydroxyphenyl)acetaldehyde + NH3 + H2O2
show the reaction diagram
-
-
-
-
?
tyramine + H2O + O2
(4-hydroxyphenyl)acetaldehyde + NH3 + H2O2
show the reaction diagram
-
-
-
-
?
tyramine + H2O + O2
(4-hydroxyphenyl)acetaldehyde + NH3 + H2O2
show the reaction diagram
Q6NSN2
-
-
-
?
tyramine + H2O + O2
(4-hydroxyphenyl)acetaldehyde + NH3 + H2O2
show the reaction diagram
-
-
-
-
?
tyramine + H2O + O2
(4-hydroxyphenyl)acetaldehyde + NH3 + H2O2
show the reaction diagram
-
-
-
-
?
tyramine + H2O + O2
(4-hydroxyphenyl)acetaldehyde + NH3 + H2O2
show the reaction diagram
-
-
-
-
?
tyramine + H2O + O2
(4-hydroxyphenyl)acetaldehyde + NH3 + H2O2
show the reaction diagram
-, Q0PGS2
-
-
-
?
tyramine + H2O + O2
(4-hydroxyphenyl)acetaldehyde + NH3 + H2O2
show the reaction diagram
Coregonus lavaretus ludoga
-
-
-
-
?
tyramine + H2O + O2
(4-hydroxyphenyl)acetaldehyde + NH3 + H2O2
show the reaction diagram
-
nonselective substrate
-
?
tyramine + H2O + O2
(4-hydroxyphenyl)acetaldehyde + NH3 + H2O2
show the reaction diagram
-
nonselective substrate
-
?
tyramine + H2O + O2
(4-hydroxyphenyl)acetaldehyde + NH3 + H2O2
show the reaction diagram
-
nonselective substrate
-
?
tyramine + H2O + O2
(4-hydroxyphenyl)acetaldehyde + NH3 + H2O2
show the reaction diagram
-
100% activity
-
-
?
tyramine + H2O + O2
(4-hydroxyphenyl)acetaldehyde + NH3 + H2O2
show the reaction diagram
P19643, P21396
reaction with MAO-A
-
-
?
tyramine + H2O + O2
(4-hydroxyphenyl)acetaldehyde + NH3 + H2O2
show the reaction diagram
P19643, P21396
reaction with MAO-B
-
-
?
tyramine + H2O + O2
(4-hydroxyphenyl)acetaldehyde + NH3 + H2O2
show the reaction diagram
-
H2O2-generated during tyramine oxidation by MAO-A triggers a stress-induced mitogenic signaling via the MMP2/sphingolipid pathway, which could participate in excessive remodeling and alteration of the vascular wall
-
-
?
tyramine + H2O + O2
(4-hydroxyphenyl)acetaldehyde + NH3 + H2O2
show the reaction diagram
Rattus norvegicus MAO-A
-
-
-
?
tyramine + H2O + O2
?
show the reaction diagram
-
-
-
-
?
tyramine + H2O + O2
?
show the reaction diagram
-
-
-
-
?
tyramine + O2 + H2O
(4-hydroxyphenyl)acetaldehyde + NH3 + H2O2
show the reaction diagram
P19643, P21396
-
-
-
?
methylamine + H2O + O2
formaldehyde + NH3 + H2O2
show the reaction diagram
-
34% activity compared to n-propylamine
-
-
?
additional information
?
-
-
enzyme is involved in the degradation of many biological amines in the nervous system and in peripheral organs
-
-
-
additional information
?
-
P21396
the enzyme catalyzes the degradation of neurotransmitters in the central nervous system and is the target for anti-depression drug design
-
-
-
additional information
?
-
-
the enzyme is involved in brain and peripheral oxidative catabolism of neurotransmitters and xenobiotic amines, including neurotoxic amines. Smokers have a 30% lower activity of peripheral and brain MAO-A compared to smokers, the enzyme is involved in brain and peripheral oxidative catabolism of neurotransmitters and xenobiotic amines, including neurotoxic amines. Smokers have a 40% lower activity of peripheral and brain MAO-B compared to smokers
-
-
-
additional information
?
-
-
no significant activity with serotonin
-
-
-
additional information
?
-
-
key enzyme for the degradation of neurotransmitters serotonin, norepinephrine, and dopamine. Differential regulation of MAO A by glucocorticoid and androgen
-
-
-
additional information
?
-
-
substrate activation of MAO can interact with adipocyte metabolism by mimicking diverse effects of insulin in addition to preventing tumor necrosis factor alpha-dependent responses
-
-
-
additional information
?
-
-
the enzyme is involved in brain and peripheral oxidative catabolism of neurotransmitters and xenobiotic amines
-
-
-
additional information
?
-
-
MAO-A shows no activity with 3-methyl-6-phenyl-3-aza-bicyclo[4.1.0]heptane
-
-
-
additional information
?
-
P19643, P21396
MAOB shows no activity with serotonin
-
-
-
additional information
?
-
Q64133
MAO A KO mice display attenuated endocrine responses to major stressors, such as restraint, cold temperature, prolonged water deprivation and chronic variable stress
-
-
-
additional information
?
-
-
MAO B is a stable trait marker for alcoholism. The associations obtained between platelet MAO B activity with executive neurocognitive task and hostility component may support the involvement of plateletMAOB activity in the further development of an impulsive cognitive style
-
-
-
additional information
?
-
P21397, P27338
active site structure, overview
-
-
-
additional information
?
-
P19643, P21396
active site structure, overview
-
-
-
additional information
?
-
Q64133
MAO A deficiency in Tg8 mice is accompanied by increased expression of different kinds of aggression, as well as by disruption of normal pattern of social interaction
-
-
-
additional information
?
-
P46882
the enzyme is used to successfully identify the alkaloid (+/-)-crispine A as a target for chemo-enzymatic deracemisation yielding the biologically active (R)-enantiomer in 97% enantiomeric excess
-
-
-
additional information
?
-
-
in the catalytic cycle of MAO-B, one mol each of an iminiumyl intermediate that is hydrolyzed to the aldehyde product and H2O2 are produced for each mol of monoamine substrate oxidized. These catabolic products may be neurotoxic if not rapidly inactivated by centrally located aldehyde dehydrogenase and glutathione peroxidase, respectively
-
-
-
additional information
?
-
-
MAO-A degrades monoamines including neurotransmitters
-
-
-
additional information
?
-
-
isozyme active site structures, overview
-
-
-
additional information
?
-
-
molecular modelling of MAO-B ligand binding, overview
-
-
-
additional information
?
-
-
structure-activity studies on wild-type and mutant enzymes, active site structure, overview
-
-
-
additional information
?
-
-
substrate specificity, overview, no activity with histamine
-
-
-
additional information
?
-
-
ABTS assay is used to measure total antioxidant activity of nitroindazoles against the radical ABTS*+, overview
-
-
-
additional information
?
-
-
active site cavities in MAO-B and in MAO-A, in MAO-B the cavity is extended and substrate binding is likely to occur in proximity to the outer mitochondrial membrane surface region with the entrance loop, residues 99-110, involved in the access, overview
-
-
-
additional information
?
-
-
development of a facile capillary electrophoresis method for detection of MAO-B activity in plant extracts, evaluation, overview
-
-
-
additional information
?
-
-
3-aminomethylpyridine is not a substrate
-
-
-
additional information
?
-
-
no activity with tryptamine, serotonin, dopamine, tyramine, histamine, putrescine, cadaverine, diaminodecane, spermidine, and spermine
-
-
-
additional information
?
-
-
no activity with tyramine, tryptamine, serotonin, dopamine, ethanolamine, histamine, ethylamine, n-propylamine, n-butylamine, n-pentylamine, putrescine, and spermidine
-
-
-
additional information
?
-
-
the enzyme does not deaminate histamine
-
-
-
additional information
?
-
-
the enzyme does not deaminate histamine and putrescine
-
-
-
additional information
?
-
-
the enzyme does not deaminate putrescine and cadaverine
-
-
-
NATURAL SUBSTRATES
NATURAL PRODUCTS
REACTION DIAGRAM
ORGANISM
UNIPROT ACCESSION NO.
COMMENTARY
(Substrate)
LITERATURE
(Substrate)
COMMENTARY
(Product)
LITERATURE
(Product)
REVERSIBILITY
r=reversible
ir=irreversible
?=not specified
1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine + H2O + O2
?
show the reaction diagram
-
1-methyl-4-phenylpyridinium is the ultimate product
-
-
?
2 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine + 2 H2O + 3 O2
1-methyl-4-phenyl-2,3-dihydropyridinium + 1-methyl-4-phenylpyridinium + 4 H2O2
show the reaction diagram
-
activation of the neurotoxin to neurotoxic pyridinium cations. MPTP easily crosses the blood-brain barrier and is preferentially metabolized by MAO-B present in glial cells to 1-methyl-4-phenyl-2,3-dihydropyridinium. This enzymatic metabolite is subsequently oxidized to 1-methyl-4-phenylpyridinium, which is selectively uptaken by dopaminergic cells, producing inhibition of complex I of mitochondria, energy depletion, oxidative stress and cell death
1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine is metabolically oxidized by alpha-carbon oxidation by MAO enzymes to give 1-methyl-4-phenyl-2,3-dihydropyridinium and hydrogen peroxide, which, in a further step, is readily oxidized to 1-methyl-4-phenylpyridinium, that is a directly-acting neurotoxic substance
-
?
2-phenylethylamine + H2O + O2
2-phenylethanal + NH3 + H2O2
show the reaction diagram
Coregonus lavaretus ludoga
-
-
-
-
?
2-phenylethylamine + H2O + O2
?
show the reaction diagram
-
-
-
-
?
3-phenylethylamine + H2O + O2
?
show the reaction diagram
-
-
-
-
?
4-dimethylaminophenylethylamine + H2O + O2
?
show the reaction diagram
-
substrate of MAO-B
-
-
?
4-tyramine + H2O + O2
4-hydroxyphenylacetaldehyde + NH3 + H2O2
show the reaction diagram
-
in vivo activity, overview
-
-
?
5-hydroxytryptamine + H2O + O2
(5-hydroxy-1H-indol-3-yl)acetaldehyde + NH3 + H2O2
show the reaction diagram
-
-
-
-
?
5-methoxy-N,N-dimethyltryptamine + H2O O2
?
show the reaction diagram
-
i.e. 5-MeO-DMT, a psychoactive indolealkylamine drug found in a variety of plant preparations, e.g. Virola snuffs and Ayahuasca, and venom of psychoactive toads, e.g. Colorado River Bufo alvarius. 5-MeO-DMT is known as a nonselective 5-HT receptor agonist. MAO-A eliminates the drug 5-MeO-DMT through oxidative deamination
-
-
?
benzylamine + H2O + O2
benzaldehyde + NH3 + H2O2
show the reaction diagram
-
-
-
-
?
benzylamine + H2O + O2
benzaldehyde + NH3 + H2O2
show the reaction diagram
-
-
-
-
?
benzylamine + H2O + O2
benzaldehyde + NH3 + H2O2
show the reaction diagram
-
-
-
-
?
benzylamine + H2O + O2
benzaldehyde + NH3 + H2O2
show the reaction diagram
-
-
-
-
?
benzylamine + H2O + O2
benzaldehyde + NH3 + H2O2
show the reaction diagram
Coregonus lavaretus ludoga
-
-
-
-
?
benzylamine + H2O + O2
benzaldehyde + NH3 + H2O2
show the reaction diagram
-
MAO-A
-
-
?
benzylamine + H2O + O2
benzylaldehyde + NH3 + H2O2
show the reaction diagram
-
-
-
-
?
benzylamine + H2O + O2
benzylaldehyde + NH3 + H2O2
show the reaction diagram
-
-
-
-
?
dopamine + H2O + O2
(3,4-dihydroxyphenyl)acetaldehyde + NH3 + H2O2
show the reaction diagram
-
-
-
-
?
dopamine + H2O + O2
(3,4-dihydroxyphenyl)acetaldehyde + NH3 + H2O2
show the reaction diagram
-
-
-
-
?
dopamine + H2O + O2
(3,4-dihydroxyphenyl)acetaldehyde + NH3 + H2O2
show the reaction diagram
-
-
-
-
?
dopamine + H2O + O2
?
show the reaction diagram
-
-
-
-
?
epinephrine + H2O + O2
?
show the reaction diagram
-
-
-
-
?
histamine + H2O + O2
1H-imidazol-4-ylacetaldehyde + NH3 + H2O2
show the reaction diagram
Coregonus lavaretus ludoga
-
-
-
-
?
histamine + H2O + O2
?
show the reaction diagram
-
-
-
-
?
kynuramine + H2O + O2
3-(2-aminophenyl)-3-oxopropanal + NH3 + H2O2
show the reaction diagram
-
-
-
-
?
kynuramine + H2O + O2
3-(2-aminophenyl)-3-oxopropanal + NH3 + H2O2
show the reaction diagram
-
-
-
-
?
kynuramine + H2O + O2
3-(2-aminophenyl)-3-oxopropanal + NH3 + H2O2
show the reaction diagram
-
-
-
-
?
noradrenaline + H2O + O2
?
show the reaction diagram
-
-
-
-
?
norepinephrine + H2O + O2
?
show the reaction diagram
-
-
-
-
?
phenylethylamine + H2O + O2
2-phenylethanal + NH3 + H2O2
show the reaction diagram
-
-
-
-
?
phenylethylamine + H2O + O2
2-phenylethanal + NH3 + H2O2
show the reaction diagram
-
MAO-A
-
-
?
RCH2NH2 + H2O + O2
RCHO + NH3 + H2O2
show the reaction diagram
-
-
-
-
?
RCH2NH2 + H2O + O2
RCHO + NH3 + H2O2
show the reaction diagram
-
-
-
-
?
RCH2NH2 + H2O + O2
RCHO + NH3 + H2O2
show the reaction diagram
-
responsible for the catabolism of various biogenic amine neurotransmitters as well as for the metabolism of certain exogenous amines
-
?
RCH2NH2 + H2O + O2
RCHO + NH3 + H2O2
show the reaction diagram
-
responsible for the catabolism of various biogenic amine neurotransmitters as well as for the metabolism of certain exogenous amines
-
-
-
RCH2NH2 + H2O + O2
RCHO + NH3 + H2O2
show the reaction diagram
-
responsible for the catabolism of various biogenic amine neurotransmitters as well as for the metabolism of certain exogenous amines
-
-
?
RCH2NH2 + H2O + O2
RCHO + NH3 + H2O2
show the reaction diagram
-
important functions in the metabolism of biogenic amines in the central nervous system and peripheral tissues
-
?
RCH2NH2 + H2O + O2
RCHO + NH3 + H2O2
show the reaction diagram
-
important functions in the metabolism of biogenic amines in the central nervous system and peripheral tissues
-
-
?
RCH2NH2 + H2O + O2
RCHO + NH3 + H2O2
show the reaction diagram
-
important functions in the metabolism of biogenic amines in the central nervous system and peripheral tissues
-
?
RCH2NH2 + H2O + O2
RCHO + NH3 + H2O2
show the reaction diagram
Rattus norvegicus MAO-A
-
-
-
-
?
serotonin + H2O + O2
(5-hydroxy-1H-indol-3-yl)acetaldehyde + NH3 + H2O2
show the reaction diagram
-
-
-
-
?
serotonin + H2O + O2
(5-hydroxy-1H-indol-3-yl)acetaldehyde + NH3 + H2O2
show the reaction diagram
-
-
-
-
?
serotonin + H2O + O2
(5-hydroxy-1H-indol-3-yl)acetaldehyde + NH3 + H2O2
show the reaction diagram
-
-
-
-
?
serotonin + H2O + O2
(5-hydroxy-1H-indol-3-yl)acetaldehyde + NH3 + H2O2
show the reaction diagram
-
-
-
-
?
serotonin + H2O + O2
(5-hydroxy-1H-indol-3-yl)acetaldehyde + NH3 + H2O2
show the reaction diagram
-
-
-
-
?
serotonin + H2O + O2
(5-hydroxy-1H-indol-3-yl)acetaldehyde + NH3 + H2O2
show the reaction diagram
Coregonus lavaretus ludoga
-
-
-
-
?
serotonin + H2O + O2
(5-hydroxy-1H-indol-3-yl)acetaldehyde + NH3 + H2O2
show the reaction diagram
-
MAO-A
-
-
?
serotonin + H2O + O2
(5-hydroxy-1H-indol-3-yl)acetaldehyde + NH3 + H2O2
show the reaction diagram
-
MAO-A
-
-
?
serotonin + H2O + O2
(5-hydroxy-1H-indol-3-yl)acetaldehyde + NH3 + H2O2
show the reaction diagram
-
MAO A catalyzes the oxidative deamination of monoamine neurotransmitters, such as serotonin. MAO A is a putative target gene directly regulated by a transcription factor encoded by the sex-determining region Y, SRY, gene located on the Y chromosome, via the functional SRY-binding site in the MAO A core promoter
-
-
?
serotonin + H2O + O2
(5-hydroxy-1H-indol-3-yl)acetaldehyde + NH3 + H2O2
show the reaction diagram
-
substrate of MAO-A
-
-
?
serotonin + H2O + O2
(5-hydroxy-1H-indol-3-yl)acetaldehyde + NH3 + H2O2
show the reaction diagram
-
substrate of MAO-A
-
-
?
serotonin + H2O + O2
(5-hydroxy-1H-indol-3-yl)acetaldehyde + NH3 + H2O2
show the reaction diagram
Danio rerio Turku
-
MAO-A
-
-
?
tryptamine + H2O + O2
1-H-indol-3-yl-acetaldehyde + NH3 + H2O2
show the reaction diagram
Coregonus lavaretus ludoga
-
-
-
-
?
tryptamine + H2O + O2
(1H-indol-3-yl)acetaldehyde + NH3 + H2O2
show the reaction diagram
-
-
-
-
?
tyramine + H2O + O2
(4-hydroxyphenyl)acetaldehyde + NH3 + H2O2
show the reaction diagram
-
-
-
-
?
tyramine + H2O + O2
(4-hydroxyphenyl)acetaldehyde + NH3 + H2O2
show the reaction diagram
Coregonus lavaretus ludoga
-
-
-
-
?
tyramine + H2O + O2
(4-hydroxyphenyl)acetaldehyde + NH3 + H2O2
show the reaction diagram
-
H2O2-generated during tyramine oxidation by MAO-A triggers a stress-induced mitogenic signaling via the MMP2/sphingolipid pathway, which could participate in excessive remodeling and alteration of the vascular wall
-
-
?
tyramine + H2O + O2
?
show the reaction diagram
-
-
-
-
?
tyramine + H2O + O2
?
show the reaction diagram
-
-
-
-
?
kynuramine + H2O + O2
3-(2-aminophenyl)-3-oxopropanal + NH3 + H2O2
show the reaction diagram
-
MAO-A
-
-
?
additional information
?
-
-
enzyme is involved in the degradation of many biological amines in the nervous system and in peripheral organs
-
-
-
additional information
?
-
P21396
the enzyme catalyzes the degradation of neurotransmitters in the central nervous system and is the target for anti-depression drug design
-
-
-
additional information
?
-
-
the enzyme is involved in brain and peripheral oxidative catabolism of neurotransmitters and xenobiotic amines, including neurotoxic amines. Smokers have a 30% lower activity of peripheral and brain MAO-A compared to smokers, the enzyme is involved in brain and peripheral oxidative catabolism of neurotransmitters and xenobiotic amines, including neurotoxic amines. Smokers have a 40% lower activity of peripheral and brain MAO-B compared to smokers
-
-
-
additional information
?
-
-
key enzyme for the degradation of neurotransmitters serotonin, norepinephrine, and dopamine. Differential regulation of MAO A by glucocorticoid and androgen
-
-
-
additional information
?
-
-
substrate activation of MAO can interact with adipocyte metabolism by mimicking diverse effects of insulin in addition to preventing tumor necrosis factor alpha-dependent responses
-
-
-
additional information
?
-
-
the enzyme is involved in brain and peripheral oxidative catabolism of neurotransmitters and xenobiotic amines
-
-
-
additional information
?
-
Q64133
MAO A KO mice display attenuated endocrine responses to major stressors, such as restraint, cold temperature, prolonged water deprivation and chronic variable stress
-
-
-
additional information
?
-
-
MAO B is a stable trait marker for alcoholism. The associations obtained between platelet MAO B activity with executive neurocognitive task and hostility component may support the involvement of plateletMAOB activity in the further development of an impulsive cognitive style
-
-
-
additional information
?
-
-
in the catalytic cycle of MAO-B, one mol each of an iminiumyl intermediate that is hydrolyzed to the aldehyde product and H2O2 are produced for each mol of monoamine substrate oxidized. These catabolic products may be neurotoxic if not rapidly inactivated by centrally located aldehyde dehydrogenase and glutathione peroxidase, respectively
-
-
-
additional information
?
-
-
MAO-A degrades monoamines including neurotransmitters
-
-
-
COFACTOR
ORGANISM
UNIPROT ACCESSION NO.
COMMENTARY
LITERATURE
IMAGE
8alpha-S-cysteinyl-FAD
-
1 mol per mol of enzyme
FAD
-
the attachment to the enzyme may require a pocket constructed partially of tyrosine residues. Through the interactions among the aromatic rings of the tyrosine residues and that of FAD via pi-pi cloud, the enzyme forms a catalytic center and adopts a stable conformation
FAD
-
covalently bound
FAD
-
Lys296, Trp388, and Tyr398 may be involved in the non-covalent binding to FAD; Lys305, Trp397, and Tyr407 may be involved in the non-covalent binding to FAD
FAD
-
cofactor burried in the inside of the molecule, cofactor acts covalently with Cys406
FAD
-
one mol of covalent FAD per mol of enzyme
FAD
-
dependent on
FAD
-
covalently bound; the enzyme contains a covalently bound FAD
FAD
-
covalently bound at the active site
FAD
-
covalently bound at the active site, MAO-A and MAO-B binding structure, overview
FAD
-
covalently bound at the active site
FAD
-
FAD-binding site sequence, overview
FAD
-
one mol of covalent flavin cofactor per mol of enzyme
FAD
-
the enzyme contains 2 mol of FAD per 220000 g of enzyme
FAD
Coregonus lavaretus ludoga
-
-
FAD
-
dependent on
flavin
-
noncovalently bound flavin
flavin
-
1 mol of flavin: per 100000 g of protein
flavin
-
1 mol FAD per 114000 g of protein
flavin
-
1 mol FAD per mol of MAO B is covalently bound by an 8-alpha-S-cysteinyl 397 linkage
flavin
-
MAO-A contain 1 mol of 8-alpha-S-cysteinyl 406 FAD per mol
flavin
-
tyrosine residues near Cys406 may form a pocket to facilitate FAD incorporation and a stable conformation, probably through interactions among the aromatic rings of the tyrosine residues and FAD
flavin
-
1 mol FAD per 115000 g of protein; flavoprotein
flavin
-
flavoprotein
flavin
-
1 flavin per subunit; flavoprotein
flavin
-
flavoprotein
flavin
-
FAD covalently attached to each subunit of the apoprotein; flavoprotein
flavin
-
contains 2 subunits: only one of which possesses covalently linked flavin
flavin
-
only one of two subunits contains 8-alpha-cysteinyl FAD
flavin
-
covalent coupling of FAD to MAO occurs specifically at the -SH-groups of cysteine
flavin
-
two forms of the enzyme: a catalytically active form with covalently bound FAD and an inactive form
flavin
-
FAD is positioned in MAO-B through noncovalent binding at Glu34 and Tyr44 and covalent linkage at Cys397
flavin
-
FAD is covalent linkage at Cys406 in MAO-A and is not essentiell for the catalytically activity
flavin
-
speculation that, when an amine oxidized, electrons pass from the amine to the disulfide and then to the flavin
flavin
P21397
characterization of the covalently bound anionic flavin radical in monoamine oxidase A by electron paramagnetic resonance
flavin
P21397, P27338
covalent flavin cofactor present in the MAO active sites; covalent flavin cofactor present in the MAO active sites
flavin
-
covalent flavin cofactor present in the MAO active sites; covalent flavin cofactor present in the MAO active sites
flavin
-, P27338
;
flavin
-
dependent on; dependent on
flavin
-
comparison of flavin fluorescence and circular dichroism spectral properties of wild-type MAO A and of the MAO A Ser209 mutant proteins
METALS and IONS
ORGANISM
UNIPROT ACCESSION NO.
COMMENTARY
LITERATURE
Cu2+
-
0.00014-0.00015 mg copper per mg of protein, nonessential for activity
Cu2+
-
1 gatom of copper per 59000 g of protein
Cu2+
-
negligible amounts in the purified enzym
Cu2+
-
the enzyme contains 2.44 mol of copper atoms per mole of enzyme
Mn2+
-
133% activity at 0.1 mM Mn2+
INHIBITORS
ORGANISM
UNIPROT ACCESSION NO.
COMMENTARY
LITERATURE
IMAGE
(+)-amphetamine
-
reversible competitive inhibitor
-
(+/-)-6-hydroxytrypargine
-
an indolylalkaloid toxin enzyme inhibitor from the venom of the colonial spider Parawixia bistriata, synthesized by reaction of 5-hydroxytryptamine hydrochloride with N-(3-[1,3]dioxolan-2-yl-propyl)-guanidine sulfate, overview
(-)-deprenyl
P21936
;
(-)-L-deprenyl
-
-
(1E,2E)-3-(furan-2-yl)-N-(prop-2-yn-1-yl)prop-2-en-1-imine
-
-
(1R,2R)-(-)-psi-ephedrine
-
IC50 for soluble enzyme: 5.03 mM, IC50 for immobilized enzyme: 88 mM, monoamine oxidase B; IC50 for soluble enzyme: 5.35 mM, IC50 for immobilized enzyme: 14.86 mM, monoamine oxidase A
(1S,2S)-(+)-psi-ephedrine
-
IC50 for soluble enzyme: 0.88 mM, IC50 for immobilized enzyme: 1.77 mM, monoamine oxidase A; IC50 for soluble enzyme: 10 mM, IC50 for immobilized enzyme: 234 mM, monoamine oxidase B
(1Z)-2-methylcyclohexanone (4-phenyl-1,3-thiazol-2-yl)hydrazone
-
pKi: 7.39
(2-methylprop-2-en-1-yl)hydrazine
-
;
(2-phenylprop-2-en-1-yl)hydrazine
-
;
(2E)-1,3-diphenylprop-2-en-1-one
-
-
(2E)-1-(2-hydroxy-4-[(3-methylbut-2-en-1-yl)oxy]phenyl)-3-(4-methoxyphenyl)prop-2-en-1-one
-
-
-
(2E)-1-(2-hydroxy-4-[(3-methylbut-2-en-1-yl)oxy]phenyl)-3-(4-methylphenyl)prop-2-en-1-one
-
-
-
(2E)-1-(2-hydroxy-4-[(3-methylbut-2-en-1-yl)oxy]phenyl)-3-phenylprop-2-en-1-one
-
-
-
(2E)-1-[4-(benzyloxy)phenyl]-3-(4-chlorophenyl)prop-2-en-1-one
-
-
(2E)-2-[6-[(3-chlorobenzyl)oxy]-1-benzofuran-3(2H)-ylidene]-N-methylacetamide
-
-
-
(2E)-3-(3-chlorophenyl)-N-(2-methyl-1H-indol-5-yl)prop-2-enamide
-
-
-
(2E)-3-(4-chlorophenyl)-1-(2,4-dihydroxyphenyl)prop-2-en-1-one
-
inhibits MAO-A and MAO-B
(2E)-3-(4-chlorophenyl)-1-(2-hydroxy-4-methoxyphenyl)prop-2-en-1-one
-
-
(2E)-3-(4-chlorophenyl)-1-(2-hydroxy-4-[(3-methylbut-2-en-1-yl)oxy]phenyl)prop-2-en-1-one
-
-
-
(2E)-3-(4-chlorophenyl)-1-(2-hydroxyphenyl)prop-2-en-1-one
-
-
(2E)-3-(4-chlorophenyl)-1-(4-fluoro-2-hydroxyphenyl)prop-2-en-1-one
-
-
(2E)-3-(4-chlorophenyl)-1-(4-hydroxyphenyl)prop-2-en-1-one
-
-
(2E)-3-(4-chlorophenyl)-1-(4-methoxyphenyl)prop-2-en-1-one
-
-
(2E)-3-[4-(benzyloxy)phenyl]-1-(2-hydroxy-4-[(3-methylbut-2-en-1-yl)oxy]phenyl)prop-2-en-1-one
-
-
-
(2E)-3-[4-(benzyloxy)phenyl]-1-(4-fluorophenyl)prop-2-en-1-one
-
-
(2E)-3-[4-(benzyloxy)phenyl]-1-(4-methoxyphenyl)prop-2-en-1-one
-
-
(2E)-N-(2-methyl-1H-indol-5-yl)-3-phenylprop-2-enamide
-
-
-
(2E,4E)-5-(1,3-benzodioxol-5-yl)-N-(2-methylpropyl)penta-2,4-dienamide
-
i.e. guineensine, isolated from dried fruits of Piper longum, competitive inhibition; i.e. guineensine, isolated from dried fruits of Piper longum, competitive inhibition
(2E,4E,12E)-13-(1,3-benzodioxol-5-yl)-N-(2-methylpropyl)trideca-2,4,12-trienamide
-
i.e. methylpiperate, isolated from dried fruits of Piper longum, competitive inhibition; i.e. methylpiperate, isolated from dried fruits of Piper longum, competitive inhibition
(2E,6E)-farnesol
-
-
(2R)-1-(3-methoxyphenoxy)-3-(1-methylhydrazino)propan-2-ol
-
-
(2R)-1-cyclohexyl-N-methyl-N-(1H-pyrrol-2-ylmethyl)propan-2-amine
-
;
(2S)-1-(3-methoxyphenoxy)-3-(1-methylhydrazino)propan-2-ol
-
-
(2S)-2-[4-(3-fluorobenzyloxy)benzylamino]propionamide
-
i.e. safinamide, a potent selective and reversible MAO-B inhibitor, occurs in two polymorphic forms. Both forms are orthorhombic and regarded as conformational polymorphs due to the differences in the orientation of the 3-fluorobenzyloxy and propanamide groups. Both structures pack with layers in the ac plane, structure overview
-
(2S)-amphetamine
-
-
(3E)-3-[2-(ethylamino)-2-oxoethylidene]-2,3-dihydro-1-benzofuran-6-yl 3-chlorobenzenesulfonate
-
1% inhibition of isoform MAO-B at 0.01 mM, 14% inhibition of isoform MAO-A at 0.01 mM
-
(3E)-3-[2-(isopropylamino)-2-oxoethylidene]-2,3-dihydro-1-benzofuran-6-yl 3-chlorobenzenesulfonate
-
4% inhibition of isoform MAO-B at 0.01 mM
-
(3E)-3-[2-(methylamino)-2-oxoethylidene]-2,3-dihydro-1-benzofuran-6-yl 3,3,3-trifluoropropane-1-sulfonate
-
5% inhibition of isoform MAO-B at 0.01 mM
-
(3E)-3-[2-(methylamino)-2-oxoethylidene]-2,3-dihydro-1-benzofuran-6-yl 3-chlorobenzenesulfonate
-
-
-
(3E)-3-[2-(methylamino)-2-oxoethylidene]-2,3-dihydro-1-benzofuran-6-yl 3-cyanobenzenesulfonate
-
-
-
(3E)-3-[2-(methylamino)-2-oxoethylidene]-2,3-dihydro-1-benzofuran-6-yl 3-fluorobenzenesulfonate
-
6% inhibition of isoform MAO-B at 0.01 mM
-
(3E)-3-[2-(methylamino)-2-oxoethylidene]-2,3-dihydro-1-benzofuran-6-yl 4-(methylsulfonyl)benzenesulfonate
-
6%inhibition of isoform MAO-B at 0.01 mM
-
(3E)-3-[2-(methylamino)-2-oxoethylidene]-2,3-dihydro-1-benzofuran-6-yl 4-acetylbenzenesulfonate
-
13% inhibition of isoform MAO-B at 0.01 mM
-
(3E)-3-[2-(methylamino)-2-oxoethylidene]-2,3-dihydro-1-benzofuran-6-yl 4-chlorobenzenesulfonate
-
-
-
(3E)-3-[2-(methylamino)-2-oxoethylidene]-2,3-dihydro-1-benzofuran-6-yl 4-cyanobenzenesulfonate
-
6% inhibition of isoform MAO-B at 0.01 mM
-
(3E)-3-[2-(methylamino)-2-oxoethylidene]-2,3-dihydro-1-benzofuran-6-yl 4-methoxybenzenesulfonate
-
5% inhibition of isoform MAO-B at 0.01 mM
-
(3E)-3-[2-(methylamino)-2-oxoethylidene]-2,3-dihydro-1-benzofuran-6-yl 4-nitrobenzenesulfonate
-
10% inhibition of isoform MAO-B at 0.01 mM
-
(3E)-3-[2-(methylamino)-2-oxoethylidene]-2,3-dihydro-1-benzofuran-6-yl 5-chlorothiophene-2-sulfonate
-
2% inhibition of isoform MAO-B at 0.01 mM
-
(3E)-3-[2-(methylamino)-2-oxoethylidene]-2,3-dihydro-1-benzofuran-6-yl benzenesulfonate
-
-
-
(3E)-7-methyl-3-[2-(methylamino)-2-oxoethylidene]-2,3-dihydro-1-benzofuran-6-yl 3,3,3-trifluoropropane-1-sulfonate
-
-
-
(3E)-7-methyl-3-[2-(methylamino)-2-oxoethylidene]-2,3-dihydro-1-benzofuran-6-yl 3-chlorobenzenesulfonate
-
-
-
(3E)-7-methyl-3-[2-(methylamino)-2-oxoethylidene]-2,3-dihydro-1-benzofuran-6-yl 4-cyanobenzenesulfonate
-
-
-
(3E)-7-methyl-3-[2-(methylamino)-2-oxoethylidene]-2,3-dihydro-1-benzofuran-6-yl 4-methoxybenzenesulfonate
-
17% inhibition of isoform MAO-B at 0.01 mM
-
(3E)-7-methyl-3-[2-(methylamino)-2-oxoethylidene]-2,3-dihydro-1-benzofuran-6-yl benzenesulfonate
-
6% inhibition of isoform MAO-B at 0.01 mM
-
(4-[[bis(methylene)(4-methylphenyl)-lambda6-sulfanyl]oxy]phenoxy)hydrazine
-
0.1 mM, complete inhibition
(5R)-3-(3-fluoro-4-morpholin-4-ylphenyl)-5-(hydroxymethyl)-1,3-oxazolidin-2-one
-
-
(5R)-3-[3-fluoro-4-(4-pyrazin-2-ylpiperazin-1-yl)phenyl]-5-(hydroxymethyl)-1,3-oxazolidin-2-one
-
-
(5R)-3-[4-(4-bromo-1H-imidazol-1-yl)-3-fluorophenyl]-5-(hydroxymethyl)-1,3-oxazolidin-2-one
-
-
(5R,5'R)-3,3'-[1,4-diazepane-1,4-diylbis(3-fluorobenzene-4,1-diyl)]bis[5-(hydroxymethyl)-1,3-oxazolidin-2-one]
-
IC50: 0.001mM, at 0.15 mM kynuramine
(5S)-5-(aminomethyl)-3-(3-fluoro-4-morpholin-4-ylphenyl)-1,3-oxazolidin-2-one
-
-
(5S)-5-(aminomethyl)-3-[3-fluoro-4-(4-pyrazin-2-ylpiperazin-1-yl)phenyl]-1,3-oxazolidin-2-one
-
-
(5S)-5-(aminomethyl)-3-[4-(4-bromo-1H-imidazol-1-yl)-3-fluorophenyl]-1,3-oxazolidin-2-one
-
-
(5Z)-3-(2-aminoethyl)-5-(2-methoxybenzylidene)-1,3-thiazolidine-2,4-dione
-
L136468, binding mode, overview
(5Z)-3-(2-aminoethyl)-5-(4-ethoxybenzylidene)-1,3-thiazolidine-2,4-dione
-
A6355
(5Z)-3-(2-aminoethyl)-5-[4-(dimethylamino)benzylidene]-1,3-thiazolidine-2,4-dione
-
L136662
(5Z)-5-(quinoxalin-6-ylmethylidene)-1,3-thiazolidine-2,4-dione
-
AS605240, binding mode, overview
(6-benzyloxy-2-naphthyl)-2-aminopropane
-
;
(6-butoxy-2-naphthyl)-2-aminopropane
-
;
(6-ethoxy-2-naphthyl)-2-aminopropane
-
;
(6-methoxy-2-naphthyl)-2-aminopropane
-
;
(6-methylthio-2-naphthyl)isopropylamine
-
;
(6-propoxy-2-naphthyl)-2-aminopropane
-
;
(7-benzyloxy-2-oxo-2H-chromen-4-yl)acetonitrile
-
-
-
(7-[(3-chlorobenzyl)oxy]-2-oxo-2H-chromen-4-yl)acetonitrile
-
-
-
(aminomethyl)trimethylsilane
-
-
(E)-1-(2,3-dimethoxy-6-methylphenyl)-N-(prop-2-yn-1-yl)methanimine
-
-
(E)-1-(2,3-dimethylphenyl)-N-(prop-2-yn-1-yl)methanimine
-
-
(E)-1-(2-chloro-4-fluorophenyl)-N-(prop-2-yn-1-yl)methanimine
-
-
(E)-1-(2-chloroquinolin-3-yl)-N-(prop-2-yn-1-yl)methanimine
-
-
(E)-1-(4-methoxy-2,3-dimethylphenyl)-N-(prop-2-yn-1-yl)methanimine
-
-
(E)-1-(4-phenoxyphenyl)-N-(prop-2-yn-1-yl)methanimine
-
-
(E)-1-(5-bromo-2-methoxyphenyl)-N-(prop-2-yn-1-yl)methanimine
-
-
(E)-1-phenyl-N-(prop-2-yn-1-yl)methanimine
-
-
(E)-2-(4-fluorophenethyl)-3-fluoroallylamine
-
-
(E)-3-chlorocinnamic acid 2-oxo-2,3-dihydro-benzofuran-5-yl ester
-
-
-
(E)-5-(3-chlorostyryl)isatin
-
;
(E)-5-(3-fluorostyryl)isatin
-
;
(E)-5-styrylisatin
-
;
(E)-6-styrylisatin
-
;
(E)-8-(2-furylethenyl)caffeine
-
-
(E)-8-(2-thienylethenyl)caffeine
-
-
(E)-8-(3,4-dichlorostyryl)caffeine
-
-
(E)-8-(3,5-ditrifluoromethylstyryl)caffeine
-
-
(E)-8-(3-bromostyryl)caffeine
-
-
(E)-8-(3-chlorostyryl)caffeine
-
-
(E)-8-(3-chlorostyryl)caffeine
-
a specific reversible inhibitor of MAO-B
(E)-8-(3-chlorostyryl)caffeine
-
reversible MAO-B inhibitor, a dual-target-directed drug inhibiting MAO-B and antagonizing A2A receptors
(E)-8-(3-methylstyryl)caffeine
-
-
(E)-8-(3-trifluoromethylstyryl)caffeine
-
-
(E)-8-(4-chlorostyryl)caffeine
-
-
(E)-8-(4-fluorostyryl)caffeine
-
-
(E)-8-(4-methylstyryl)caffeine
-
-
(E)-8-(4-trifluoromethylstyryl)caffeine
-
-
(E)-8-styrylcaffeine
-
reversible MAO-B inhibitor, a dual-target-directed drug inhibiting MAO-B and antagonizing A2A receptors
(E)-cinnamic acid 2-oxo-2,3-dihydro-benzofuran-5-yl ester
-
-
-
(E)-N-(prop-2-yn-1-yl)-1-(3,4,5-trimethoxyphenyl)methanimine
-
-
(E)-N-(prop-2-yn-1-yl)-1-[4-(pyridin-2-yl)phenyl]methanimine
-
-
(N-cyclopropyl-alpha-methylbenzylamine)
-
the inhibitor forms an adduct that allows reoxidation of the flavin on denaturation
(R)-2-[(2E)-2-(2-methylcyclohexylidene)hydrazinyl]-4-(4-nitrophenyl)-1,3-thiazole
-
-
-
(R)-4-(2,4-difluorophenyl)-2-[(2E)-2-(2-methylcyclohexylidene)hydrazinyl]-1,3-thiazole
-
-
-
(R)-4-(4-fluorophenyl)-2-[(2E)-2-(2-methylcyclohexylidene)hydrazinyl]-1,3-thiazole
-
-
-
(R)-4-[2-[(2E)-2-(2-methylcyclohexylidene)hydrazinyl]-1,3-thiazol-4-yl]benzonitrile
-
-
-
(R)-amphetamine
-
IC50 for soluble enzyme: 0.0311 mM, IC50 for immobilized enzyme: 0.0991 mM, monoamine oxidase A; IC50 for soluble enzyme: 0.246 mM, IC50 for immobilized enzyme: 4.03 mM, monoamine oxidase B
(R)-deprenyl
-
i.e. selegiline, a MAO-B inhibitor
(R)-N-(alpha-cyclohexylethyl),N-methyl-1H-pyrrole-2-carboxamide
-
;
(R)-N-(alpha-cyclohexylethyl)-1H-pyrrole-2-carboxamide
-
;
(R,S)-amphetamine
-
IC50 for soluble enzyme: 0.0031 mM, IC50 for immobilized enzyme: 0.0244 mM, monoamine oxidase A; IC50 for soluble enzyme: 0.0625 mM, IC50 for immobilized enzyme: 3 mM, monoamine oxidase B
(S)-2-[(2E)-2-(2-methylcyclohexylidene)hydrazinyl]-4-(4-nitrophenyl)-1,3-thiazole
-
-
-
(S)-4-(2,4-difluorophenyl)-2-[(2E)-2-(2-methylcyclohexylidene)hydrazinyl]-1,3-thiazole
-
-
-
(S)-4-(4-fluorophenyl)-2-[(2E)-2-(2-methylcyclohexylidene)hydrazinyl]-1,3-thiazole
-
-
-
(S)-4-[2-[(2E)-2-(2-methylcyclohexylidene)hydrazinyl]-1,3-thiazol-4-yl]benzonitrile
-
-
-
(S)-5-methoxymethyl-3-[6-(4,4,4-trifluorobutoxy)-benzo[d]isoxazol-3-yl]-oxazolidin-2-one
-
SL25.1188, inhibits MAO-B in the brain with 50% unspecific binding, overview
(Z)-3-fluoro-2-(4-methoxybenzyl)allylamine hydrochloride
P27338
i.e. LJP 1586. Potent, specific, and orally available inhibitor of SSAO activity is an effective anti-inflammatory compound in vivo; i.e. LJP 1586. Potent, specific, and orally available inhibitor of SSAO activity is an effective anti-inflammatory compound in vivo
1,10 phenanthroline
-
weak inhibition
1,3,7-trimethyl-8-([3-(trifluoromethyl)benzyl]oxy)-3,7-dihydro-1H-purine-2,6-dione
-
-
-
1,3,7-trimethyl-8-[(3-methylbenzyl)oxy]-3,7-dihydro-1H-purine-2,6-dione
-
-
1,3,7-trimethyl-8-[(E)-2-(3-thienyl)vinyl]-3,7-dihydro-1H-purine-2,6-dione
-
-
1,3-dimethyl-5-nitro-1H-indazole
-
-
1,3-dimethyl-6-phenyl-1H-pteridine-2,4-dione
-
-
1,3-diphenyl-4,5-dihydro-1H-pyrazole
-
IC50: 0.0098 mM, MAO-A; IC50: 0.2 mM, MAO-B
1,4-diphenyl-1,3-butadiene
-
the experimentally tested model compound is docked computationally to the active site of the MAO-B enzyme. The AutoDock 3.0.5 program is employed to perform automated molecular docking. The free energies of binding and inhibition constants (Ki) of the docked compounds are calculated by the Lamarckian Genetic Algorithm of AutoDock 3.0.5. Excellent to good correlations between the calculated and experimental Ki values are obtained
1,4-diphenyl-1,3-butadiene
-
-
1,4-diphenyl-2-butene
-
inhibits by covalent binding to the flavin ring, reversible inhibitor of MAO-B
1,4-diphenyl-2-butene
-
monoamine oxidase B
1,4-diphenyl-2-butene
-
a component of polystyrene plasticware
1,4-diphenyl-2-butene
-
-
1-(1-methylhydrazino)-3-(phenylthio)propan-2-ol
-
-
1-(1-methylhydrazino)-3-[methyl(phenyl)amino]propan-2-ol
-
-
1-(1-naphthyl)-2-aminopropane
-
;
1-(2-naphthyl)-2-aminopropane
-
;
1-(3,5-diethoxypyridin-4-yl)methanamine dihydrochloride
-
;
1-(4-(3-methoxyphenyl)thiazol-2-yl)-2-((1H-indol-3-yl)-methylene)-hydrazine
-
-
1-(4-(3-methoxyphenyl)thiazol-2-yl)-2-(1-(coumarin-3-yl)-ethylidene)hydrazine
-
-
1-(4-(3-methoxyphenyl)thiazol-2-yl)-2-(1-(furan-2-yl)ethylidene)-hydrazine
-
-
1-(4-(3-methoxyphenyl)thiazol-2-yl)-2-(1-(naphthalen-2-yl)ethylidene)hydrazine
-
-
1-(4-(3-methoxyphenyl)thiazol-2-yl)-2-(1-(pyridin-2-yl)-ethylidene)hydrazine
-
-
1-(4-(3-methoxyphenyl)thiazol-2-yl)-2-(1-(pyridin-3-yl)-ethylidene)hydrazine
-
-
1-(4-(3-methoxyphenyl)thiazol-2-yl)-2-(1-(pyridin-4-yl)-ethylidene)hydrazine
-
-
1-(4-(3-methoxyphenyl)thiazol-2-yl)-2-(1-(thiophen-2-yl)-ethylidene)hydrazine
-
-
1-(4-(3-methoxyphenyl)thiazol-2-yl)-2-(2-methylcyclohexylidene)hydrazine
-
-
1-(4-(3-methoxyphenyl)thiazol-2-yl)-2-(2-methylcyclopentylidene)hydrazine
-
-
-
1-(4-(3-methoxyphenyl)thiazol-2-yl)-2-(3-methylcyclohexylidene)hydrazine
-
-
1-(4-(3-methoxyphenyl)thiazol-2-yl)-2-(3-methylcyclopentylidene)hydrazine
-
-
1-(4-(3-methoxyphenyl)thiazol-2-yl)-2-(4-methylcyclohexylidene)hydrazine
-
-
1-(4-(3-methoxyphenyl)thiazol-2-yl)-2-(benzodioxol-5-ylmethylene)hydrazine
-
-
1-(4-(3-methoxyphenyl)thiazol-2-yl)-2-(furan-2-ylmethylene)-hydrazine
-
-
-
1-(4-(3-methoxyphenyl)thiazol-2-yl)-2-(furan-2-ylmethylene)hydrazine
-
-
1-(4-(3-methoxyphenyl)thiazol-2-yl)-2-(heptan-2-ylidene)hydrazine
-
-
1-(4-(3-methoxyphenyl)thiazol-2-yl)-2-(naphthalen-1-ylmethylene)hydrazine
-
-
1-(4-(3-methoxyphenyl)thiazol-2-yl)-2-(octan-2-ylidene)hydrazine
-
-
1-(4-(3-methoxyphenyl)thiazol-2-yl)-2-(pentan-2-ylidene)hydrazine
-
-
1-(4-(3-methoxyphenyl)thiazol-2-yl)-2-(pentan-3-ylidene)hydrazine
-
-
1-(4-(3-methoxyphenyl)thiazol-2-yl)-2-(propan-2-ylidene)hydrazine
-
-
1-(4-(3-methoxyphenyl)thiazol-2-yl)-2-(pyridin-3-ylmethylene)hydrazine
-
-
1-(4-(3-methoxyphenyl)thiazol-2-yl)-2-(pyridin-4-ylmethylene)hydrazine
-
-
1-(4-(3-methoxyphenyl)thiazol-2-yl)-2-(thiophen-2-ylmethylene)hydrazine
-
-
1-(4-(3-methoxyphenyl)thiazol-2-yl)-2-cycloheptylidene-hydrazine
-
-
1-(4-(3-methoxyphenyl)thiazol-2-yl)-2-cyclohexylidenehydrazine
-
-
1-(4-(3-methoxyphenyl)thiazol-2-yl)-2-cyclopentylidenehydrazine
-
-
1-(4-benzyloxyphenyl)-2-aminopropane
-
;
1-(4-butoxyphenyl)-2-aminopropane
-
;
1-(4-chlorobutyl)-5-nitro-1H-indazol-3-ol
-
-
1-(4-ethoxyphenyl)-2-aminopropane
-
;
1-(4-guanidinobutoxy)-6-hydroxy-1,2,3,4-tetrahydro-beta-carboline
-
an indolylalkaloid toxin enzyme inhibitor from the venom of the colonial spider Parawixia bistriata
1-(4-methoxy-phenyl)-2-aminopropane
-
;
1-(4-methylthiophenyl)-2-aminopropane
-
;
1-(4-propoxyphenyl)-2-aminopropane
-
;
1-(benzylideneamino)-3,4-dihydroquinolin-2(1H)-one
-
selective for MAO-B
1-(N-methylthiocarbamoyl)-3-(3-methoxyphenyl)-4,5-dihydropyrazole
-
-
-
1-(N-methylthiocarbamoyl)-3-(3-methylphenyl)-4,5-dihydropyrazole
-
-
-
1-(N-methylthiocarbamoyl)-3-(4-chlorophenyl)-4-methyl-4,5-dihydropyrazole
-
-
-
1-(N-methylthiocarbamoyl)-3-(4-fluorophenyl)-4,5-dihydropyrazole
-
-
-
1-(N-methylthiocarbamoyl)-3-(4-methoxyphenyl)-4,5-dihydropyrazole
-
-
-
1-(N-methylthiocarbamoyl)-3-(4-methoxyphenyl)-4-methyl-4,5-dihydropyrazole
-
-
-
1-(N-methylthiocarbamoyl)-3-(4-methylphenyl)-4,5-dihydropyrazole
-
-
-
1-acetyl-3,5-diphenyl-4,5-dihydro-1H-pyrazole
-
IC50: 0.000009 mM, MAO-A; IC50: 0.041 mM, MAO-B
1-acetyl-3-(2,4-dimethoxyphenyl)-4,5-dihydro-1H-pyrazole
-
IC50: 0.00023 mM, MAO-A; IC50: 0.1 mM, MAO-B
1-acetyl-3-(2,5-dimethoxyphenyl)-4,5-dihydro-1H-pyrazole
-
IC50: 0.0002 mM, MAO-A; IC50: 0.14 mM, MAO-B
1-acetyl-3-(2-methoxyphenyl)-4,5-dihydro-1H-pyrazole
-
IC50: 0.00029 mM, MAO-A; IC50: 0.1 mM, MAO-B
1-acetyl-3-(2-nitrophenyl)-4,5-dihydro-1H-pyrazole
-
IC50: 0.0003 mM, MAO-A; IC50: 0.09 mM, MAO-B
1-acetyl-3-(3,4-dimethoxyphenyl)-4,5-dihydro-1H-pyrazole
-
IC50: 0.0001 mM, MAO-A; IC50: 0.088 mM, MAO-B
1-acetyl-3-(3-methoxyphenyl)-4,5-dihydro-1H-pyrazole
-
IC50: 0.00024 mM, MAO-A; IC50: 0.1 mM, MAO-B
1-acetyl-3-(4-bromophenyl)-4,5-dihydro-1H-pyrazole
-
IC50: 0.00001 mM, MAO-A; IC50: 0.1 mM, MAO-B
1-acetyl-3-(4-chlorophenyl)-4,5-dihydro-1H-pyrazole
-
IC50: 0.00001mM, MAO-A; IC50: 0.1 mM, MAO-B
1-acetyl-3-(4-methoxyphenyl)-4,5-dihydro-1H-pyrazole
-
IC50: 0.0002 mM, MAO-A; IC50: 0.1 mM, MAO-B
1-acetyl-3-(4-methylphenyl)-4,5-dihydro-1H-pyrazole
-
IC50: 0.0001 mM, MAO-A; IC50: 0.02 mM, MAO-B
1-acetyl-3-phenyl-4,5-dihydro-1H-pyrazole
-
IC50: 0.0001 mM, MAO-A; IC50: 0.1 mM, MAO-B
1-acetyl-5-(2,4-dimethoxyphenyl)-3-phenyl-4,5-dihydro-1H-pyrazole
-
IC50: 0.00001 mM, MAO-A; IC50: 0.1 mM, MAO-B
1-acetyl-5-(2-methylphenyl)-3-phenyl-4,5-dihydro-1H-pyrazole
-
IC50: 0.0001 mM, MAO-A; IC50: 0.038 mM, MAO-B
1-acetyl-5-(3,4-dimethoxyphenyl)-3-phenyl-4,5-dihydro-1H-pyrazole
-
IC50: 0.00001 mM, MAO-A; IC50: 0.025 mM, MAO-B
1-acetyl-5-(3-methylphenyl)-3-phenyl-4,5-dihydro-1H-pyrazole
-
IC50: 0.000009 mM, MAO-A; IC50: 0.083 mM, MAO-B
1-acetyl-5-(4-chlorophenyl)-3-phenyl-4,5-dihydro-1H-pyrazole
-
IC50: 0.000008 mM, MAO-A; IC50: 0.1 mM, MAO-B
1-amino-3,4-dihydroquinolin-2(1H)-one
-
selective for MAO-B
1-benzyl-5-nitro-1H-indazol-3-ol
-
-
1-guanidino-6-hydroxy-3,5-dihydro-beta-carboline
-
an indolylalkaloid toxin enzyme inhibitor from the venom of the colonial spider Parawixia bistriata
1-methoxy-3-(3-methylphenyl)pyrrole
-
-
-
1-methyl-2-[(E)-2-(4-methylphenyl)vinyl]-1H-benzimidazole
-
-
1-methyl-2-[(E)-2-phenylvinyl]-1H-benzimidazole
-
-
1-methyl-2-[(E)-2-[4-(trifluoromethyl)phenyl]vinyl]-1H-benzimidazole
-
-
1-methyl-3-(3-bromophenyl)pyrrole
-
-
-
1-methyl-3-(3-chlorophenyl)pyrrole
-
-
1-methyl-3-(3-fluorophenyl)pyrrole
-
-
-
1-methyl-3-(3-methylphenyl)-1H-pyrrole
-
-
1-methyl-3-(3-methylphenyl)pyrrole
-
-
-
1-methyl-3-(3-trifluoromethylphenyl)pyrrole
-
-
-
1-methyl-3-(4-methylphenyl)-1H-pyrrole
-
-
1-methyl-3-phenyl-1H-pyrrole
-
-
1-methyl-3-phenylpyrrole
-
-
1-methyl-3-[4-(trifluoromethyl)phenyl]-1H-pyrrole
-
-
1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine
-
-
1-methyl-4-phenylpyridinium
-
-
1-methyl-5-nitro-1H-indazol-3-ol
-
inhibits MAO-B by 34% at 0.015 mM
1-methyl-N-(2-methyl-1H-indol-5-yl)-1l4-pyridine-3-carboxamide
-
-
-
1-N-allylthiocarbamoyl-3-(4-chlorophenyl)-5-(2-pyrrolyl)-4,5-dihydro-(1H)-pyrazole
-
selective for MAO-A
1-N-allylthiocarbamoyl-3-(4-methoxyphenyl)-5-(2-pyrrolyl)-4,5-dihydro-(1H)-pyrazole
-
selective for MAO-B
1-N-allylthiocarbamoyl-3-(4-methylphenyl)-5-(2-pyrrolyl)-4,5-dihydro-(1H)-pyrazole
-
non-selective inhibitor; non-selective inhibitor
1-N-ethylthiocarbamoyl-3-(4-chlorophenyl)-5-(2-pyrrolyl)-4,5-dihydro-(1H)-pyrazole
-
selective for MAO-A
1-N-ethylthiocarbamoyl-3-(4-methoxyphenyl)-5-(2-pyrrolyl)-4,5-dihydro-(1H)-pyrazole
-
selective for MAO-B
1-N-ethylthiocarbamoyl-3-(4-methylphenyl)-5-(2-pyrrolyl)-4,5-dihydro-(1H)-pyrazole
-
non-selective inhibitor; non-selective inhibitor
1-N-methylthiocarbamoyl-3-(4-chlorophenyl)-5-(2-pyrrolyl)-4,5-dihydro-(1H)-pyrazole
-
selective for MAO-A
1-N-methylthiocarbamoyl-3-(4-methoxyphenyl)-5-(2-pyrrolyl)-4,5-dihydro-(1H)-pyrazole
-
selective for MAO-B
1-N-methylthiocarbamoyl-3-(4-methylphenyl)-5-(2-pyrrolyl)-4,5-dihydro-(1H)-pyrazole
-
non-selective inhibitor; non-selective inhibitor
1-N-phenylthiocarbamoyl-3-(4-chlorophenyl)-5-(2-pyrrolyl)-4,5-dihydro-(1H)-pyrazole
-
selective for MAO-A
1-N-phenylthiocarbamoyl-3-(4-methoxyphenyl)-5-(2-pyrrolyl)-4,5-dihydro-(1H)-pyrazole
-
selective for MAO-B
1-N-phenylthiocarbamoyl-3-(4-methylphenyl)-5-(2-pyrrolyl)-4,5-dihydro-(1H)-pyrazole
-
non-selective inhibitor; non-selective inhibitor
1-O-n-octyl-beta-D-glucopyranoside
-
at concentrations well below the critical micelle concentration
1-phenyl-2-aminopropane
-
;
1-phenyl-N-(1H-pyrrol-2-ylmethyl)methanamine
-
;
1-phenylcyclopropylamine
-
the inhibitor forms an irreversible flavin adduct
1-thiocarbamoyl-3-(4-bromophenyl)-5-(2-chloro-3,4-dimethoxyphenyl)-4,5-dihydro-1H-pyrazole
-
monoamine oxidase A; monoamine oxidase B
1-thiocarbamoyl-3-(4-bromophenyl)-5-(3,4-dimethoxyphenyl)-4,5-dihydro-1H-pyrazole
-
monoamine oxidase A; monoamine oxidase B
1-thiocarbamoyl-3-(4-chlorophenyl)-5-(2-chloro-3,4-dimethoxyphenyl)-4,5-dihydro-1H-pyrazole
-
monoamine oxidase A; monoamine oxidase B
1-thiocarbamoyl-3-(4-chlorophenyl)-5-(3,4-dimethoxyphenyl)-4,5-dihydro-1H-pyrazole
-
monoamine oxidase A; monoamine oxidase B
1-thiocarbamoyl-3-(4-methoxyphenyl)-4,5-dihydropyrazole
-
-
-
1-thiocarbamoyl-3-(4-methoxyphenyl)-4-methyl-4,5-dihydropyrazole
-
-
-
1-thiocarbamoyl-3-(4-methoxyphenyl)-5-(2-chloro-3,4-dimethoxyphenyl)-4,5-dihydro-1H-pyrazole
-
monoamine oxidase A; monoamine oxidase B
1-thiocarbamoyl-3-(4-methoxyphenyl)-5-(3,4-dimethoxyphenyl)-4,5-dihydro-1H-pyrazole
-
monoamine oxidase A; monoamine oxidase B
1-thiocarbamoyl-3-(4-methylphenyl)-4,5-dihydropyrazole
-
-
-
1-thiocarbamoyl-3-(4-methylphenyl)-5-(2-chloro-3,4-dimethoxyphenyl)-4,5-dihydro-1H-pyrazole
-
monoamine oxidase A; monoamine oxidase B
1-thiocarbamoyl-3-(4-methylphenyl)-5-(3,4-dimethoxyphenyl)-4,5-dihydro-1H-pyrazole
-
monoamine oxidase A; monoamine oxidase B
1-[3,5-bis(ethylsulfanyl)pyridin-4-yl]methanamine dihydrochloride
-
-
1-[3,5-bis(tert-butylsulfanyl)pyridin-4-yl]methanamine dihydrochloride
-
-
1-[3-(4-chlorophenoxy)-2-methoxypropyl]-1-methylhydrazine
-
-
1-[3-(benzyloxy)-5-ethoxypyridin-4-yl]methanamine dihydrochloride
-
;
11H-indolo[3,2-c]cinnoline
-
; 29% inhibition at 0.05 mM
2,2'-Bipyridyl
-
50% inhibition at 1 mM
2,2'-dipyridyl disulfide
-
-
2,2-dibutyl-3-acetyl-5-(3,5-dimethylphenyl)-1,3,4-oxadiazoline
-
0.8 mM, 42.8% inhibition
2,2-dibutyl-5-(2,4-dichlorophenyl)-N-(2,3,5-trifluoro-4-methoxybenzoyl)-1,3,4-oxadiazole-3(2H)-carboxamide
-
1 mM, 82% inhibition
2,2-dibutyl-5-(2,4-dichlorophenyl)-N-(2,6-difluorobenzoyl)-1,3,4-oxadiazole-3(2H)-carboxamid
-
1 mM, 72% inhibition
2,2-dibutyl-5-(4-chlorophenyl)-N-(2,6-difluorobenzoyl)-1,3,4-oxadiazole-3(2H)-carboxamide
-
1 mM, 59% inhibition
2,2-dibutyl-N-(2,6-difluorobenzoyl)-5-(3,4,5-trimethoxyphenyl)-1,3,4-oxadiazole-3(2H)-carboxamide
-
1 mM, 69% inhibition
2,2-dibutyl-N-(2,6-difluorobenzoyl)-5-(3,5-dimethylphenyl)-1,3,4-oxadiazole-3(2H)-carboxamide
-
1 mM, 69% inhibition
2,2-dibutyl-N-(2,6-difluorobenzoyl)-5-(furan-2-yl)-1,3,4-oxadiazole-3(2H)-carboxamide
-
1 mM, 75% inhibition
2,2-dibutyl-N-(2-chlorobenzoyl)-5-(2,4-dichlorophenyl)-1,3,4-oxadiazole-3(2H)-carboxamide
-
1 mM, 78% inhibition
2,2-dibutyl-N-(2-chlorobenzoyl)-5-(3,5-dimethylphenyl)-1,3,4-oxadiazole-3(2H)-carboxamide
-
1 mM, 73% inhibition
2,4-dichloro-N'-(nonan-5-yl)benzohydrazide
-
-
-
2,4-dichlorobenzaldehyde (4-methyl-1,3-thiazol-2-yl)hydrazone
-
pKi: 7.92
2,4-dichlorobenzaldehyde (4-phenyl-1,3-thiazol-2-yl)hydrazone
-
pKi: 7.03
2,4-dimethoxy-5-hydroxybenzaldehyde
-
IC50: 0.042 mM, monoamine oxidase A; IC50: 0.39 mM
2,6-dimethoxyphenol
-
IC50: 0.0624 mM, monoamine oxidase A; IC50: above 0.5 mM, monoamine oxidase B
2-(1-acetyl-4,5-dihydro-1H-pyrazol-3-yl)phenol
-
IC50: 0.0001 mM, MAO-A; IC50: 0.019 mM, MAO-B
2-(1-acetyl-5-phenyl-4,5-dihydro-1H-pyrazol-3-yl)benzene-1,3-diol
-
IC50: 0.001 mM, MAO-A; IC50: 0.07 mM, MAO-B
2-(1-phenyl-4,5-dihydro-1H-pyrazol-3-yl)phenol
-
IC50: 0.000072 mM, MAO-A; IC50: 0.04 mM, MAO-B
2-(2,4-dichlorophenyl)-4-(nonan-5-yl)-4H-1,3,4-oxadiazin-5(6H)-one
-
-
-
2-(2,4-dioxo-1,3-thiazolidin-5-yl)-N-(3-hydroxyphenyl)acetamide
-
6164872
2-(2,4-dioxo-1,3-thiazolidin-5-yl)-N-phenylacetamide
-
6163851
2-(2-benzofuranyl)-2-imidazoline
-
at micromolar concentrations, to a site distinct from the active site on at least two forms of the pure enzyme, probably corresponding to oxidised and reduced enzyme states
-
2-(2-chlorophenyl)-4-(nonan-5-yl)-4H-1,3,4-oxadiazin-5(6H)-one
-
-
-
2-(2-cycloheptylidenehydrazinyl)-4-(2,4-dichlorophenyl)-1,3-thiazole
-
-
2-(2-cycloheptylidenehydrazinyl)-4-(2,4-difluorophenyl)-1,3-thiazole
-
-
2-(2-cycloheptylidenehydrazinyl)-4-(4-fluorophenyl)-1,3-thiazole
-
-
2-(2-cycloheptylidenehydrazinyl)-4-(4-methoxyphenyl)-1,3-thiazole
-
-
2-(2-cycloheptylidenehydrazinyl)-4-(4-methylphenyl)-1,3-thiazole
-
-
2-(2-cycloheptylidenehydrazinyl)-4-(4-nitrophenyl)-1,3-thiazole
-
-
2-(2-cycloheptylidenehydrazinyl)-4-phenyl-1,3-thiazole
-
-
2-(2-cyclohexylidenehydrazinyl)-4-(2,4-difluorophenyl)-1,3-thiazole
-
-
2-(2-cyclohexylidenehydrazinyl)-4-(4-fluorophenyl)-1,3-thiazole
-
-
2-(2-cyclohexylidenehydrazinyl)-4-(4-methoxyphenyl)-1,3-thiazole
-
-
2-(2-cyclohexylidenehydrazinyl)-4-(4-methylphenyl)-1,3-thiazole
-
-
2-(2-cyclohexylidenehydrazinyl)-4-(4-nitrophenyl)-1,3-thiazole
-
-
2-(2-cyclohexylidenehydrazinyl)-4-phenyl-1,3-thiazole
-
-
2-(2-cyclopentylidenehydrazinyl)-4-(2,4-dichlorophenyl)-1,3-thiazole
-
-
2-(2-cyclopentylidenehydrazinyl)-4-(2,4-difluorophenyl)-1,3-thiazole
-
-
2-(2-cyclopentylidenehydrazinyl)-4-(4-fluorophenyl)-1,3-thiazole
-
-
2-(2-cyclopentylidenehydrazinyl)-4-(4-methoxyphenyl)-1,3-thiazole
-
-
2-(2-cyclopentylidenehydrazinyl)-4-(4-methylphenyl)-1,3-thiazole
-
-
2-(2-cyclopentylidenehydrazinyl)-4-(4-nitrophenyl)-1,3-thiazole
-
-
2-(2-cyclopentylidenehydrazinyl)-4-phenyl-1,3-thiazole
-
-
2-(2-ethoxylpyridin-3-yl)-4-(nonan-5-yl)-4H-1,3,4-oxadiazin-5(6H)-one
-
-
-
2-(3,4,5-trimethoxyphenyl)-4-(nonan-5-yl)-4H-1,3,4-oxadiazin-5(6H)-one
-
-
-
2-(3,5-dimethylphenyl)-4-(nonan-5-yl)-4H-1,3,4-oxadiazin-5(6H)-one
-
-
-
2-(3-methylphenyl)-4-(butoxycarbonylethyl)-4H-1,3,4-oxadiazin-5(6H)-one
-
-
-
2-(3-nitrophenyl)-9H-indeno[2,1-d]pyrimidin-9-one
-
12% inhibition at 0.001 mM; 5% inhition at 0.001 mM
2-(4'-benzyloxyphenyl)thiomorpholin-5-one
-
-
2-(4'-benzyloxyphenyl)thiomorpholine oxalate
-
-
2-(4'-butoxyphenyl)thiomorpholin-5-one
-
-
2-(4'-butoxyphenyl)thiomorpholine oxalate
-
-
2-(4'-ethoxyphenyl)thiomorpholin-5-one
-
-
2-(4'-ethoxyphenyl)thiomorpholine oxalate
-
-
2-(4'-methoxyphenyl)thiomorpholin-5-one
-
-
2-(4'-methoxyphenyl)thiomorpholine oxalate
-
-
2-(4'-propoxyphenyl)thiomorpholin-5-one
-
-
2-(4'-propoxyphenyl)thiomorpholine oxalate
-
-
2-(4,5-dihydroimidazol-2-yl)-isoquinoline
-
reversible non-competitive/mixed inhibitor
-
2-(4,5-dihydroimidazol-2-yl)-quinoline
-
reversible non-competitive/mixed inhibitor
-
2-(4-bromophenyl)cyclopropanamine
-
-
2-(4-chlorophenyl)-4-(nonan-5-yl)-4H-1,3,4-oxadiazin-5(6H)-one
-
-
-
2-(4-chlorophenyl)-N-cyclohexyl-2-(3-ethynyl-2-oxo-4-phenylquinolin-1(2H)-yl)acetamide
-
selective for MAO-B
2-(4-ethylphenyl)-4-(cyanoethyl)-4H-1,3,4-oxadiazin-5(6H)-one
-
-
-
2-(4-ethylphenyl)-4-(nonan-5-yl)-4H-1,3,4-oxadiazin-5(6H)-one
-
-
-
2-(4-fluorophenyl)-4-(cyanoethyl)-4H-1,3,4-oxadiazin-5(6H)-one
-
-
-
2-(4-methoxyphenyl)cyclopropanamine
-
-
2-(5,7-dibromobenzofuran-2-yl)-imidazoline
-
reversible non-competitive/mixed inhibitor
-
2-(7-[(3-chlorobenzyl)oxy]-2-oxo-2H-chromen-4-yl)-N,N-dimethylacetamide
-
-
-
2-(7-[(3-chlorobenzyl)oxy]-2-oxo-2H-chromen-4-yl)-N-methylacetamide
-
-
-
2-(7-[(3-chlorobenzyl)oxy]-2-oxo-2H-chromen-4-yl)acetamide
-
-
-
2-(7-[(3-fluorobenzyl)oxy]-2-oxo-2H-chromen-4-yl)acetamide
-
-
-
2-(7-[(3-fluorobenzyl)oxy]-2-oxo-2H-chromen-4-yl)propanamide
-
-
-
2-(7-[(3-hydroxybenzyl)oxy]-2-oxo-2H-chromen-4-yl)acetamide
-
-
-
2-(aminooxy)-1-(3,4-dimethoxyphenyl)ethanol
-
;
2-(aminooxy)-1-phenylethanol
-
;
2-(benzo[d][1,3]dioxol-5-yl)-4-(nonan-5-yl)-4H-1,3,4-oxadiazin-5(6H)-one
-
-
-
2-(methyl[4-[(E)-(prop-2-yn-1-ylimino)methyl]phenyl]amino)ethanol
-
-
2-(naphthalen-1-yl)cyclopropanamine
-
-
2-(naphthalen-2-yl)-4-(nonan-5-yl)-4H-1,3,4-oxadiazin-5(6H)-one
-
-
-
2-(thiophen-3-yl)cyclopropanamine
-
-
2-bromo-N-(2-morpholinoethyl)nicotinamide
-
-
-
2-bromo-N-(3-morpholinopropyl)nicotinamide
-
-
-
2-Bromoethylamine
-
complete inhibition at 0.01 mM
2-chloro-5-[(E)-(prop-2-yn-1-ylimino)methyl]phenol
-
-
2-chloro-6-methyl-N-(2-morpholinoethyl)nicotinamide
-
-
-
2-chloro-6-methyl-N-(3-morpholinopropyl)nicotinamide
-
-
-
2-chloro-N'-(nonan-5-yl)benzohydrazide
-
-
-
2-chloro-N-(2-morpholinoethyl)nicotinamide
-
-
-
2-chloro-N-(3-morpholinopropyl)nicotinamide
-
-
-
2-ethoxy-6-[(E)-(prop-2-yn-1-ylimino)methyl]phenol
-
-
2-ethoxy-N'-(nonan-5-yl)nicotinohydrazide
-
-
-
2-ethylaminobenzylamine dihydrochloride
-
-
2-hydroxy-N-(2-morpholinoethyl)nicotinamide
-
-
-
2-hydroxy-N-(3-morpholinopropyl)nicotinamide
-
-
-
2-Hydroxyquinoline
-
reversible by dialysis
2-methoxyphenol
-
IC50: 0.175 mM, monoamine oxidase A; IC50: above 0.5 mM, monoamine oxidase B
2-methyl-5-methylaniline
-
IC50: 0.15 mM, monoamine oxidase A; IC50: above 0.5 mM
2-methyl-9H-indeno[2,1-d]pyrimidin-9-one
-
;
2-methylaminobenzylamine dihydrochloride
-
-
2-methylbenzaldehyde (4-methyl-1,3-thiazol-2-yl)hydrazone
-
pKi: 7.45
2-methylbenzaldehyde (4-phenyl-1,3-thiazol-2-yl)hydrazone
-
pKi: 7.18
2-oxo-2H-chromen-7-yl benzenesulfonate
-
-
2-oxo-N-(2,3,5,6-tetrafluoropyridin-4-yl)-2H-chromene-3-carboxamide
-
-
2-oxo-N-(pentafluorophenyl)-2H-chromene-3-carboxamide
-
-
2-oxo-N-(propan-2-yl)-2H-chromene-3-carboxamide
-
-
2-oxo-N-[3-(trifluoromethyl)phenyl]-2H-chromene-3-carboxamide
-
-
2-oxo-N-[4-(propan-2-yl)phenyl]-2H-chromene-3-carboxamide
-
-
2-phenyl-2H-indeno[1,2-c]pyridazine-3,5-dione
-
; 46% inhibition at 0.05 mM
2-phenyl-4-(cyanoethyl)-4H-1,3,4-oxadiazin-5(6H)-one
-
-
-
2-phenyl-5H-indeno[1,2-d]pyrimidine
-
; 37% inhibition at 0.02 mM
2-phenyl-9H-indeno[2,1-d]pyrimidine
-
;
2-phenyl-N-(1H-pyrrol-2-ylmethyl)ethanamine
-
;
2-phenylcyclopropylamine
-
the inhibitor forms an adduct that allows reoxidation of the flavin on denaturation
2-Phenylethylamine
-
time-dependent, slowly reversible suicide inhibition. Addition of 2-phenylethylamine (10mM) to the enzyme results in immediate bleaching of the absorbance peak at 460 nm, a consequence of rapid reduction of the flavin cofactor by 2-phenylethylamine at steady state
2-phenylthiomorpholin-5-one
-
-
2-phenylthiomorpholine oxalate
-
-
2-[(1E,3E)-4-(3-chlorophenyl)buta-1,3-dien-1-yl]-3,5,7-trimethyl-3H-imidazo[4,5-c]pyridine-4,6(5H,7H)-dione
-
-
2-[(2E)-2-(2-methylcyclohexylidene)hydrazinyl]-4-(4-methylphenyl)-1,3-thiazole
-
-
2-[(2E)-2-(2-methylcyclohexylidene)hydrazinyl]-4-(4-nitrophenyl)-1,3-thiazole
-
-
2-[(2E)-2-(2-methylcyclohexylidene)hydrazinyl]-4-phenyl-1,3-thiazole
-
-
2-[(E)-(prop-2-yn-1-ylimino)methyl]benzene-1,4-diol
-
-
2-[(E)-2-(4-bromophenyl)vinyl]-1-methyl-1H-benzimidazole
-
-
2-[(E)-2-(4-chlorophenyl)vinyl]-1-methyl-1H-benzimidazole
-
-
2-[(E)-2-(4-fluorophenyl)vinyl]-1-methyl-1H-benzimidazole
-
-
2-[(E)-2-(4-methoxyphenyl)vinyl]-1-methyl-1H-benzimidazole
-
-
2-[1-(4-chlorophenyl)-5-(2,3-dimethoxyphenyl)-4,5-dihydro-1H-pyrazol-3-yl]phenol
-
IC50: 0.008 mM, MAO-A; IC50: 0.3 mM, MAO-B
2-[1-(4-chlorophenyl)-5-(2,4-dichlorophenyl)-4,5-dihydro-1H-pyrazol-3-yl]phenol
-
IC50: 0.009 mM, MAO-A; IC50: 0.3 mM, MAO-B
2-[1-(4-chlorophenyl)-5-(2-methoxyphenyl)-4,5-dihydro-1H-pyrazol-3-yl]phenol
-
IC50: 0.0094 mM, MAO-A; IC50: 0.48 mM, MAO-B
2-[1-(4-chlorophenyl)-5-(2-nitrophenyl)-4,5-dihydro-1H-pyrazol-3-yl]phenol
-
IC50: 0.025 mM, MAO-B; IC50: 0.097 mM, MAO-A
2-[1-(4-chlorophenyl)-5-(3-methoxyphenyl)-4,5-dihydro-1H-pyrazol-3-yl]phenol
-
IC50: 0.098 mM, MAO-A; IC50: 2.0 mM, MAO-B
2-[1-(4-chlorophenyl)-5-(3-nitrophenyl)-4,5-dihydro-1H-pyrazol-3-yl]phenol
-
IC50: 0.013 mM, MAO-A; IC50: 3.8 mM, MAO-B
2-[1-(4-chlorophenyl)-5-(4-methoxyphenyl)-4,5-dihydro-1H-pyrazol-3-yl]phenol
-
IC50: 0.09 mM, MAO-A; IC50: 1.0 mM, MAO-B
2-[1-(4-chlorophenyl)-5-(4-methylphenyl)-4,5-dihydro-1H-pyrazol-3-yl]phenol
-
IC50: 0.094 mM, MAO-A; IC50: 1.8 mM, MAO-B
2-[1-(4-chlorophenyl)-5-(4-nitrophenyl)-4,5-dihydro-1H-pyrazol-3-yl]phenol
-
IC50: 0.088 mM, MAO-A; IC50: 0.2 mM, MAO-B
2-[1-(4-chlorophenyl)-5-[4-(dimethylamino)phenyl]-4,5-dihydro-1H-pyrazol-3-yl]phenol
-
IC50: 0.0095 mM, MAO-A
2-[1-acetyl-5-(2,4-dimethoxyphenyl)-4,5-dihydro-1H-pyrazol-3-yl]phenol
-
IC50: 0.0000086 mM, MAO-A; IC50: 0.1 mM, MAO-B
2-[1-acetyl-5-(2-methylphenyl)-4,5-dihydro-1H-pyrazol-3-yl]benzene-1,3-diol
-
IC50: 0.00001 mM, MAO-A; IC50: 0.0001 mM, MAO-B
2-[1-acetyl-5-(2-methylphenyl)-4,5-dihydro-1H-pyrazol-3-yl]phenol
-
IC50: 0.000008 mM, MAO-A; IC50: 0.019 mM, MAO-B
2-[1-acetyl-5-(3,4-dimethoxyphenyl)-4,5-dihydro-1H-pyrazol-3-yl]phenol
-
IC50: 0.0001 mM, MAO-A; IC50: 0.04 mM, MAO-B
2-[1-acetyl-5-(3-methylphenyl)-4,5-dihydro-1H-pyrazol-3-yl]benzene-1,3-diol
-
IC50: 0.000028 mM, MAO-A; IC50: 0.00006 mM, MAO-B
2-[1-acetyl-5-(3-methylphenyl)-4,5-dihydro-1H-pyrazol-3-yl]phenol
-
IC50: 0.000009 mM, MAO-A; IC50: 0.0072 mM, MAO-B
2-[1-acetyl-5-(4-chlorophenyl)-4,5-dihydro-1H-pyrazol-3-yl]benzene-1,3-diol
-
IC50: 0.002 mM, MAO-A; IC50: 0.1 mM, MAO-B
2-[1-acetyl-5-(4-chlorophenyl)-4,5-dihydro-1H-pyrazol-3-yl]phenol
-
IC50: 0.0000088 mM, MAO-A; IC50: 0.1 mM, MAO-B
2-[1-acetyl-5-(4-methoxyphenyl)-4,5-dihydro-1H-pyrazol-3-yl]benzene-1,3-diol
-
IC50: 0.0001 mM, MAO-A; IC50: 0.06 mM, MAO-B
2-[2-(4-methylcyclohexylidene)hydrazinyl]-4-(4-methylphenyl)-1,3-thiazole
-
-
2-[2-(4-methylcyclohexylidene)hydrazinyl]-4-(4-nitrophenyl)-1,3-thiazole
-
-
2-[2-(4-methylcyclohexylidene)hydrazinyl]-4-phenyl-1,3-thiazole
-
-
2-[2-oxo-7-(pyridin-3-ylmethoxy)-2H-chromen-4-yl]acetamide
-
-
-
2-[2-oxo-7-(pyridin-4-ylmethoxy)-2H-chromen-4-yl]acetamide
-
-
-
2-[4-(trifluoromethyl)phenyl]cyclopropanamine
-
-
2-[5-(3-bromophenyl)-1-(4-chlorophenyl)-4,5-dihydro-1H-pyrazol-3-yl]phenol
-
IC50: 0.089 mM, MAO-A; IC50: 0.25 mM, MAO-B
2-[5-(4-bromophenyl)-1-(4-chlorophenyl)-4,5-dihydro-1H-pyrazol-3-yl]phenol
-
IC50: 0.12 mM, MAO-A; IC50: 1 mM, MAO-B
2-[6-[(3-chlorobenzyl)oxy]-1-benzofuran-3-yl]-N-methylacetamide
-
-
-
2-[7-(3-chlorobenzyloxy)-2-oxo-2H-chromen-4-yl]acetohydrazide
-
-
-
2-[7-(benzyloxy)-2-oxo-2H-chromen-4-yl]-N,N-dimethylacetamide
-
-
-
2-[7-(benzyloxy)-2-oxo-2H-chromen-4-yl]-N-methylacetamide
-
-
-
2-[7-(benzyloxy)-2-oxo-2H-chromen-4-yl]acetamide
-
-
-
2-[7-(benzyloxy)-2-oxo-2H-chromen-4-yl]acetohydrazide
-
-
-
2-[7-(benzyloxy)-2-oxo-2H-chromen-4-yl]propanamide
-
-
-
2-{1-(4-chlorophenyl)-5-[4-(dimethylamino)phenyl]-4,5-dihydro-1H-pyrazol-3-yl}phenol
-
IC50: 0.4 mM, MAO-B
2-{[(3,4-dimethyl-2-oxo-2H-chromen-7-yl)oxy]methyl}benzonitrile
-
-
3,3'-[[4-(aminomethyl)pyridine-3,5-diyl]bis(oxy)]dipropan-1-ol dihydrochloride
-
;
3,4,5-trimethoxy-N'-(nonan-5-yl)benzohydrazide
-
-
-
3,4-dichloro-N-(2-methyl-1H-indol-5-yl)benzamide
-
-
-
3,4-dimethoxy-(benzylidene)-prop-2-ynylamine
-
-
3,4-dimethoxyaniline
-
IC50: 0.131 mM, monoamine oxidase A
3,4-dimethoxybenzaldehyde (4-methyl-1,3-thiazol-2-yl)hydrazone
-
pKi: 7.88
3,4-dimethoxybenzaldehyde (4-phenyl-1,3-thiazol-2-yl)hydrazone
-
pKi: 7.52
3,4-dimethyl-2-oxo-2H-chromen-7-yl 4-methoxybenzenesulfonate
-
-
3,4-dimethyl-2-oxo-2H-chromen-7-yl benzenesulfonate
-
-
3,4-dimethyl-7-(2-oxo-2-phenylethoxy)-2H-chromen-2-one
-
-
3,4-dimethyl-7-(2-phenoxyethoxy)-2H-chromen-2-one
-
pIC50 for MAO-A: 4.99; pIC50 for MAO-B: 7.57
3,4-dimethyl-7-(2-phenylethyl)-2H-chromen-2-one
-
pIC50 for MAO-A: 5.15; pIC50 for MAO-B: 6.34
3,4-dimethyl-7-phenoxy-2H-chromen-2-one
-
pIC50 for MAO-A: 4.5; pIC50 for MAO-B: 5.49
3,4-dimethyl-7-[(3-nitrobenzyl)oxy]-2H-chromen-2-one
-
-
3,4-dimethyl-7-[(pentafluorobenzyl)oxy]-2H-chromen-2-one
-
-
3,4-dimethyl-7-{[3-(trifluoromethoxy)benzyl]oxy}-2H-chromen-2-one
-
-
3,5,7-trimethyl-2-[(1E,3E)-4-phenylbuta-1,3-dien-1-yl]-3H-imidazo[4,5-c]pyridine-4,6(5H,7H)-dione
-
-
3,5-bis(4-methylphenyl)-4,5-dihydro-1H-pyrazole-1-carbothioamide
-
;
3,5-di-2-thienyl-4,5-dihydro-1H-pyrazole-1-carbothioamide
-
;
3,5-dimethyl-(1H-pyrrol-2-ylmethylene)-prop-2-ynyl-amine
-
-
3,5-dimethyl-N'-(nonan-5-yl)benzohydrazide
-
-
-
3,5-diphenyl-1-propionyl-4,5-dihydro-1H-pyrazole
-
-
3-(1-piperidinyl)-4-aminomethylpyridine dihydrochloride hemihydrate
-
;
3-(2,4-dimethoxyphenyl)-1-phenyl-4,5-dihydro-1H-pyrazole
-
IC50: 0.0018 mM, MAO-A; IC50: 0.04 mM, MAO-B
3-(2-chlorophenyl)-1-phenyl-4,5-dihydro-1H-pyrazole
-
IC50: 0.01 mM, MAO-A; IC50: 0.5 mM, MAO-B
3-(2-chlorophenyl)-5H-indeno[1,2-c]pyridazin-5-one
-
-
3-(2-furyl)-2-(N-allylthiocarbamoyl)-3,3a,4,5,6,7-hexahydro-2H-indazol
-
-
-
3-(2-furyl)-2-(N-ethylthiocarbamoyl)-3,3a,4,5,6,7-hexahydro-2H-indazol
-
-
-
3-(2-furyl)-2-(N-methylthiocarbamoyl)-3,3a,4,5,6,7-hexahydro-2H-indazol
-
-
-
3-(2-furyl)-2-(N-phenyllthiocarbamoyl)-3,3a,4,5,6,7-hexahydro-2H-indazol
-
-
-
3-(2-furyl)-2-thiocarbamoyl-2,3,4,5,6,7-hexahydro-1H-indazol
-
-
-
3-(2-naphthyl)-5H-indeno[1,2-c]pyridazin-5-one
-
-
3-(2-nitrophenyl)-5H-indeno[1,2-c]pyridazin-5-one
-
-
3-(2-thienyl)-2-(N-allylthiocarbamoyl)-3,3a,4,5,6,7-hexahydro-2H-indazol
-
-
-
3-(2-thienyl)-2-(N-ethylthiocarbamoyl)-3,3a,4,5,6,7-hexahydro-2H-indazol
-
-
-
3-(2-thienyl)-2-(N-methylthiocarbamoyl)-3,3a,4,5,6,7-hexahydro-2H-indazol
-
-
-
3-(2-thienyl)-2-thiocarbamoyl-2,3,4,5,6,7-hexahydro-1H-indazol
-
-
-
3-(3,4-dimethoxyphenyl)-1-phenyl-4,5-dihydro-1H-pyrazole
-
IC50: 0.003 mM, MAO-A; IC50: 0.017 mM, MAO-B
3-(3-aminophenyl)-9H-indeno[1,2-e][1,2,4]triazin-9-one
-
12% inhibition at 0.01 mM; 17% inhibition at 0.01 mM
3-(3-bromophenyl)-1-methyl-1H-pyrrole
-
-
3-(3-bromophenyl)-5H-indeno[1,2-c]pyridazin-5-one
-
-
3-(3-chlorophenyl)-1-methyl-1H-pyrrole
-
-
3-(3-fluorophenyl)-1-methyl-1H-pyrrole
-
-
3-(3-fluorophenyl)-5H-indeno[1,2-c]pyridazin-5-one
-
-
3-(3-methoxyphenyl)-1-methyl-1H-pyrrole
-
-
3-(3-methoxyphenyl)-1-phenyl-4,5-dihydro-1H-pyrazole
-
IC50: 0.000014 mM, MAO-A; IC50: 0.001 mM, MAO-B
3-(3-methoxyphenyl)-5H-indeno[1,2-c]pyridazin-5-one
-
-
3-(3-methylphenyl)-1-phenyl-4,5-dihydro-1H-pyrazole
-
IC50: 0.09 mM, MAO-A; IC50: 0.98 mM, MAO-B
3-(3-nitrophenyl)-5H-indeno[2,1-e][1,2,4]triazin-5-one
-
; 3% inhibition at 0.01 mM
3-(3-nitrophenyl)-9H-indeno[1,2-e][1,2,4]triazin-9-one
-
; 23% inhibition at 0.01 mM
3-(3-tert-butylphenyl)-1-methyl-1H-pyrrole
-
-
3-(4-bromophenyl)-1-methyl-1H-pyrrole
-
-
3-(4-bromophenyl)-1-phenyl-4,5-dihydro-1H-pyrazole
-
IC50: 0.0074 mM, MAO-A; IC50: 0.087 mM, MAO-B
3-(4-bromophenyl)-5H-indeno[1,2-c]pyridazin-5-one
-
-
3-(4-chlorophenyl)-1-methyl-1H-pyrrole
-
-
3-(4-chlorophenyl)-1-phenyl-4,5-dihydro-1H-pyrazole
-
IC50: 0.0099 mM, MAO-A; IC50: 0.1 mM, MAO-B
3-(4-chlorophenyl)-5-(4-fluorocyclohexa-1,5-dien-1-yl)-1-propionyl-4,5-dihydro-1H-pyrazole
-
-
3-(4-chlorophenyl)-5-(4-methoxycyclohexa-1,5-dien-1-yl)-1-propionyl-4,5-dihydro-1H-pyrazole
-
-
3-(4-chlorophenyl)-5-(4-methylcyclohexa-1,5-dien-1-yl)-1-propionyl-4,5-dihydro-1H-pyrazole
-
-
3-(4-chlorophenyl)-5-cyclohexa-1,5-dien-1-yl-1-propionyl-4,5-dihydro-1H-pyrazole
-
-
3-(4-fluorophenyl)-1-methyl-1H-pyrrole
-
-
3-(4-fluorophenyl)-5-(2-furyl)-4,5-dihydro-1H-pyrazole-1-carbothioamide
-
;
3-(4-fluorophenyl)-5-(4-methoxycyclohexa-1,5-dien-1-yl)-1-propionyl-4,5-dihydro-1H-pyrazole
-
-
3-(4-fluorophenyl)-5-(4-methylcyclohexa-1,5-dien-1-yl)-1-propionyl-4,5-dihydro-1H-pyrazole
-
-
3-(4-fluorophenyl)-5-(4-methylphenyl)-4,5-dihydro-1H-pyrazole-1-carbothioamide
-
;
3-(4-hydroxyphenyl)propionic acid
-
-
3-(4-methoxyphenyl)-1-methyl-1H-pyrrole
-
-
3-(4-methoxyphenyl)-1-phenyl-4,5-dihydro-1H-pyrazole
-
IC50: 0.00011 mM, MAO-A; IC50: 0.0125 mM, MAO-B
3-(4-methoxyphenyl)-5-(4-methylcyclohexa-1,5-dien-1-yl)-1-propionyl-4,5-dihydro-1H-pyrazole
-
-
3-(4-methoxyphenyl)-5H-indeno[1,2-c]pyridazin-5-one
-
-
3-(4-methylphenyl)-1-phenyl-4,5-dihydro-1H-pyrazole
-
IC50: 0.0069 mM, MAO-A; IC50: 0.05 mM, MAO-B
3-(4-nitrophenyl)-1-phenyl-4,5-dihydro-1H-pyrazole
-
IC50: 0.000086 mM, MAO-A; IC50: 0.00145 mM, MAO-B
3-(4-nitrophenyl)-5H-indeno[1,2-c]pyridazin-5-one
-
-
3-(5-oxo-5H-indeno[1,2-c]pyridazin-3-yl)benzonitrile
-
-
3-(benzyloxy)-5-nitro-1H-indazole
-
-
3-(benzyloxy)-5H-indeno[1,2-c]pyridazin-5-one
-
-
3-(benzyloxy)-6a,10a-dihydro-6H-benzo[c]chromen-6-one
-
-
3-(phenoxymethyl)-5H-indeno[1,2-c]pyridazin-5-one
-
-
3-amino-4-aminomethylpyridine dihydrochloride
-
;
3-benzyl-5-nitro-1H-indazole
-
-
3-benzyl-5H-indeno[1,2-c]pyridazin-5-one
-
-
3-chloro-N-(2-methyl-1H-indol-5-yl)benzamide
-
-
-
3-chlorobenzoic acid 2-oxo-2,3-dihydro-benzofuran-5-yl ester
-
-
-
3-cycloheptylamino-4-aminomethylpyridine dihydrochloride monohydrate
-
;
3-cyclohexylamino-4-aminomethylpyridine dihydrochloride monohydrate
-
;
3-cyclohexylmethylamino-4-aminomethylpyridine dihydrochloride monohydrate
-
;
3-cyclopentylamino-4-aminomethylpyridine dihydrochloride hemihydrate
-
;
3-cyclopropylamino-4-aminomethylpyridine dihydrochloride sesquihydrate
-
;
3-ethylamino-4-aminomethylpyridine dihydrochloride
-
;
3-hydroxyphenylacetic acid
-
-
3-methoxy-1-methyl-5-nitro-1H-indazole
-
inhibits MAO-B by 52% at 0.015 mM
3-methoxy-5-nitro-1H-indazole
-
-
3-methoxyphenol
-
IC50: 0.024 mM, monoamine oxidase A
3-methyl-5-nitro-1H-indazole
-
-
3-methyl-8-(4,4,4-trifluoro-butoxy)indeno[1.2-c]pyridazin-5-one
-
the experimentally tested model compound is docked computationally to the active site of the MAO-B enzyme. The AutoDock 3.0.5 program is employed to perform automated molecular docking. The free energies of binding and inhibition constants (Ki) of the docked compounds are calculated by the Lamarckian Genetic Algorithm of AutoDock 3.0.5. Excellent to good correlations between the calculated and experimental Ki values are obtained
3-methylamino-4-aminomethylpyridine dihydrochloride
-
;
3-oxo-2,3-dihydro-1-benzofuran-6-yl 3-chlorobenzenesulfonate
-
-
-
3-phenyl-9H-indeno[1,2-e][1,2,4]triazin-9-one
-
; 21% inhibition at 0.01 mM
3-[(1-methylethyl)amino]-4-aminomethylpyridine dihydrochloride
-
;
3-[(2-methyl-1H-indol-5-yl)carbamoyl]benzene-1-sulfonic acid
-
-
-
3-[(4-fluorophenoxy)methyl]-5H-indeno[1,2-c]pyridazin-5-one
-
; 12% inhibition at 0.01 mM
3-[(E)-(2,4-dioxo-1,3-thiazolidin-5-ylidene)amino]benzoic acid
-
R598127
3-[(E)-(prop-2-yn-1-ylimino)methyl]naphthalen-2-ol
-
-
3-[(E)-2-phenylvinyl]-5H-indeno[1,2-c]pyridazin-5-one
-
-
3-[2-(ethylamino)-2-oxoethyl]-1-benzofuran-6-yl 3-chlorobenzenesulfonate
-
17% inhibition of isoform MAO-A at 0.01 mM
-
3-[2-(methylamino)-2-oxoethyl]-1-benzofuran-6-yl 3-chlorobenzenesulfonate
-
31% inhibition of isoform MAO-A at 0.01 mM
-
3-[4-(trifluoromethyl)phenyl]-5H-indeno[1,2-c]pyridazin-5-one
-
-
3-[[4-(trifluoromethyl)phenoxy]methyl]-5H-indeno[1,2-c]pyridazin-5-one
-
48% inhibition at 0.01 mM
3-{[(3,4-dimethyl-2-oxo-2H-chromen-7-yl)oxy]methyl}benzonitrile
-
-
4,4'-[[4-(aminomethyl)pyridine-3,5-diyl]bis(oxy)]dibutan-1-ol dihydrochloride
-
-
4-(1-acetyl-4,5-dihydro-1H-pyrazol-3-yl)benzene-1,2,3-triol
-
IC50: 0.0001 mM, MAO-A; IC50: 0.39 mM, MAO-B
4-(1-acetyl-4,5-dihydro-1H-pyrazol-3-yl)benzene-1,3-diol
-
IC50: 0.0001 mM, MAO-A; IC50: 0.08 mM, MAO-B
4-(1-acetyl-4,5-dihydro-1H-pyrazol-3-yl)phenol
-
IC50: 0.00005 mM, MAO-A; IC50: 0.062 mM, MAO-B
4-(1-acetyl-5-phenyl-4,5-dihydro-1H-pyrazol-3-yl)benzene-1,3-diol
-
IC50: 0.0001 mM, MAO-A; IC50: 0.03 mM, MAO-B
4-(1-phenyl-4,5-dihydro-1H-pyrazol-3-yl)phenol
-
IC50: 0.000073 mM, MAO-A; IC50: 0.003 mM, MAO-B
4-(2,4-dichlorophenyl)-2-[(2E)-2-(2-methylcyclohexylidene)hydrazinyl]-1,3-thiazole
-
-
4-(2,4-dichlorophenyl)-2-[2-(4-methylcyclohexylidene)hydrazinyl]-1,3-thiazole
-
-
4-(2,4-difluorophenyl)-2-[(2E)-2-(2-methylcyclohexylidene)hydrazinyl]-1,3-thiazole
-
-
4-(2,4-difluorophenyl)-2-[2-(4-methylcyclohexylidene)hydrazinyl]-1,3-thiazole
-
-
4-(2-aminoethyl)-7-[(3-chlorobenzyl)oxy]-2H-chromen-2-one
-
-
-
4-(4-chlorophenyl)-2-(2-cycloheptylidenehydrazinyl)-1,3-thiazole
-
-
4-(4-chlorophenyl)-2-(2-cyclohexylidenehydrazinyl)-1,3-thiazole
-
-
4-(4-chlorophenyl)-2-(2-cyclopentylidenehydrazinyl)-1,3-thiazole
-
-
4-(4-chlorophenyl)-2-[(2E)-2-(2-methylcyclohexylidene)hydrazinyl]-1,3-thiazole
-
-
4-(4-chlorophenyl)-2-[2-(4-methylcyclohexylidene)hydrazinyl]-1,3-thiazole
-
-
4-(4-chlorophenyl)-5H-indeno[1,2-c]pyridazin-5-one
-
-
4-(4-fluorophenyl)-2-[(2E)-2-(2-methylcyclohexylidene)hydrazinyl]-1,3-thiazole
-
-
4-(4-fluorophenyl)-2-[2-(4-methylcyclohexylidene)hydrazinyl]-1,3-thiazole
-
-
4-(4-methoxyphenyl)-2-[(2E)-2-(2-methylcyclohexylidene)hydrazinyl]-1,3-thiazole
-
-
4-(4-methoxyphenyl)-2-[2-(4-methylcyclohexylidene)hydrazinyl]-1,3-thiazole
-
-
4-(aminomethyl)-2-oxo-2H-chromen-7-yl 3-chlorobenzenesulfonate
-
-
-
4-(aminomethyl)-7-(benzyloxy)-2H-chromen-2-one
-
-
-
4-(aminomethyl)-7-[(3-chlorobenzyl)oxy]-2H-chromen-2-one
-
-
-
4-(aminomethyl)-N,N'-dibutylpyridine-3,5-diamine dihydrochloride
-
;
4-(aminomethyl)-N,N'-diethylpyridine-3,5-diamine dihydrochloride
-
;
4-(aminomethyl)-N,N'-dimethylpyridine-3,5-diamine dihydrochloride
-
;
4-(aminomethyl)-N-methylpyridine-3,5-diamine dihydrochloride
-
;
4-([benzyl(methyl)amino]methyl)-7-[(3-chlorobenzyl)oxy]-2Hchromen-2-one
-
-
-
4-benzyl-1-cyclopropyl-1,2,3,6-tetrahydropyridine
-
-
4-chloro-N'-(nonan-5-yl)benzohydrazide
-
-
-
4-chloro-N-(2-morpholinoethyl)nicotinamide
-
-
-
4-chloro-N-(3-morpholinopropyl)nicotinamide
-
-
-
4-chlorobenzaldehyde (4-methyl-1,3-thiazol-2-yl)hydrazone
-
pKi: 7.42
4-chlorobenzaldehyde (4-phenyl-1,3-thiazol-2-yl)hydrazone
-
pKi: 7.0
4-Cyanophenol
-
weak inhibition
4-Cyanophenol
-
-
4-ethyl-N'-(nonan-5-yl)benzohydrazide
-
-
-
4-hydroxy-3-methoxy-alpha(methylaminomethyl)benzyl alcohol
-
IC50: 0.0089 mM, monoamine oxidase B; IC50: 0.0134 mM, monoamine oxidase A
4-Hydroxy-3-methoxybenzylamine
-
IC50: 0.13 mM, monoamine oxidase A; IC50: 0.382 mM, monoamine oxidase B
4-hydroxy-3-methoxyphenethyl alcohol
-
IC50: 0.18 mM, monoamine oxidase A
4-hydroxy-3-methoxyphenyl acetone
-
IC50: 0.0302 mM, monoamine oxidase A
4-hydroxyphenylacetic acid
-
-
4-methoxybenzaldehyde (4-methyl-1,3-thiazol-2-yl)hydrazone
-
pKi: 7.72
4-methoxybenzaldehyde (4-phenyl-1,3-thiazol-2-yl)hydrazone
-
pKi: 7.3
4-methylbenzaldehyde (4-methyl-1,3-thiazol-2-yl)hydrazone
-
pKi: 6.69
4-methylbenzaldehyde (4-phenyl-1,3-thiazol-2-yl)hydrazone
-
pKi: 7.67
4-methylcyclohexanone (4-phenyl-1,3-thiazol-2-yl)hydrazone
-
pKi: 7.0
4-oxo-4H-chromene-3-carboxylic acid
-
specific for MAO-B
4-phenyl-5H-indeno[1,2-d]pyrimidin-5-one
-
;
4-[(2E)-3-(4-chlorophenyl)prop-2-enoyl]phenyl methanesulfinate
-
-
4-[(benzylamino)methyl]-7-[(3-chlorobenzyl)oxy]-2H-chromen-2-one
-
-
-
4-[(dimethylamino)methyl]-7-[(3-fluorobenzyl)oxy]-2H-chromen-2-one
-
-
-
4-[(ethylamino)methyl]-7-[(3-fluorobenzyl)oxy]-2H-chromen-2-one methanesulfonate
-
-
-
4-[(methylamino)carbonyl]-2-oxo-2H-chromen-7-yl 3-chlorobenzenesulfonate
-
9% inhibition of isoform MAO-B at 0.01 mM, 8% inhibition of isoform MAO-A at 0.01 mM
-
4-[(methylamino)methyl]-2-oxo-2H-chromen-7-yl 3-chlorobenzenesulfonate
-
-
-
4-[1-acetyl-5-(2,4-dimethoxyphenyl)-4,5-dihydro-1H-pyrazol-3-yl]benzene-1,3-diol
-
IC50: 0.0001 mM, MAO-A; IC50: 0.038 mM, MAO-B
4-[1-acetyl-5-(2,4-dimethoxyphenyl)-4,5-dihydro-1H-pyrazol-3-yl]phenol
-
IC50: 0.00001 mM, MAO-A; IC50: 0.02 mM, MAO-B
4-[1-acetyl-5-(2-chlorophenyl)-4,5-dihydro-1H-pyrazol-3-yl]phenol
-
IC50: 0.0000086 mM, MAO-A; IC50: 0.087 mM, MAO-B
4-[1-acetyl-5-(2-methoxyphenyl)-4,5-dihydro-1H-pyrazol-3-yl]benzene-1,3-diol
-
IC50: 0.000008 mM, MAO-A; IC50: 0.13 mM, MAO-B
4-[1-acetyl-5-(2-methoxyphenyl)-4,5-dihydro-1H-pyrazol-3-yl]phenol
-
IC50: 0.0000088 mM, MAO-A; IC50: 0.1 mM, MAO-B
4-[1-acetyl-5-(2-methylphenyl)-4,5-dihydro-1H-pyrazol-3-yl]benzene-1,3-diol
-
IC50: 0.00001 mM, MAO-A; IC50: 0.00002 mM, MAO-B
4-[1-acetyl-5-(3-chlorophenyl)-4,5-dihydro-1H-pyrazol-3-yl]phenol
-
IC50: 0.00001 mM, MAO-A; IC50: 0.023 mM, MAO-B
4-[1-acetyl-5-(3-methylphenyl)-4,5-dihydro-1H-pyrazol-3-yl]benzene-1,3-diol
-
IC50: 0.000013 mM, MAO-A; IC50: 0.000038 mM, MAO-B
4-[1-acetyl-5-(3-methylphenyl)-4,5-dihydro-1H-pyrazol-3-yl]phenol
-
IC50: 0.000008 mM, MAO-A; IC50: 0.019 mM, MAO-B
4-[1-acetyl-5-(4-chlorophenyl)-4,5-dihydro-1H-pyrazol-3-yl]benzene-1,3-diol
-
IC50: 0.00001 mM, MAO-A; IC50: 0.12mM, MAO-B
4-[1-acetyl-5-(4-chlorophenyl)-4,5-dihydro-1H-pyrazol-3-yl]phenol
-
IC50: 0.0001 mM, MAO-A; IC50: 0.04 mM, MAO-B
4-[1-acetyl-5-(4-methoxyphenyl)-4,5-dihydro-1H-pyrazol-3-yl]benzene-1,3-diol
-
IC50: 0.000009 mM, MAO-A; IC50: 0.083 mM, MAO-B
4-[1-acetyl-5-(4-methoxyphenyl)-4,5-dihydro-1H-pyrazol-3-yl]phenol
-
IC50: 0.000009 mM, MAO-A; IC50: 0.0072 mM, MAO-B
4-[1-acetyl-5-(4-methylphenyl)-4,5-dihydro-1H-pyrazol-3-yl]benzene-1,3-diol
-
IC50: 0.000009 mM, MAO-A; IC50: 0.042 mM, MAO-B
4-[1-acetyl-5-(4-methylphenyl)-4,5-dihydro-1H-pyrazol-3-yl]phenol
-
IC50: 0.0001mM, MAO-A; IC50: 0.03 mM, MAO-B
4-[2-(2-cycloheptylidenehydrazinyl)-1,3-thiazol-4-yl]benzonitrile
-
-
4-[2-(2-cyclohexylidenehydrazinyl)-1,3-thiazol-4-yl]benzonitrile
-
-
4-[2-(2-cyclopentylidenehydrazinyl)-1,3-thiazol-4-yl]benzonitrile
-
-
4-[2-(methylamino)-2-oxoethyl]-2-oxo-2H-chromen-7-yl 3-chlorobenzenesulfonate
-
-
-
4-[2-[(2E)-2-(2-methylcyclohexylidene)hydrazinyl]-1,3-thiazol-4-yl]benzonitrile
-
-
4-[2-[2-(4-methylcyclohexylidene)hydrazinyl]-1,3-thiazol-4-yl]benzonitrile
-
-
4-[2-[4-(benzyloxy)phenoxy]hydrazino]butanenitrile
-
0.1 mM, 39% inhibition
4-{[(2-oxo-2H-chromen-3-yl)carbonyl]amino}benzoic acid
-
-
5,6-dichloro-N-(2-morpholinoethyl)nicotinamide
-
-
-
5,6-dichloro-N-(3-morpholinopropyl)nicotinamide
-
-
-
5,7-diethyl-3-methyl-2-[(1E,3E)-4-phenylbuta-1,3-dien-1-yl]-3H-imidazo[4,5-c]pyridine-4,6(5H,7H)-dione
-
-
5-(2-furyl)-3-(2-thienyl)-4,5-dihydro-1H-pyrazole-1-carbothioamide
-
;
5-(2-furyl)-3-(4-methylphenyl)-4,5-dihydro-1H-pyrazole-1-carbothioamide
-
;
5-(4-(2-[methyl(pyridin-2-yl)amino]ethoxy)benzyl)-1,3-thiazolidine-2,4-dione
-
i.e. rosiglitazone
-
5-(4-chlorocyclohexa-1,5-dien-1-yl)-3-(4-chlorophenyl)-1-propionyl-4,5-dihydro-1H-pyrazole
-
-
5-(4-chlorocyclohexa-1,5-dien-1-yl)-3-(4-fluorophenyl)-1-propionyl-4,5-dihydro-1H-pyrazole
-
-
5-(4-chlorocyclohexa-1,5-dien-1-yl)-3-(4-methoxyphenyl)-1-propionyl-4,5-dihydro-1H-pyrazole
-
-
5-(4-chlorocyclohexa-1,5-dien-1-yl)-3-(4-methylphenyl)-1-propionyl-4,5-dihydro-1H-pyrazole
-
-
5-(4-chlorophenyl)-3-(2-thienyl)-4,5-dihydro-1H-pyrazole-1-carbothioamide
-
;
5-(4-chlorophenyl)-3-(4-fluorophenyl)-4,5-dihydro-1H-pyrazole-1-carbothioamide
-
;
5-(4-chlorophenyl)-3-(4-methylphenyl)-4,5-dihydro-1H-pyrazole-1-carbothioamide
-
;
5-(4-chlorophenyl)-3-phenyl-1-propionyl-4,5-dihydro-1H-pyrazole
-
-
5-(4-fluorocyclohexa-1,5-dien-1-yl)-3-(4-fluorophenyl)-1-propionyl-4,5-dihydro-1H-pyrazole
-
-
5-(4-fluorocyclohexa-1,5-dien-1-yl)-3-(4-methoxyphenyl)-1-propionyl-4,5-dihydro-1H-pyrazole
-
-
5-(4-fluorocyclohexa-1,5-dien-1-yl)-3-(4-methylphenyl)-1-propionyl-4,5-dihydro-1H-pyrazole
-
-
5-(4-fluorophenyl)-3-phenyl-1-propionyl-4,5-dihydro-1H-pyrazole
-
-
5-(4-methoxycyclohexa-1,5-dien-1-yl)-3-(4-methoxyphenyl)-1-propionyl-4,5-dihydro-1H-pyrazole
-
-
5-(4-methoxycyclohexa-1,5-dien-1-yl)-3-(4-methylphenyl)-1-propionyl-4,5-dihydro-1H-pyrazole
-
-
5-(4-methoxycyclohexa-1,5-dien-1-yl)-3-phenyl-1-propionyl-4,5-dihydro-1H-pyrazole
-
-
5-(4-methylcyclohexa-1,5-dien-1-yl)-3-(4-methylphenyl)-1-propionyl-4,5-dihydro-1H-pyrazole
-
-
5-(4-methylcyclohexa-1,5-dien-1-yl)-3-phenyl-1-propionyl-4,5-dihydro-1H-pyrazole
-
-
5-(4-methylphenyl)-3-(2-thienyl)-4,5-dihydro-1H-pyrazole-1-carbothioamide
-
;
5-(4-[(1-methylcyclohexyl)methoxy]benzyl)-1,3-thiazolidine-2,4-dione
-
i.e. ciglitazone
-
5-(4-[(6-hydroxy-2,5,7,8-tetramethyl-3,4-dihydro-2H-chromen-2-yl)methoxy]benzyl)-1,3-thiazolidine-2,4-dione
-
i.e. troglitazone
-
5-(4-[2-(5-ethylpyridin-2-yl)ethoxy]benzyl)-1,3-thiazolidine-2,4-dione
-
i.e. pioglitazone, docking of R-pioglitazone in the substrate cavity of MAO-B
-
5-(aminomethyl)-3-aryl-2-oxazolidinones
-
-
5-(benzo[d][1,3]dioxol-5-yl)-2,2-dibutyl-N-(2,6-difluorobenzoyl)-1,3,4-oxadiazole-3(2H)-carboxamide
-
1 mM, 78% inhibition
5-(benzo[d][1,3]dioxol-5-yl)-2,2-dibutyl-N-(2-chlorobenzoyl)-1,3,4-oxadiazole-3(2H)-carboxamide
-
1 mM, 75% inhibition
5-bromo-N-(2-morpholinoethyl)nicotinamide
-
-
-
5-bromo-N-(3-morpholinopropyl)nicotinamide
-
-
-
5-chloro-2-[(E)-(prop-2-yn-1-ylimino)methyl]phenol
-
-
5-chloro-2-[(prop-2-yn-1-ylamino)methyl]phenol
-
-
5-chloro-6-hydroxy-N-(2-morpholinoethyl)nicotinamide
-
-
-
5-chloro-6-hydroxy-N-(3-morpholinopropyl)nicotinamide
-
-
-
5-cyclohexa-1,5-dien-1-yl-3-(4-fluorophenyl)-1-propionyl-4,5-dihydro-1H-pyrazole
-
-
5-cyclohexa-1,5-dien-1-yl-3-(4-methoxyphenyl)-1-propionyl-4,5-dihydro-1H-pyrazole
-
-
5-cyclohexa-1,5-dien-1-yl-3-(4-methylphenyl)-1-propionyl-4,5-dihydro-1H-pyrazole
-
-
5-fluoro-alpha-methyltryptamine
-
a drug causing head-twitch response, IC50: 0.00018 mM
5-fluorotryptamine
-
a drug causing head-twitch response, IC50: 0.00018 mM
5-nitro-1-(pyridin-2-ylmethyl)-1H-indazol-3-ol
-
-
5-nitroindazole
-
inhibits MAO-B by 98.5% at 0.015 mM
-
6,11-dihydro-5H-benzo[a]carbazole
-
; 38% inhibition at 0.025 mM
6-(3-chlorophenyl)-1,3-dimethyl-1H-pteridine-2,4-dione
-
-
6-amino-1,3-dimethyl-5-([1-phenylmeth-(E)-ylidene]-amino)-1H-pyrimidine-2,4-dione
-
-
6-amino-1,3-dimethyl-5-[(E)-3-phenyl-prop-2-en-(E)-ylideneamino]-1H-pyrimidine-2,4-dione
-
-
6-amino-5-([1-(3-chlorophenyl)-meth-(E)-ylidene]-amino)-1,3-dimethyl-1H-pyrimidine-2,4-dione
-
-
6-amino-5-[(E)-3-(3-chloro-phenyl)-prop-2-en-(E)-ylideneamino]-1,3-dimethyl-1H-pyrimidine-2,4-dione
-
-
6-chloro-N-(2-morpholinoethyl)nicotinamide
-
-
-
6-chloro-N-(3-morpholinopropyl)nicotinamide
-
-
-
6-fluoro-alpha-methyltryptamine
-
a drug causing head-twitch response, IC50: 0.00018 mM
6-fluoro-N-(2-morpholinoethyl)nicotinamide
-
-
-
6-fluoro-N-(3-morpholinopropyl)nicotinamide
-
-
-
6-fluorotryptamine
-
a drug causing head-twitch response, IC50: 0.00018 mM
6-hydroxy-N-(2-morpholinoethyl)nicotinamide
-
-
-
6-hydroxy-N-(3-morpholinopropyl)nicotinamide
-
-
-
6-hydroxy-N-propargyl-1(R)-aminoindan
-
the experimentally tested model compound is docked computationally to the active site of the MAO-B enzyme. The AutoDock 3.0.5 program is employed to perform automated molecular docking. The free energies of binding and inhibition constants (Ki) of the docked compounds are calculated by the Lamarckian Genetic Algorithm of AutoDock 3.0.5. Excellent to good correlations between the calculated and experimental Ki values are obtained
6-methyl-N-(2-morpholinoethyl)nicotinamide
-
-
-
6-methyl-N-(3-morpholinopropyl)nicotinamide
-
-
-
6-nitroindazole
-
inhibits MAO-B by 89% at 0.015 mM, also inhibits MAO-A
-
6-[(E)-2-(3-chloro-phenyl)-vinyl]-1,3-dimethyl-1H-pteridine-2,4-dione
-
-
6-[(E)-2-(3-chlorostyryl)]-1,3-dimethyl-1H-pteridine-2,4-dione
-
-
7-(1,3-benzodioxol-5-ylmethoxy)-4-[(methylamino)methyl]-2H-chromen-2-one
-
-
-
7-(2-hydroxy-2-phenylethyloxy)-3,4-dimethyl-2H-chromen-2-one
-
;
7-(3-chlorobenzyloxy)-3-methyl-2H-chromen-2-one
-
pIC50 for MAO-A: 4.9; pIC50 for MAO-B: 8.29
7-(3-chlorobenzyloxy)-4-(methylamino)methylcoumarin
-
; binds noncovalently to MAO B, occupying both the entrance and the substrate cavities
7-(3-chlorobenzyloxy)-4-carboxaldehydecoumarin
-
; binds noncovalently to MAO B, occupying both the entrance and the substrate cavities
7-(3-chlorobenzyloxy)-4-formylcoumarin
-
-
-
7-(3-phenylprop-2-en-1-yloxy)-3,4-dimethyl-2H-chromen-2-one
-
pIC50 for MAO-A: 4.5; pIC50 for MAO-B: 6.95
7-(anilinomethyl)-2H-chromen-2-one
-
-
7-(benzenesulfonylmethoxy)-3,4-dimethyl-2H-chromen-2-one
-
pIC50 for MAO-A: 5.55; pIC50 for MAO-B: 6.06
7-(benzylamino)-3,4-dimethyl-2H-chromen-2-one
-
-
7-(benzyloxy)-2H-chromen-2-one
-
-
7-(benzyloxy)-3,4-dimethyl-2H-chromen-2-one
-
-
7-(benzyloxy)-4-methyl-2H-chromen-2-one
-
-
7-(benzyloxy)-4-phenyl-2H-chromen-2-one
-
-
7-(benzyloxy)-4-[(dimethylamino)methyl]-2H-chromen-2-one
-
-
-
7-(benzyloxy)-4-[(methylamino)methyl]-2H-chromen-2-one
-
-
-
7-(benzyloxy)-4-[2-(dimethylamino)ethyl]-2H-chromen-2-one
-
-
-
7-benzenesulfonyloxy-2H-chromen-2-one
-
pIC50 for MAO-A: 6.35; pIC50 for MAO-B: 4.26
7-benzyloxy-3-methyl-2H-chromen-2-one
-
pIC50 for MAO-A: 5.26; pIC50 for MAO-B: 8.18
7-benzylsulfonyl-3,4-dimethyl-2H-chromen-2-one
-
pIC50 for MAO-A: 4.73; pIC50 for MAO-B: 5.56
7-benzylthio-3,4-dimethyl-2H-chromen-2-one
-
pIC50 for MAO-A: 5.0; pIC50 for MAO-B: 7.4
7-nitroindazole
-
inhibits MAO-B by 35% at 0.015 mM
7-[(3-chlorobenzyl)oxy]-4-(chloromethyl)-2H-chromen-2-one
-
-
-
7-[(3-chlorobenzyl)oxy]-4-[(dimethylamino)methyl]-2H-chromen-2-one
-
-
-
7-[(3-chlorobenzyl)oxy]-4-[(methylamino)methyl]-2H-chromen-2-one
-
-
-
7-[(3-chlorobenzyl)oxy]-4-[(methylamino)methyl]-2H-chromen-2-one methanesulfonate
-
-
-
7-[(3-chlorobenzyl)oxy]-4-[2-(methylamino)ethyl]-2H-chromen-2-one
-
-
-
7-[(3-chlorophenyl)methoxy]-4-(methylaminomethyl)chromen-2-one
-
-
-
7-[(3-fluorobenzyl)oxy]-4-[(isopropylamino)methyl]-2H-chromen-2-one methanesulfonate
-
-
-
7-[(3-fluorobenzyl)oxy]-4-[(methylamino)methyl]-2H-chromen-2-one
-
-
-
7-[(3-fluorobenzyl)oxy]-4-[(methylamino)methyl]-2H-chromen-2-one methanesulfonate
-
-
-
8-(-3-chlorostyryl)-caffeine
P19643
by means of its dual action as A2A antagonist and MAO-B inhibitor 8-(-3-chlorostyryl)-caffeine reverses behavior and biochemical alterations, observed in the 6-OHDA-lesioned rats, pointing out to its potential benefit for the treatment of Parkinson's disease
8-(3-chloro)styrylcaffeine
-
-
8-(3-chlorostrylyl)caffeine
-
the experimentally tested model compound is docked computationally to the active site of the MAO-B enzyme. The AutoDock 3.0.5 program is employed to perform automated molecular docking. The free energies of binding and inhibition constants (Ki) of the docked compounds are calculated by the Lamarckian Genetic Algorithm of AutoDock 3.0.5. Excellent to good correlations between the calculated and experimental Ki values are obtained
8-(3-chlorostyryl)-caffeine
-
-
8-(3-chlorostyryl)caffeine
-
monoamine oxidase B
8-(benzyloxy)-1,3,7-trimethyl-3,7-dihydro-1H-purine-2,6-dione
-
-
8-hydroxyquinoline
-
reversible by the addition of Zn2+, Ni2+, Co2+
8-[(3-bromobenzyl)oxy]-1,3,7-trimethyl-3,7-dihydro-1H-purine-2,6-dione
-
-
8-[(3-chlorobenzyl)oxy]-1,3,7-trimethyl-3,7-dihydro-1H-purine-2,6-dione
-
-
8-[(3-fluorobenzyl)oxy]-1,3,7-trimethyl-3,7-dihydro-1H-purine-2,6-dione
-
-
8-[(3-methoxybenzyl)oxy]-1,3,7-trimethyl-3,7-dihydro-1H-purine-2,6-dione
-
-
9,11-dimethylpurino[7,8-c]quinazoline-8,10(9H,11H)-dione
-
-
Acetylcholine
P19643, P21396
competitively inhibits monoamine oxidase A in the brain in a tissue-dependent manner, inhibition of MAO-A in cerebellum; competitively inhibits monoamine oxidase B in the brain in a tissue-dependent manner, inhibition of MAO-B in basal ganglia
acridine
-
derivatives, irrevrsible inhibition, sensitivity of isozymes, overview
alpha-Naphthol
-
reversible by dialysis
alpha-Naphthol
-
-
Aminoguanidine
-
complete impairment of SSAO activity produced by aminoguanidine-treatment in obese rats is likely responsible for a weak limitation of fat deposition. Aminoguanidine may be useful for treating obesity via its SSAO blocking properties
amitriptyline
-
competive inhibition with 2-phenylethylamine as substrate
amphetamine
-
-
amphetamine
-
a competitive inhibitor of MAO-A
befloxatone
-
the inhibitor induces changes in the spectrum of MAO A, consistent with stacking of inhibitor with the flavin in the active site
benzaldehyde
-
strong competitive inhibitor
benzaldehyde (4-methyl-1,3-thiazol-2-yl)hydrazone
-
pKi: 8.14
benzaldehyde (4-phenyl-1,3-thiazol-2-yl)hydrazone
-
pKi: 5.92
benzhydrylidene-prop-2-ynyl-amine
-
-
benzoic acid (2H-2-oxochromen-7-yl)methyl ester
-
pIC50 for MAO-A: 5.02; pIC50 for MAO-B: 5.62
benzoic acid 2-oxo-2,3-dihydro-benzofuran-5-yl ester
-
-
-
Benzyl cyanide
-
reversible inhibitor
benzylhydrazine
-, P27338
the mode of irreversible MAO inhibition involves covalent modification of the flavin coenzyme, overview; the three-dimensional structures of phenylethylhydrazine- and benzylhydrazine-inhibited MAO B show that alkylation occurs at the N5 position on the re-face of the covalent flavin with loss of the hydrazyl nitrogens, mechanism, the mode of irreversible MAO inhibition involves covalent modification of the flavin coenzyme, overview
beta-carbolines
-
competitive reversible and potent inhibitor
beta-Naphthol
-
reversible by dialysis
beta-Naphthol
-
-
beta-phenylethylidenehydrazine
P21936
a neuroprotective drug, inhibits MAO-A by 26.7%; a neuroprotective drug, inhibits MAO-B by 14.9%
brofaromine
-
-
-
brofaromine
-
inhibitor of MAO-A
-
brofaromine
-
inhibits MAO-A reversibly
-
Caffeine
-
a dual-target-directed drug inhibiting MAO-B and antagonizing A2A receptors
CdSO4
-
1 mM, 10% inhibition, monoamine oxidase B; 1 mM, 90% inhibition with serotonin as substrate, monoamine oxidase A
chelidonine
-
-
-
chlorgilin
-
-
-
chlorgilin
Coregonus lavaretus ludoga
-
i.e. N-[2,4-dichlorophenoxy]propyl-N-methyl-2-propynylamine
-
chlorgylin
-
-
-
chlorgyline
-
-
-
chlorgyline
-
; specific inhibitor of isoform MAO-A
-
ciglitazone
-
-
cinnamyl alcohol
-
compound from Rhodiola rosea extract, inhibits both MAO A and MAO B
cis-2,4,5-trimethoxypropenylbenzene
-
IC50: 0.142 mM, monoamine oxidase A; IC50: 0.362 mM, monoamine oxidase B
cis-3-(2-thienyl)-2-(N-phenylthiocarbamoyl)-3,3a,4,5,6,7-hexahydro-2H-indazol
-
-
-
Clorgyline
-
MAO-A highly sensitive and MAO-B less sensitive to inhibition
Clorgyline
-
irreversible inhibitor
Clorgyline
-
MAO-A highly sensitive and MAO-B less sensitive to inhibition; poor inhibition
Clorgyline
-
MAO-A highly sensitive and MAO-B less sensitive to inhibition
Clorgyline
-
IC50: 0.00042 mM; IC50: 1.2 nM
Clorgyline
-
MAOA-specific irreversible inhibitor, used clinically as antidepressant. It foms a covalent bond with FAD
Clorgyline
-
IC50: 0.000014 mM
Clorgyline
-
monoamine oxidase A
Clorgyline
-
addition of the MAO-A inhibitor caused an increase in the maximal levels of extracellular serotonin achieved when challenged with 3,4-methylenedioxymethamphetamine
Clorgyline
-
the reversible and selective MAO-A inhibitor produces increases in 5-hydroxytryptamine syndrome in the 5-hydroxytryptamine-treated rats
Clorgyline
-
;
Clorgyline
P21396
addition of a 10fold molar excess of the acetylenic inhibitor clorgyline to rat MAO-A results in the formation of flavocyanine adduct
Clorgyline
P21397, P27338
;
Clorgyline
-
the irreversible MAO-A inhibitor shows anti-oncogenic and pro-differentiation effects on high grade prostate cancer cells, inhibition of MAO-A might restore differentiation and reverse the aggressive behavior of high grade prostate cancer cells, overview. The inhibitor has significant gene regulatory effects on the beta-catenin and ERBB2 pathways in vivo, overview
Clorgyline
-
complete inhibition at 0.01 mM
Clorgyline
Q0PGS2
complete inhibition at 0.01 mM
Clorgyline
-
an acetylenic inhibitor, addition of it results in the conversion of the oxidized flavin cofactors to their respective N(5) flavocyanine adducts
Clorgyline
-
inhibition of MAO A and MAO B
Clorgyline
-
; MAO-A forms a N(5) flavocyanine adduct on inhibition by clorgyline, MAO A is blocked at an N-terminal threonyl residue
Clorgyline
-
selective inhibition of MAO-A
Clorgyline
-
inhibits both MAO-A and MAO-B
Clorgyline
-
inhibitor of MAO-A
Clorgyline
-
inhibits MAO-A irreversibly
cordyline
P19643, P21396
-
-
CuSO4
-
1 mM, 95% inhibition with serotonin as substrate, monoamine oxidase A
cyanidin
-
competitive interaction of cyanidin with MAO A plus a mixed competitive and non-competitive mode of interaction of cyanidin with MAO B
cyanidin-3,5-diglucoside
-
-
cyanidin-3-O-beta-D-galactoside
-
-
cyanidin-3-O-beta-D-glucoside
-
mixed competitive and non-competitive mode of interaction with both enzyme isozymes
cyanidin-3-O-beta-D-rutinoside
-
-
cyclohexanone (4-phenyl-1,3-thiazol-2-yl)hydrazone
-
pKi: 7.69
cyclopentanone (4-phenyl-1,3-thiazol-2-yl)hydrazone
-
pKi: 6.85
D-amphetamine
-
-
D-amphetamine
-
the inhibitor induces changes in the spectrum of MAO A, consistent with stacking of inhibitor with the flavin in the active site. Inhibitor stabilizes the semiquinone form of FAD during reduction of MAO A by dithionite and no further reduction of the inhibitor-MAO A complex occurs
D-amphetamine
-
competitive inhibition
D-amphetamine
-
a nonselective reversible MAO inhibitor, inhibits the MAO A S209E mutant with much lower affinity, 160fold and 20fold, respectively, than the wild-type enzyme
D-amphetamine
-
reversible inhibitor; reversible inhibitor
D-amphetamine
-
-
dehydroepiandrosterone
P19643, P21396
at 0.1 mM, inhibition of MAO-A by 44.2%; at 0.1 mM, inhibition of MAO-B by 61.2%
delphinidin
-
-
delphinidin-3-O-beta-D-glucoside
-
-
deoxycholate
-
-
Deprenyl
-
MAO-B sensitive
Deprenyl
-
IC50: 0.0023 mM; IC50: 3.3 mM
Deprenyl
-
IC50: 0.020 mM
Deprenyl
P19643, P21396
;
Deprenyl
-
complete inhibition at 0.01 mM
Deprenyl
Q0PGS2
complete inhibition at 0.01 mM
Deprenyl
-
inhibits the enzyme in vivo by 34-70% depending on the age, reversible by 4-chlorophenylalanine. Deprenyl administration decreases locomotion, altered vertical positioning and increased heart rate in larvae in vivo, 4-chlorophenylalanine normalizes serotonin levels and rescues the behavioral alteration
Deprenyl
-
selective inhibition of MAO-B
Deprenyl
-
an acetylenic compound that forms covalent adducts with the N5 of the covalent FAD of MAO-B, pharmacologically inert as MAO-A inhibitor
Deprenyl
Coregonus lavaretus ludoga
-
i.e. N-1-phenylisopropyl-N-methyl-2-propynylamine
di(2-hydroxyethyl)methyldodecylammonium
-
reversible competitive inhibitor
-
di(2-hydroxyethyl)methyldodecylammonium ion
-
a biocide, inhibits MAO-B
-
epigallocatechin gallate dimer
-
compound from Rhodiola rosea extract, inhibits both MAO A and MAO B
esuprone
-
inhibits MAO-A reversibly
-
ethyl 4-hydroxy-3-methoxycinnamate
-
IC50: 0.0057 mM, monoamine oxidase B; IC50: 0.0247 mM, monoamine oxidase A
ethyl 4-{[(2-oxo-2H-chromen-3-yl)carbonyl]amino}benzoate
-
-
ethyl-4-hydroxy-3-methoxyphenylacetate
-
IC50: 0.081 mM, monoamine oxidase A
Eugenol
-
IC50: 0.0344 mM, monoamine oxidase A; IC50: 0.288 mM, monoamine oxidase B
eugenol methyl ether
-
IC50: 0.11 mM, monoamine oxidase A; IC50: 0.269 mM, monoamine oxidase B
Harmaline
-
-
Harmaline
-
-
Harmaline
P21396
the ability of harmaline to modify the behavioral effects of 5-methoxy-N,N-dimethyltryptamine is mediated by the inhibition of MAOA. Serotonin2A receptors are responsible for the late hyperactivity induced by 5-methoxy-N,N-dimethyltryptamine in the presence of MAOA inhibitors
Harmaline
-
MAOI harmaline significantly reduces 5-MeO-DMT depletion and increases bufotenine formation in human hepatocytes
Harmaline
-
-
Harmaline
-
identification by HPLC-ESI-mass spectrometry. Potent reversible and strong inhibition of MAO-A, poor inhibition of MAO-B, from seeds
harmalol
-
identification by HPLC-ESI-mass spectrometry
harman
-
inhibition of MAO A
Harmane
-
an MAO A specific reversible inhibitor
Harmane
-
reversible enzyme-specific inhibitor
harmine
-
the inhibitor induces changes in the spectrum of MAO A, consistent with stacking of inhibitor with the flavin in the active site. Inhibitor stabilizes the semiquinone form of FAD during reduction of MAO A by dithionite and no further reduction of the inhibitor-MAO A complex occurs
harmine
-
identification by HPLC-ESI-mass spectrometry. Potent reversible and strong inhibition of MAO-A, poor inhibition of MAO-B, from seeds
harmol
-
identification by HPLC-ESI-mass spectrometry
indol -2,3-dione
-
the experimentally tested model compound is docked computationally to the active site of the MAO-B enzyme. The AutoDock 3.0.5 program is employed to perform automated molecular docking. The free energies of binding and inhibition constants (Ki) of the docked compounds are calculated by the Lamarckian Genetic Algorithm of AutoDock 3.0.5. Excellent to good correlations between the calculated and experimental Ki values are obtained
Iproniazid
-
-
Iproniazid
-
nonselective inhibitor
Iproniazide
-
inhibits both MAO-A and MAO-B
Iproniazide
-
inhibitor of MAO-A and MAO-B
isatin
-
monoamine oxidase A; monoamine oxidase B
isatin
-
a nonselective reversible MAO inhibitor, inhibits the MAO A S209E mutant with much lower affinity, 160fold and 20fold, respectively, than the wild-type enzyme
isatin
-
reversible inhibitor; reversible inhibitor
isatin
-
inhibitor of MAO-B
isatin
-
non-specific reversible inhibitor
isocarboxazide
-
-
-
isocarboxazide
-
inhibitor of MAO-A and MAO-B
-
isocarboxazide
-
inhibits MAO-A and MAO-B irreversibly
-
isoproniazide
-
inhibits MAO-A and MAO-B irreversibly
-
KF-17837
-
a dual-target-directed drug inhibiting MAO-B and antagonizing A2A receptors
KW-6002
-
a dual-target-directed drug inhibiting MAO-B and antagonizing A2A receptors
L-deprenyl
-
-
L-deprenyl
-
inhibition of MAO A and MAO B
L-deprenyl
-
irreversible cerebral MAO-B inhibitor
ladostigil
-
nonselective inhibitor
-
lamotrigine
-
its in vivo MAO-B inhibiting effect might contribute in part to its antidepressant activity
lazabemide
-
the experimentally tested model compound is docked computationally to the active site of the MAO-B enzyme. The AutoDock 3.0.5 program is employed to perform automated molecular docking. The free energies of binding and inhibition constants (Ki) of the docked compounds are calculated by the Lamarckian Genetic Algorithm of AutoDock 3.0.5. Excellent to good correlations between the calculated and experimental Ki values are obtained
lazabemide
-
selective inhibition of MAO-B
lazabemide
-
inhibitor of MAO-B
lazabemide
-
inhibits MAO-B reversibly
LU-53439
-
inhibits MAO-B reversibly
-
malvidin-3,5-diglucoside
-
-
-
malvidin-3-O-beta-D-galactoside
-
-
-
malvidin-3-O-beta-D-glucoside
-
-
Mesobuthus gibbosus venom peptide
-
with specific MAO-A inhibitory activity, reversible, non-competitive, may be responsible for the anxiogenic effects of the scorpion venom on animals and humans
-
metanephrine
-
IC50: 0.252 mM, monoamine oxidase A
methyl (2E,4E)-5-(1,3-benzodioxol-5-yl)penta-2,4-dienoate
-
;
methyl 4'-[(E)-(prop-2-yn-1-ylimino)methyl]biphenyl-4-carboxylate
-
-
methylene blue
-
reversible enzyme-specific inhibitor
methylene blue
-
-
methylene blue
-
-
moclobemide
-
the MAO inhibitor is promising in the therapeutic management of post-traumatic stress disorder and panic disorder; the MAO inhibitor is promising in the therapeutic management of post-traumatic stress disorder and panic disorder
moclobemide
-
-
moclobemide
-
inhibitor of MAO-A
moclobemide
-
inhibits MAO-A reversibly
moclobemide
-
specific for MAO-A
moclobemide
-
specific inhibitor of isoform MAO-A
mofegiline
-
mechanism-based irreversible, competitive inhibition versus substrate of MAO-B with a 1:1 molar stoichiometry, also competitively inhibits MAO-A. Effects on UV absorption spectra of flavin, and inhibitor-bound enzyme structure, overview
N'-(2-cyanoethyl)-4-ethylbenzohydrazide
-
-
-
N'-(nonan-5-yl)-2-naphthohydrazide
-
-
-
N'-(nonan-5-yl)benzo[d][1,3]dioxole-5-carbohydrazide
-
-
-
N'-phenyl-7-benzyloxy-2-oxo-2H-chromene-3-carbohydrazide
-
-
N,1-dimethyl-N-prop-2-yn-1-yl-1H-pyrrole-2-carboxamide
-
-
N,N'-(1R,2S)-cyclohexane-1,2-diylbis(2-oxo-2H-chromene-3-carboxamide)
-
;
N,N'-(1R,2S)-cyclohexane-1,2-diylbis(2-oxo-2H-chromene-3-carboxamide)
-
-
N,N'-1,2-phenylenebis(2-oxo-2H-chromene-3-carboxamide)
-
;
N,N'-1,2-phenylenebis(2-oxo-2H-chromene-3-carboxamide)
-
-
N,N'-1,4-phenylenebis(2-oxo-2H-chromene-3-carboxamide)
-
;
N,N'-1,4-phenylenebis(2-oxo-2H-chromene-3-carboxamide)
-
-
N,N'-bis[[(5S)-3-(3-fluoro-4-morpholin-4-ylphenyl)-2-oxo-1,3-oxazolidin-5-yl]methyl]butanediamide
-
IC50: 0.09 mM, at 0.15 mM kynuramine
N,N'-butane-1,4-diylbis(2-oxo-2H-chromene-3-carboxamide)
-
potent inhibitor of MAO-A with high selectivity towards MAO-B; potent inhibitor of MAO-A with high selectivity towards MAO-B
N,N'-butane-1,4-diylbis(2-oxo-2H-chromene-3-carboxamide)
-
potent inhibitor of MAO-A with high selectivity towards MAO-B
N,N'-butane-1,4-diylbis(7-methoxy-2-oxo-2H-chromene-3-carboxamide)
-
;
N,N'-butane-1,4-diylbis(7-methoxy-2-oxo-2H-chromene-3-carboxamide)
-
-
N,N'-ethane-1,2-diylbis(2-oxo-2H-chromene-3-carboxamide)
-
;
N,N'-ethane-1,2-diylbis(2-oxo-2H-chromene-3-carboxamide)
-
-
N,N'-hexane-1,6-diylbis(2-oxo-2H-chromene-3-carboxamide)
-
potent inhibitor of MAO-A with high selectivity towards MAO-B; potent inhibitor of MAO-A with high selectivity towards MAO-B
N,N'-hexane-1,6-diylbis(2-oxo-2H-chromene-3-carboxamide)
-
potent inhibitor of MAO-A with high selectivity towards MAO-B
N,N'-[(1,5-dioxopentane-1,5-diyl)bis[piperazine-4,1-diyl(3-fluorobenzene-4,1-diyl)[(5R)-2-oxo-1,3-oxazolidine-3,5-diyl]methanediyl]]diacetamide
-
IC50: 0.0005 mM, at 0.15 mM kynuramine
N-((4-isopropylphenyl)-2-oxo-2H-chromene-3-carboxamide)-amide
-
-
N-(1-hydroxy-2,2,6,6-tetramethylpiperidin-4-yl)-2-(4-[[methyl(prop-2-yn-1-yl)amino]methyl]phenyl)acetamide
-
;
N-(1-hydroxy-2,2,6,6-tetramethylpiperidin-4-yl)-2-(4-[[methyl(prop-2-yn-1-yl)amino]methyl]phenyl)acetamide
-
i.e. ParSL-1, a TEMPO-conjugated pargyline analogue; i.e. ParSL-1, a TEMPO-conjugated pargyline analogue
N-(1-hydroxy-2,2,6,6-tetramethylpiperidin-4-yl)-3-[[methyl(prop-2-yn-1-yl)amino]methyl]benzamide
-
i.e. ParSL-3, a TEMPO-conjugated pargyline analogue, specifically inhibits MAO-A
N-(1-hydroxy-2,2,6,6-tetramethylpiperidin-4-yl)-4-[[methyl(prop-2-yn-1-yl)amino]methyl]benzamide
-
i.e. ParSL-2, a TEMPO-conjugated pargyline analogue, specifically inhibits MAO-B
N-(1-phenylethyl)-1H-pyrrole-2-carboxamide
-
;
N-(1H-pyrrol-2-ylmethyl)prop-2-yn-1-amine
-
;
N-(2,3-dimethylphenyl)-2-oxo-2H-chromene-3-carboxamide
-
-
N-(2,4-dimethylphenyl)-2-oxo-2H-chromene-3-carboxamide
-
-
N-(2,6-difluorophenyl)-2-oxo-2H-chromene-3-carboxamide
-
-
N-(2,6-dimethylphenyl)-2-oxo-2H-chromene-3-carboxamide
-
-
N-(2-aminoethyl)-2-(7-[(3-chlorobenzyl)oxy]-2-oxo-2H-chromen-4-yl)acetamide
-
-
-
N-(2-aminoethyl)-2-oxo-2H-chromene-3-carboxamide
-
-
N-(2-aminoethyl)-4-chlorobenzamide
-
-
N-(2-aminoethyl)-aryl-carboxamide
-
-
N-(2-aminoethyl)-p-chlorobenzamide
-
inhibits by covalent binding to the flavin ring
N-(2-aminoethyl)-p-chlorobenzamide
-
-
N-(2-benzylphenyl)-2-oxo-2H-chromene-3-carboxamide
-
-
N-(2-benzylphenyl)-7-(4-fluorobenzyloxy)-2-oxo-2H-chromene-3-carboxamide
-
-
N-(2-benzylphenyl)-7-benzyloxy-2-oxo-2H-chromene-3-carboxamide
-
-
N-(2-chloro-6-methylphenyl)-2-oxo-2H-chromene-3-carboxamide
-
-
N-(2-cyclohexylethyl)-N-methyl-1H-pyrrole-2-carboxamide
-
;
N-(2-methyl-1H-indol-5-yl)benzamide
-
-
-
N-(2-methyl-1H-indol-5-yl)cyclohexanecarboxamide
-
-
-
N-(2-methyl-6-chlorophenyl)-7-(4-fluorobenzyloxy)-2-oxo-2H-chromene-3-carboxamide
-
-
N-(2-methyl-6-chlorophenyl)-7-benzyloxy-2-oxo-2H-chromene-3-carboxamide
-
-
N-(2-morpholinoethyl)nicotinamide
-
-
-
N-(2-phenylethyl),N-methyl-1H-pyrrole-2-carboxamide
-
;
N-(3,4-dimethoxyphenyl)-2-oxo-2H-chromene-3-carboxamide
-
-
N-(3,4-dimethoxyphenyl)-7-(4-fluorobenzyloxy)-2-oxo-2H-chromene-3-carboxamide
-
-
N-(3,4-dimethoxyphenyl)-7-benzyloxy-2-oxo-2H-chromene-3-carboxamide
-
-
N-(3,4-dimethoxyphenyl)-7-benzyloxy-8-methyl-2-oxo-2H-chromene-3-carboxamide
-
-
N-(3,4-dimethoxyphenyl)-8-methyl-2-oxo-7-(2-phenylethyl)-2H-chromene-3-carboxamide
-
-
N-(3,4-dimethyl-2-oxo-2H-chromen-7-yl)benzamide
-
-
N-(3,4-dimethyl-2H-2-oxochromen-7-yl)-N,4-dimethylbenzensulfonamide
-
pIC50 for MAO-A: 5.34; pIC50 for MAO-B: 4.5
N-(3,4-dimethylphenyl)-2-oxo-2H-chromene-3-carboxamide
-
-
N-(3,5-dimethoxyphenyl)-2-oxo-2H-chromene-3-carboxamide
-
-
N-(3,5-dimethoxyphenyl)-7-(4-fluorobenzyloxy)-2-oxo-2H-chromene-3-carboxamide
-
-
N-(3,5-dimethoxyphenyl)-7-benzyloxy-2-oxo-2H-chromene-3-carboxamide
-
-
N-(3,5-dimethylphenyl)-2-oxo-2H-chromene-3-carboxamide
-
-
N-(3-fluorophenyl)-2-oxo-2H-chromene-3-carboxamide
-
-
N-(3-methylphenyl)-2-oxo-2H-chromene-3-carboxamide
-
-
N-(3-morpholinopropyl)nicotinamide
-
-
-
N-(3-phenylpropyl),N-methyl-1H-pyrrole-2-carboxamide
-
;
N-(3-phenylpropyl)-1H-pyrrole-2-carboxamide
-
;
N-(3-trifluoromethylphenyl)-2-oxo-2H-chromene-3-carboxamide
-
-
N-(3-{[(3,4-dimethyl-2-oxo-2H-chromen-7-yl)oxy]methyl}phenyl)acetamide
-
-
N-(4-benzyloxybenzyl)-4-methylthioamphetamine
-
-
N-(4-butoxybenzyl)-4-methylthioamphetamine
-
-
N-(4-cyano-2,3,5,6-tetrafluorophenyl)-2-oxo-2H-chromene-3-carboxamide
-
-
N-(4-cyano-2,3,5,6-tetrafluorophenyl)-7-(4-fluorobenzyloxy)-2-oxo-2H-chromene-3-carboxamide
-
-
N-(4-cyano-2,3,5,6-tetrafluorophenyl)-7-benzyloxy-2-oxo-2H-chromene-3-carboxamide
-
-
N-(4-ethylphenyl)-2-oxo-2H-chromene-3-carboxamide
-
-
N-(4-fluorophenyl)-2-oxo-2H-chromene-3-carboxamide
-
-
N-(4-hydroxybenzyl)-4-methylthioamphetamine
-
weak inhibition of MAO-A; weak inhibition of MAO-B
N-(4-isopropylphenyl)-7-(4-fluorobenzyloxy)-2-oxo-2H-chromene-3-carboxamide
-
-
N-(4-isopropylphenyl)-7-benzyloxy-2-oxo-2H-chromene-3-carboxamide
-
-
N-(4-methanesulfonylphenyl)-2-oxo-2H-chromene-3-carboxamide
-
-
N-(4-methoxybenzyl)-4-methylthioamphetamine
-
-
N-(4-methoxyphenyl)-2-oxo-2H-chromene-3-carboxamide
-
-
N-(4-phenylbutyl),N-methyl 1H-pyrrole-2-carboxamide
-
;
N-(4-phenylbutyl)-1H-pyrrole-2-carboxamide
-
;
N-(biphenyl-2-yl)-2-oxo-2H-chromene-3-carboxamide
-
-
N-(butan-2-yl)-2-oxo-2H-chromene-3-carboxamide
-
-
N-(cycloheptylidenemethyl)-4-(3-methoxyphenyl)-1,3-thiazol-2-amine
-
-
N-(prop-2-ynyl)-2-oxo-2H-chromene-3-carboxamide
-
-
N-([(5S)-3-[3-fluoro-4-(4-pyrazin-2-ylpiperazin-1-yl)phenyl]-2-oxo-1,3-oxazolidin-5-yl]methyl)acetamide
-
-
N-([(5S)-3-[4-(4-bromo-1H-imidazol-1-yl)-3-fluorophenyl]-2-oxo-1,3-oxazolidin-5-yl]methyl)acetamide
-
-
N-2-phenylethyl-1H-pyrrole-2-carboxamide
-
-
N-benzyl,N-methyl-1H-pyrrole-2-carboxamide
-
;
N-benzyl-(4-methylthioamphetamine)
-
weak inhibition of MAO-A; weak inhibition of MAO-B
N-benzyl-(6-butoxy-2-naphthyl)-2-aminopropane
-
;
N-benzyl-(6-methoxy-2-naphthyl)-2-aminopropane
-
;
N-benzyl-1-(1-methyl-1H-pyrrol-2-yl)methanamine
-
; most selective MAO-A inhibitor
N-benzyl-1H-pyrrole-2-carboxamide
-
;
N-benzyl-2-(7-[(3-chlorobenzyl)oxy]-2-oxo-2H-chromen-4-yl)-acetamide
-
-
-
N-benzyl-2-oxo-2H-chromene-3-carboxamide
-
-
N-benzyl-7-benzyloxy-2-oxo-2H-chromene-3-carboxamide
-
-
N-benzyl-N-methyl-1-(1-methyl-1H-pyrrol-2-yl)methanamine
-
;
N-benzyl-N-methyl-2-oxo-2H-chromene-3-carboxamide
-
-
N-benzyl-N-methylprop-2-yn-1-amine
-
i.e. pargyline
N-benzylprop-2-yn-1-amine
-
-
N-butyl-2-(7-[(3-chlorobenzyl)oxy]-2-oxo-2H-chromen-4-yl)-acetamide
-
-
-
N-butyl-2-(7-[(3-chlorobenzyl)oxy]-2-oxo-2H-chromen-4-yl)-N-methylacetamide
-
-
-
N-cyclohexyl-2-oxo-2H-chromene-3-carboxamide
-
-
N-cyclohexyl-7-benzyloxy-2-oxo-2H-chromene-3-carboxamide
-
-
N-isobutyl-7-benzyloxy-2-oxo-2H-chromene-3-carboxamide
-
-
N-isopropyl-7-benzyloxy-2-oxo-2H-chromene-3-carboxamide
-
-
N-methoxy-2-(3-methylphenyl)maleimide
-
-
-
N-methyl,N-(benzyl),N-(pyrrol-2-ylmethyl)amine
-
; pH 7.4, 38°Cmost selective MAO-B inhibitor
N-methyl-1-phenyl-N-(1H-pyrrol-2-ylmethyl)ethanamine
-
;
N-methyl-2-(3-bromophenyl)maleimide
-
-
-
N-methyl-2-(3-chlorophenyl)maleimide
-
-
-
N-methyl-2-(3-fluorophenyl)maleimide
-
-
-
N-methyl-2-(3-methylphenyl)maleimide
-
-
-
N-methyl-2-(3-trifluoromethylphenyl)maleimide
-
-
-
N-methyl-2-phenyl-N-(1H-pyrrol-2-ylmethyl)ethanamine
-
;
N-methyl-2-phenylmaleimide
-
-
-
N-methyl-3-phenyl-N-(1H-pyrrol-2-ylmethyl)propan-1-amine
-
;
N-methyl-4-phenyl-N-(1H-pyrrol-2-ylmethyl)butan-1-amine
-
;
N-methyl-N-(1-phenylethyl)-1H-pyrrole-2-carboxamide
-
;
N-methyl-N-benzyl-2-oxo-2H-chromene-3-carboxamide
-
-
N-methyl-N-phenyl-2-oxo-2H-chromene-3-carboxamide
-
-
N-methyl-N-phenyl-7-benzyloxy-2-oxo-2H-chromene-3-carboxamide
-
-
N-methyl-N-propargyl-1(R)-aminoindan
-
the experimentally tested model compound is docked computationally to the active site of the MAO-B enzyme. The AutoDock 3.0.5 program is employed to perform automated molecular docking. The free energies of binding and inhibition constants (Ki) of the docked compounds are calculated by the Lamarckian Genetic Algorithm of AutoDock 3.0.5. Excellent to good correlations between the calculated and experimental Ki values are obtained
N-methyl-N-[(1-methyl-1H-pyrrol-2-yl)methyl]prop-2-yn-1-amine
-
-
N-phenyl-1H-pyrrole-2-carboxamide
-
-
N-prop-2-yn-1-yl-1H-pyrrole-2-carboxamide
-
;
N-propargyl-1(R)-aminoindan
-
the experimentally tested model compound is docked computationally to the active site of the MAO-B enzyme. The AutoDock 3.0.5 program is employed to perform automated molecular docking. The free energies of binding and inhibition constants (Ki) of the docked compounds are calculated by the Lamarckian Genetic Algorithm of AutoDock 3.0.5. Excellent to good correlations between the calculated and experimental Ki values are obtained
N-propargyl-l(R)-aminoindan
-
i.e. rasagiline. N-Propargyl-l(R)-aminoindan is well tolerated and effective in the treatment of early Parkinson's disease and as adjunctive treatment in levodopa-treated patients with Parkinson's disease experiencing motor fluctuations
N-[(1R)-1-cyclohexylethyl]-1H-pyrrole-2-carboxamide
-
;
N-[(1S)-1-cyclohexylethyl]-1H-pyrrole-2-carboxamide
-
;
N-[3-(2,4-dichlorophenoxy)propyl]-N-methyl-prop-2-yn-1-amine
-
i.e. clorgiline
N-[4-(methylsulfonyl)phenyl]-2-oxo-2H-chromene-3-carboxamide
-
-
N-[[(5S)-3-(3-fluoro-4-morpholin-4-ylphenyl)-2-oxo-1,3-oxazolidin-5-yl]methyl]acetamide
-
-
Naringenin
-
the content of naringenin in Mentha aquatica might explain its use in traditional medicine for depression-like conditions; the content of naringenin in Mentha aquatica might explain its use in traditional medicine for depression-like conditions
norharman
-
; competitive reversible and potent inhibitor
norharman
-
inhibition of MAO A; inhibition of MAO B
NW 1772
-
specific inhibitor of isoform MAO-B
-
o-eugenol
-
IC50: 0.101 mM, monoamine oxidase A; IC50: above 0.5 mM, monoamine oxidase B
oleamide
-
inhibits MAO B
p-(propylthio)-phenylisopropylamine
-
-
p-nitrobenzylamine
-
substrate for wild-type enzyme, competitive inhibitor for mutant enzyme Y435L
Pargyline
-
MAO-B sensitive
Pargyline
-
MAO-B sensitive
Pargyline
-
irreversible inhibitor
Pargyline
-
the experimentally tested model compound is docked computationally to the active site of the MAO-B enzyme. The AutoDock 3.0.5 program is employed to perform automated molecular docking. The free energies of binding and inhibition constants (Ki) of the docked compounds are calculated by the Lamarckian Genetic Algorithm of AutoDock 3.0.5. Excellent to good correlations between the calculated and experimental Ki values are obtained
Pargyline
-
monoamine oxidase B
Pargyline
-
the irreversible and non-selective MAO inhibitor produces increases in 5-hydroxytryptamine syndrome in the 5-hydroxytryptamine-treated rats
Pargyline
-
irreversible inhibitor. Pargyline + semicarbazide-induced reduction of fat deposition results from decreased food intake and from impaired MAO and SSAO-dependent lipogenic and antilipolytic actions of endogenous or alimentary amines
Pargyline
P21397, P27338
;
Pargyline
-
construction of three TEMPO-conjugated pargyline analogues ParSL-1, ParSL-2, and ParSL-3, which differ in flexibility and substituent positions of the linkers connecting the TEMPO group to the pargyline phenyl ring. The variations in conformational flexibility and substituent position have profound effects in tuning the specificities of these analogues toward the MAO isoforms, inhibitor synthesis, overview; construction of three TEMPO-conjugated pargyline analogues ParSL-1, ParSL-2, and ParSL-3, which differ in flexibility and substituent positions of the linkers connecting the TEMPO group to the pargyline phenyl ring. The variations in conformational flexibility and substituent position have profound effects in tuning the specificities of these analogues toward the MAO isoforms, inhibitor synthesis, overview
Pargyline
-
inhibitor of MAO-A and MAO-B
Pargyline
-
inhibits MAO-A and MAO-B irreversibly
ParSL
P21397, P27338
a pargyline based nitroxide spin labeled irreversible inhibitor, active site binding, structure, overview; a pargyline based nitroxide spin labeled irreversible inhibitor, active site binding, structure, overview
ParSL
-
a pargyline based nitroxide spin labeled irreversible inhibitor, active site binding, structure, overview; a pargyline based nitroxide spin labeled irreversible inhibitor, active site binding, structure, overview
pelargonidin
-
-
pelargonidin-3,5-diglucoside
-
-
-
peonidin-3-O-beta-D-glucoside
-
-
petunidin
-
-
Phenelzine
-
the nonselective irreversible inhibitor of monoamine oxidase causes an increase in brain ornithine that is prevented by prior monoamine oxidase inhibition
Phenelzine
P21936
; weak inhibition of MAO-A
Phenelzine
-
-
Phenelzine
-
concentration-dependent inhibition
phenelzine sulfate
P21397, Q5UL99
mixed irreversible MAO inhibitors (MAOI-A/B) tranylcypromine hydrochloride and phenelzine sulfate. Treatment with monoamine oxidase inhibitors (contained in cigarette smoke) dramatically prolong the aversive state associated with nicotine withdrawal but have little effect on the somatic signs of nicotine withdrawal; mixed irreversible MAO inhibitors (MAOI-A/B) tranylcypromine hydrochloride and phenelzine sulfate. Treatment with monoamine oxidase inhibitors (contained in cigarette smoke) dramatically prolong the aversive state associated with nicotine withdrawal but have little effect on the somatic signs of nicotine withdrawal
pheniprazine
-
i.e. (1-methyl-2-phenylethyl)hydrazine. Mechanism-based MAO inhibitor
pheniprazine
-
i.e. (1-methyl-2-phenylethyl)hydrazine. As a reversible inhibitor it is selective towards rat liver MAO-A but the rate of irreversible inhibition of that enzyme is considerably slower; i.e. (1-methyl-2-phenylethyl)hydrazine. Mechanism-based MAO inhibitor
phentermine
P21396
-
phentermine
-
binding to the S209E mutant is reduced by 13fold compatred to the wild-type MAO A
phentermine
-
reversible inhibitor; reversible inhibitor
Phenylethylhydrazine
-
-
Phenylethylhydrazine
-, P27338
the mode of irreversible MAO inhibition involves covalent modification of the flavin coenzyme, overview; the three-dimensional structures of phenylethylhydrazine- and benzylhydrazine-inhibited MAO B show that alkylation occurs at the N5 position on the re-face of the covalent flavin with loss of the hydrazyl nitrogens, mechanism, the mode of irreversible MAO inhibition involves covalent modification of the flavin coenzyme, overview
phenylhydrazine
-
-
phenylhydrazine
-, P27338
weak binding; weak binding
pirlindole
-
an MAO A specific reversible inhibitor
pirlindole mesylate
-
reversible enzyme-specific inhibitor
-
pirlindole mesylate
-
-
-
R-(-)-deprenyl
-
inhibits both MAO-A and MAO-B
R-(-)-deprenyl
-
inhibitor of MAO-B
R-(-)-deprenyl
-
-
R-(-)-deprenyl
-
inhibits MAO-B irreversibly
R-(-)-deprenyl
-
highly active with MAO-B
R-deprenyl
-
-
R-rasagiline
-
-
-
raisin extract
-
;
-
rasagiline
P21396
-
rasagiline
-
i.e. N-propargyl-1-R-aminoindan. Irreversible MAO B inhibitor. Rasagiline is initiated at 1 mg once-daily dosage as monotherapy in early Parkinson’s disease patients and at 0.5-1 mg once-daily as adjunctive to levodopa in advanced Parkinson’s disease patients. Rasagiline treatment is not associated with cheese effect and up to 20 mg per day is well tolerated. In Parkinson’s disease patients with hepatic impairment, rasagiline dosage should be carefully adjusted. Rasagiline should not be administered with other MAO inhibitors and coadministration with certain antidepressants and opioids should be avoided. This drug provides an additional tool for Parkinson’s disease therapy improvement in motor performance
rasagiline
-
an acetylenic compound that forms covalent adducts with the N5 of the covalent FAD of MAO-B, pharmacologically inert as MAO-A inhibitor. A rasagiline analog methylated on the amino moiety of the propargyline chain connecting the inhibitor to the flavin loses this characteristic specificity for MAO-B
rasagiline
-
inhibitor of MAO-B
rasagiline
-
i.e. AGN 1135
rasagiline
-
inhibits MAO-B irreversibly
rasaglilline
-
specific inhibitor of isoform MAO-B
-
rhodiocyanoside A
-
compound from Rhodiola rosea extract, inhibits MAO B, not MAO A
rhodioloside B
-
compound from Rhodiola rosea extract, inhibits MAO B, not MAO A
Ro 19-6327
-
-
Ro 41-1049
-
-
Ro 41-1049
-
potent
rosiglitazone
-
-
rosiridin
-
compound from Rhodiola rosea extract, inhibits both MAO A and MAO B
safinamide
-
; binds noncovalently to MAO B, occupying both the entrance and the substrate cavities
safinamide
-
a very specific MAO B non-covalent inhibitor, may function effectively as a neuroprotectant
safinamide
-
-
safinamide
-
-
salidroside
-
compound from Rhodiola rosea extract, inhibits MAO B, not MAO A
Sanguinarine
-
-
-
selegiline
-
the experimentally tested model compound is docked computationally to the active site of the MAO-B enzyme. The AutoDock 3.0.5 program is employed to perform automated molecular docking. The free energies of binding and inhibition constants (Ki) of the docked compounds are calculated by the Lamarckian Genetic Algorithm of AutoDock 3.0.5. Excellent to good correlations between the calculated and experimental Ki values are obtained
selegiline
-
the MAO B inhibitor is efficacious in the therapeutic management of Parkinson's disease
selegiline
-
administration of the irreversible and selective MAO-B inhibitor selegiline does not produce any increase in 5-hydroxytryptamine syndrome in the 5-hydroxytryptamine-treated rats, compared with the saline control
selegiline
-
;
selegiline
-
an effective and well-tolerated monoamine oxidase inhibitor for the treatment of depression
selegiline
-
irreversible cerebral MAO-B inhibitor
selegiline
-
-
selegilline
-
specific inhibitor of isoform MAO-B
-
Semicarbazide
-
-
Semicarbazide
P19643, P21396
;
Semicarbazide
-
complete inhibition at 0.01 mM
Sodium diethyldithiocarbamate
-
weak inhibition
syringic acid
-
-
tert-butyl (2-[[2-(cyclohexylamino)-1-(3-hydroxyphenyl)-2-oxoethyl](phenyl)amino]-2-oxoethyl)carbamate
-
non-selective; non-selective
tert-butyl (2-[[2-(cyclohexylamino)-1-(3-hydroxyphenyl)-2-oxoethyl][2-(phenylcarbonyl)phenyl]amino]-2-oxoethyl)carbamate
-
selective for MAO-B
tetrahydroharmine
-
identification by HPLC-ESI-mass spectrometry
-
tetrahydropyridines
-
-
tetrindole
-
the inhibitor induces changes in the spectrum of MAO A, consistent with stacking of inhibitor with the flavin in the active site. Inhibitor stabilizes the semiquinone form of FAD during reduction of MAO A by dithionite and no further reduction of the inhibitor-MAO A complex occurs
tetrindole
-
an MAO A specific reversible inhibitor
tetrindole mesylate
-
reversible enzyme-specific inhibitor
-
tetrindole mesylate
-
-
-
toloxatone
-
-
-
toloxatone
-
inhibitor of MAO-A
-
toloxatone
-
inhibits MAO-A reversibly
-
trans,trans-Farnesol
-
monoamine oxidase B
trans-2,4,5-trimethoxypropenylbenzene
-
IC50: 0.124 mM, monoamine oxidase A; IC50: 0.338 mM, monoamine oxidase B
trans-2-phenylcyclopropylamine
-
inhibits by covalent binding to the flavin ring
trans-2-phenylcyclopropylamine
-
2-PCPA; 2-PCPA
trans-3-(2-thienyl)-2-(N-phenylthiocarbamoyl)-3,3a,4,5,6,7-hexahydro-2H-indazol
-
-
-
trans-trans-1,4-diphenyl-1,3-butadiene
-
-
Tranylcypromine
-
-
Tranylcypromine
-
inhibition of MAO-B
Tranylcypromine
-
inactivation of recombinant human MAO-B with tranylcypromine results in the formation of a high affinity I2 site on the enzyme, measured as an increase in binding of 2-(2-benzofuranyl)-2-imidazoline. Inhibition by tranylcypromine results in displacement of Q206 and closure of the I199 gate
Tranylcypromine
-
nonselective inhibitor
tranylcypromine hydrochloride
P21397, Q5UL99
mixed irreversible MAO inhibitors (MAOI-A/B) tranylcypromine hydrochloride and phenelzine sulfate. Treatment with monoamine oxidase inhibitors (contained in cigarette smoke) dramatically prolong the aversive state associated with nicotine withdrawal but have little effect on the somatic signs of nicotine withdrawal; mixed irreversible MAO inhibitors (MAOI-A/B) tranylcypromine hydrochloride and phenelzine sulfate. Treatment with monoamine oxidase inhibitors (contained in cigarette smoke) dramatically prolong the aversive state associated with nicotine withdrawal but have little effect on the somatic signs of nicotine withdrawal
triandrin
-
compound from Rhodiola rosea extract, inhibits MAO B, not MAO A
troglitazone
-
-
tyrosol
-
compound from Rhodiola rosea extract, inhibits MAO B, not MAO A
Vanillic acid
-
-
ZnSO4
-
1 mM, 10% inhibition, monoamine oxidase B; 1 mM, 85% inhibition with serotonin as substrate, competitive, reversible, monoamine oxidase A
ZnSO4
-
1 mM, about 20% inhibition, monoamine oxidase A
[(2E)-3-fluoro-2-phenylprop-2-en-1-yl]hydrazine
-
;
[(5E)-2,4-dioxo-5-(phenylimino)-1,3-thiazolidin-3-yl]acetonitrile
-
R598119
[(E)-1,3-dipropyl-7-methyl-8-(2-(3-thienyl)ethenyl)]xanthine
-
a dual-target-directed drug inhibiting MAO-B and antagonizing A2A receptors
[(E)-N-(2-propynyl)-2-(phenyl)ethylidene]-hydrazine
P21936
synthesis and inhibition of MAO isozymes, overview; synthesis and inhibition of MAO isozymes, overview
[(E)-N-bis-(2-propynyl)-2-(phenyl)ethyidene]hydrazine
P21936
synthesis and inhibition of MAO isozymes, overview; synthesis and inhibition of MAO isozymes, overview
[(Z)-N-(2-propynyl)-2-(phenyl)ethylidene]-hydrazine
P21936
synthesis and inhibition of MAO isozymes, overview; synthesis and inhibition of MAO isozymes, overview
[2-(2-methylphenyl)prop-2-en-1-yl]hydrazine
-
;
[2-(4-chlorophenyl)prop-2-en-1-yl]hydrazine
-
;
[2-(4-fluorophenyl)prop-2-en-1-yl]hydrazine
-
;
[4-(benzyloxy)phenoxy]hydrazine
-
0.1 mM, 43% inhibition
mofegiline
-
a vinyl fluoroamine
additional information
-
inhibitors with a substitution at the 5-position in 2-[N-(2-propynyl) aminomethyl]-1-methyl indole
-
additional information
-
overview: selective inhibitors of form A and B
-
additional information
-
cigarette smoke is a potent inhibitor of MAO-A. Inhibition is partly reversible, competitive. beta-Carboline alkaloids from cigarette smoke acting as potent reversible inhibitors may contribute to the MAO reduced activity produced by tobacco smoke in smokers; cigarette smoke is a potent inhibitor of MAO-B. Inhibition is partly reversible, competitive. Veta-carboline alkaloids from cigarette smoke acting as potent reversible inhibitors may contribute to the MAO reduced activity produced by tobacco smoke in smokers
-
additional information
-
no inhibition by Mesobuthus gibbosus venom peptide
-
additional information
-
no inhibition by 4-hydroxy-3-methoxyophenylethyl alcohol, ethyl-4-hydroxy-3-methoxyphenylacetate, metanephrine, 3,4-dimethoxy-5-hydroxybenzaldehyde and 3-methoxyphenol
-
additional information
-
recombinant ezyme obtained from a Baculovirus expression system is validated as convenient enzyme source for MAO B inhibitor screening
-
additional information
-
both the MAO-A and MAO-B isoforms, deposited in the Protein Data bank as the 2BXR and 1GOS models, respectively, are considered in a computational sttudy performed with docking techniques to explain the selective inhibitory activity towards the MAO-A and MAO-B enzymes; both the MAO-A and MAO-B isoforms, deposited in the Protein Data bank as the 2BXR and 1GOS models, respectively, are considered in a computational sttudy performed with docking techniques to explain the selective inhibitory activity towards the MAO-A and MAO-B enzymes
-
additional information
-
no inhibition of monoamine oxidase B: trans,trans-farnesol, 8-(3-chlorostyryl)caffeine or 1,4-diphenyl-2-butene
-
additional information
-
no inhibition of monoamine oxidase A: trans,trans-farnesol, 8-(3-chlorostyryl)caffeine, 1,4-diphenyl-2-butene
-
additional information
-
no inhibition of monoamine oxidase B: isatin, trans,trans-farnesol, 8-(3-chlorostyryl)caffeine or 1,4-diphenyl-2-butene
-
additional information
-
alkylamino derivatives of 4-aminomethylpyridine, substrate-like, reversible inhibitors
-
additional information
-
coffee contains compounds acting as reversible and competitive inhibitors for MAO A; coffee contains compounds acting as reversible and competitive inhibitors for MAO B
-
additional information
-
no inhibition: 1-thiocarbamoyl-3-phenyl-5-(3,4-dimethoxyphenyl)-4,5-dihydro-1H-pyrazole, thiocarbamoyl-3-phenyl-5-(2-chloro-3,4-dimethoxyphenyl)-4,5-dihydro-1H-pyrazole
-
additional information
-
evaluation of the application of UCSF DOCK to screen for inhibitors of MAO-B
-
additional information
-
the active site cavities in rat MAOs are significantly different compared to those in the two human enzymes, which correlates with the differences in the inhibitor specificities between human and rat MAOs; the active site cavities in rat MAOs are significantly different compared to those in the two human enzymes, which correlates with the differences in the inhibitor specificities between human and rat MAOs
-
additional information
-
monoamine oxidase-B inhibitors and antiinflammatory agents might be effective in treating Alzheimer’s disease
-
additional information
P21397
no inhibition: 1,4-diphenyl-2-butene and chlorostyrylcaffeine
-
additional information
P21396
no inhibition: 1,4-diphenyl-2-butene and chlorostyrylcaffeine
-
additional information
-
SSAO inhibition is not sufficient to impair fat deposition. Combined MAO and SSAO inhibition limits adiposity in non-obese as well as in obese rats
-
additional information
-
inhibitory potencies of methylpiperate derivatives from Piper longum, no inhibition by isolated piperlonguminine; inhibitory potencies of methylpiperate derivatives from Piper longum, no inhibition by isolated piperlonguminine
-
additional information
-
synthesis of mechanism-based substituted trans-2-arylcyclopropylamine inhibitors, overview. No inhibition by 7; synthesis of mechanism-based substituted trans-2-arylcyclopropylamine inhibitors, overview. No inhibition by 7
-
additional information
-
synthesis and inhibhitory potencies of (E)-styrylisatin analogues on the enzyme, overview. No inhibition of MAO-A by (E)-8-(3-chlorostyryl)caffeine; synthesis and inhibhitory potencies of (E)-styrylisatin analogues on the enzyme, overview. The (E)-5-styrylisatin analogue binds more tightly than the (E)-6 analogue although the latter exhibits the highest MAO-B selectivity
-
additional information
-
naphthylisopropylamine and N-benzylamphetamine derivatives as monoamine oxidase inhibitors of isozymes MAO-A and MAO-B, molecular docking, overview. Replacement of the phenyl ring of amphetamine derivatives by a naphthalene system resulted in more potent compounds results in increased electron-donating capacity and size of the aromatic moiety; naphthylisopropylamine and N-benzylamphetamine derivatives as monoamine oxidase inhibitors of isozymes MAO-B, molecular docking, overview. Replacement of the phenyl ring of amphetamine derivatives by a naphthalene system resulted in more potent compounds results in increased electron-donating capacity and size of the aromatic moiety. No inhibition of MAOB by N-4-methoxybenzyl-(4-methylthioamphetamine) hydrochloride, N-4-butoxybenzyl-(4-methylthioamphetamine) hydrochloride, and N-4-benzyloxybenzyl-(4-methylthioamphetamine) hydrochloride
-
additional information
-
potent reversible pteridine-2,4-dione analogue inhibitor development and synthesis, molecular modelling of MAO-B ligand binding, overview
-
additional information
-
successful SRY knockdown inhibits MAO A catalytic activity by 45%
-
additional information
-
Rhodiola rosea roots have potent antidepressant activity by inhibiting MAO A and may also find application in the control of senile dementia by their inhibition of MAO B, no inhibition of both isozymes by rosavin, rosarin, and rosin
-
additional information
P19643, P21396
no inhibhition of MAO-A by selegiline; no inhibition of MAO-B by clorgyline
-
additional information
-
the inhibitors show no neuroprotective effects in female scrapie-infected hamsters, overview
-
additional information
-
inhibitors of MAO-B can be adjunctive drugs to levodopa. Neuroprotective and anti-Parkinsonian effects of A2A receptor antogonistic drugs, overview
-
additional information
-
no inhibition of MAO-A by farnesol, chlorostyrylcaffeine, and 1,4-diphenyl-2-butene; not inhibited by farnesol, chlorostyrylcaffeine and 1,4-diphenyl-2-butene
-
additional information
-
the enzyme is not inhibted by semicarbazide
-
additional information
-
inhibitor binding affects the active site structures of MAO-A and MAO-B, overview
-
additional information
-
inhibitor binding affects the active site structures of MAO A and MAO B, overview
-
additional information
-
development and synthesis of benzylidene-prop-2-ynyl-amines analogues as monoamine oxidase inhibitors, ligand docking and molecular modelling, overview. In the active center, Ile199 is the gate residue, and two hydrophobic areas of the enzyme are implicated in the most stable binding mode. Hydrophobic pocket is delimited by Ile198, Ile199, Gln206, Phe343, and aromatic cage contains FAD, Tyr398 and Tyr435
-
additional information
-
evaluation of chromone carboxylic acids as enzyme inhibitors, only chromone-3-carboxylic acid is a potent MAO-B inhibitor, with a high degree of selectivity for MAO-B compared to MAO-A, no inhibition by 4-oxo-4H-chromene-2-carboxylic acid at 0.1 mM, molecular docking, overview
-
additional information
-
synthesis and molecular modeling of some hexahydroindazole derivatives as potent monoamine oxidase inhibitors, overview
-
additional information
-
inhibition of monoamine oxidase by 8-benzyloxycaffeine analogues, quantitative structure-activity relationship studies, overview
-
additional information
-
2-arylthiomorpholine and 2-arylthiomorpholin-5-one derivatives, designed as rigid and/or non-basic phenylethylamine analogues, as monoamine oxidase inhibitors, molecular docking using crystal structures of human MAO-B, PDB ID 1S3E, and MAO-A, PDB ID 2BXS, overview
-
additional information
-
2-arylthiomorpholine and 2-arylthiomorpholin-5-one derivatives, designed as rigid and/or non-basic phenylethylamine analogues, as monoamine oxidase inhibitors, overview
-
additional information